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Abstract
Myelin Basic Protein is a major structural protein of vertebrate myelin. 
The gene that codes for MBP is contained within the golli-MBP complex. This 
gene complex consists of two overlapping transcription units, golli and MBP, 
which are regulated by two distinct promoters.
The golli unit is expressed in cells of the oligodendrocyte lineage 
(Central Nervous System), neurons, B and T lymphocytes, testis and thymus. 
However, the MBP unit is expressed exclusively in oligodendrocytes and 
Schwann cells (Peripheral Nervous System).
The expression of the MBP unit is regulated mainly at the level of 
transcription by proteins that bind in a specific manner to DNA sequences 
located within its promoter region. The identification of these proteins and 
DNA sequences is essential to understanding the mechanisms that regulate 
the transcription of the MBP unit.
This project was initiated by the isolation of the putative promoter 
region of the mouse myelin basic protein (MBP) gene. To achieve this the 
Hind III -  Sac I fragment of pEX1 plasmid was subcloned in the vector 
pBluescript. The cloned insert, which corresponds to the region between 
nucleotides -  1319 and + 227 relative to the transcription start site of the 
mouse MBP gene, was subsequently sequenced manually using the chain 
termination method. Sequence analysis revealed a number of putative binding 
sites for transcription factors. The region -  609 to -  577 was selected for 
further studies because work published by other groups suggested that it 
contains a cell-type specific (for oligodendrocytes) transcription activator. The 
presence of protein factors specifically binding to the region -  609 to -  577 
was demonstrated by electrophoretic mobility shift assay (EMSA).
For this purpose, nuclear extracts were prepared from rodent brain or 
established glial cell lines e.g. C6 glioma cells. Extracts from tissues and cell 
lines, which do not express myelin basic protein e.g., HeLa cells served as a 
control. Nuclei were isolated by Dounce homogenisation of cultured cells or 
brain tissue. The proteins were then isolated by high salt extraction of the 
nuclei followed by ammonium sulphate fractionation.
Putative protein(s) binding to the region located between nucleotides 
-  609 to -  577 of the myelin basic protein gene promoter were identified 
using the yeast one-hybrid system. This assay is based on the interaction 
between a specific protein DNA binding domain and the target DNA 
sequence. Proteins are expressed as fusions to the GAL4 activation domain 
(AD) in the yeast reporter strain in which the target sequence has been 
inserted upstream of the HIS3 gene minimal promoter. Binding of AD fusions 
to the target sequence increases activity of the HIS3 promoter enabling 
growth on medium lacking histidine. In this work a yeast reporter strain 
containing four copies of the -609 to -577 region tandemly repeated 
upstream of the HIS3 gene minimal promoter was constructed. A library 
containing rat brain cDNAs fused to the activation domain of GAL4 was 
screened using this strain as a host. Seven clones were obtained on medium 
lacking histidine in the presence of 30 mM 3-aminotriazole. DNA from these 
clones was automatically sequenced and analysed for sequence homology 
with known transcription factors by comparing the nucleotide and protein 
sequences to EMBL/Genbank and Swissprot/Swall databases using the
FastA and Blast search tools. From the results of the homology searches the 
clones were identified as follows: the activating transcription factor 2 (ATF-2), 
the pituitary specific positive transcription factor 1 (Pit-1) or general 
transcription factor 2i, the E2F family transcription factor, the PASK protein 
and two of the clones were identified as c-jun. One clone, however, remains 
unidentified and this could be a novel transcription factor.
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Chapter 1
Introduction
The principal role of the myelin sheath is to allow the faster 
transmission of the nerve impulse along the axons, which it surrounds, by 
acting as an insulator. The membrane of the myelinated axon expresses 
several physiologically active molecules that intervene directly in the 
transmission of the nervous impulse e.g. the voltage-sensitive sodium 
channels are responsible for the propagation of the action potential along 
the axon and are concentrated at the non-insulated axonal segments known 
as the nodes of Ranvier (Figure 1), and the fast and slow potassium 
channels responsible for various secondary electrophysiological activities 
involved in the recovery to resting-state conditions following the passage of 
the action potential (nerve impulse) (Waxman and Ritchie, 1993; Salzer, 
1997). The myelin sheath, through its electrical resistance and low 
capacitance, allows the depolarisation of the internodal axonal membrane 
with a minimal consumption of energy (Sutcliffe, 1987). Due to the segmental 
nature of the electrically insulating myelin membrane, the action potential 
appears to jump from one node of Ranvier to the next: hence the term 
‘saltatory conduction’. By imposing a saltatory conduction on the nerve 
impulse, myelin not only allows an increased speed of conduction, it also 
saves energy and space, e.g. in order to achieve an equal conduction 
velocity, an unmyelinated axon would need to have a 40 times greater 
diameter than a myelinated one and would consume 5000 times more
energy (Garbay etal., 2000). The myelin sheath is produced in the central 
nervous system (CNS) by oligodendrocytes and in the peripheral nervous 
system (PNS) by Schwann cells. At the outset it consists of loosely spirally 
wrapped extensions of the oligodendrocyte or Schwann cell plasma 
membrane. During maturation of myelin, compaction at both the apposed 
cytoplasmic and extracellular membrane surfaces occurs to form the tight 
multilamellar structure characteristic of myelin (Lemke, 1986). This 
compacted, spirally wrapped multilayer membrane system consists of 
approximately 80% complex lipids and cholesterol, and 20 % protein 
(Streicher and Stoffel, 1989). The decision to myelinate is critical both for the 
functioning of the nervous system and for the physiology of the sheath cell. 
For the cell, the formation of myelin entails a radical reorganisation of both 
morphology and metabolism, the most obvious being the massive increase 
in plasma membrane biosynthesis and surface area, and in the induction 
and high-level expression of a set of genes and proteins unique to the 
myelinating glia (Lees and Brostoff, 1984).
Myelination is a major event in the development of the nervous 
system of higher animals. In the central nervous system of rats and mice it 
occurs postnatally and follows a period of rapid proliferation of 
oligodendroglial cells. Myelination generally proceeds from the top of the 
spinal column and the base of the brain towards the frontal areas of the 
brain.
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Figure 1. A diagrammatic representation of nerve conduction in a 
myelinated and unmyelinated axon.
KEY:
1. The arrival of an action potential in the form of a wave sodium ions. 
2 and 4. Entry of sodium ions by the activation of sodium channels.
3. The passive diffusion of the wave of sodium ions along the axon 
following the concentration gradient.
(After Garbay et al., 2000)
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In the myelin of the central nervous system the major proteins are the 
basic proteins and the proteolipid protein (representing 70 - 80% of the 
protein content of the membrane). The proteolipid protein plays both a 
structural role in the association of apposed extracellular myelin membrane 
surfaces, and functions as an ionophore. Both the myelin basic protein and 
the proteolipid protein consist of multiple polypeptide chains derived through 
alternative splicing of single genes (deFerra et al. 1985). Less abundant 
CNS proteins include myelin -  associated glycoprotein (MAG) and 2’, 3’ -  
cyclicnucleotide 3'-phosphodiesterase (CNP). Schwann cells form the myelin 
of the peripheral nervous system; with the major proteins being P0 
glycoprotein and myelin -  associated glycoprotein (MAG) (Campagnoni, 
1988).
P0 is an integral membrane glycoprotein serving as a bi-functional 
structural element linking adjacent lamellae and therefore stabilising the 
myelin assembly. The myelin-associated glycoprotein has been localised to 
the periaxonal regions and is involved in the association of the myelin 
membrane with the axon, with its structure related to a cell adhesion 
molecule (Salzer etal., 1987).
The myelin basic proteins (MBPs) represent a family of structurally 
related proteins, varying in molecular mass from 14 to 21.5 kDa (deFerra et 
al., 1985, Newman etal., 1987a; 1987b). The mouse myelin basic protein 
isoforms are referred to by their apparent molecular weights on SDS 
polyacrylamide gels or by their masses obtained through cDNA or protein 
sequencing studies. There are four isoforms in humans (Kamholz et al.,
1986, Roth etal., 1986, Roth etal., 1987).
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The myelin basic proteins are hydrophilic extrinsic membrane proteins 
with isoelectric points greater than 10.6 (more basic than the histones), 
which have been localised to the major dense line of myelin that is formed by 
apposition of the cytoplasmic surfaces of the extruded oligodendroglial 
plasma cell membrane during myelinogenesis (Morell etal., 1994). Unlike 
the proteolipid proteins, which are believed to be transmembrane proteins 
traversing the unit bilayer, the myelin basic proteins appear to remain 
associated with the cytoplasmic side of the unit bilayer. The myelin basic 
proteins undergo a number of post-translational modifications, including N- 
terminal acetylation, phosphorylation and methylation. Evidence suggests 
that methylation of the myelin basic protein may be important for the 
compaction of the membrane during myelin maturation (Amur et al., 1986,
Kim etal., 1997).
1.1. Myelin Basic Protein gene structure
Cell-free translation of rat and mouse brain mRNA indicated that the
major isoforms of the myelin basic proteins were encoded by separate MBP
mRNAs (Yu and Campagnoni, 1982 and Colman etal., 1982) and this
understandably led to investigations into whether or not more than one gene
codes for the multiple myelin basic protein isoforms. Southern blot analysis
showed the presence of only a single gene in the mouse and the human,
suggesting these isoforms, which are homologous over most of their
sequences, are produced from a single primary MBP transcript through
alternative patterns of RNA splicing (Takahashi etal., 1985 and deFerra et
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al., 1985). In situ hybridisation and somatic cell hybridisation studies have 
mapped the gene to the distal end of chromosome 18 in both the mouse 
(Roach et al., 1985) and the human (Saxe et al., 1985 and Sparkes et al., 
1987).
The mouse MBP gene is large and part of a complex genetic locus, 
termed the golli-mbp locus, (Figure 2). The term golli-mbp signifies the fact 
that most of the products of the gene are expressed in the o/igodendrocyte 
lineage in the brain as myelin basic proteins. Structural analysis has shown 
this locus to be conserved among most species (Pribyl etal., 1993). The 
murine golli-mbp is distributed over a length of 215 kb and comprises 11 
exons, with exons 5b -  11 encoding the myelin basic proteins. The human 
locus is smaller (179 kb) with 10 exons. The exons are interrupted by introns 
some of which are quite long (Takahashi etal., 1985 and deFerra etal.,
1985).
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Figure 2. A diagrammatic representation of the mouse MBP gene and its 
relationship to the golli-mbp gene.
Exons 1 to 11 represent the golli-mbp gene (marked above the 
horizontal line representing the introns).
MBP represents the ‘classical’ MBP gene comprising exons 0 to 7 
(marked below the horizontal line representing the introns).
Boxes indicating the exons are interrupted by introns indicated by the solid 
lines. Window-type boxes represent exons unique to golli-mbp transcripts. 
The stippled box represents an embryonic exon; transcripts containing this 
exon are initiated at the S2 site. Cross-striped boxes represent the exons 
shared by ‘classical’ MBP isoforms.
51 represents the transcriptional start site of the golli-mbp gene transcripts.
52 corresponds to the transcriptional start site for embryonic MBP gene 
transcripts.
53 represents the transcriptional initiation site of the ‘classical’ MBP gene 
transcripts.
Alternative splicing of the primary transcripts results in a diversity of golli- 
mbp and MBP isoforms.
(After Asipu and Blair, 1997).
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The MBP mRNA coding unit of the golli-mbp gene spans 32 kb. Exon 5a is a 
region of high transcriptional complexity, functioning as a promoter for the 
transcription of the MBP gene. Exon 5a is also the site for the alternative 
splicing of several of the golli-mbp transcripts. Not unexpectedly, this region 
is highly conserved among sharks, mice and humans (Fors etal., 1993). 
Several laboratories have isolated cDNAs of mRNAs encoding a wider 
variety of MBP isoforms than had at first been anticipated, (deFerra et al., 
1985, Kamholz etal., 1986, Roth etal., 1986, Roth etal., 1987, Newman et 
al., 1987a, Kitamura et al., 1990, Aruga et al., 1991, Nakajima et al., 1993) 
for example, cDNAs of mRNAs encoding twelve forms of the mouse MBP 
have now been isolated. These cDNAs are derived from mRNAs that arise 
through the alternative splicing of the second, fifth and sixth exons of the 
‘classical’ MBP gene primary transcript. The relationship between their 
molecular masses and exon usage is outlined as follows: the 14 kDa isoform 
contains exons 1b, 3, 4, 5b and 7, the 17 kDa -  1 isoform utilises exons 1b,
2, 3, 4, 5b and 7, the 17 kDa -  2 isoform utilises exons 1b, 3, 4, 6, and 7, the
18.5 kDa isoform contains exons 1b, 3, 4, 5b 6 and 7, and the 21.5 kDa 
isoform contains all 7 exons (Figure 3). Immunoblot studies have indicated 
the existence of additional minor myelin basic proteins such as a 13 kDa 
form (containing exons 1b, 3, 4 and 7), a 15 kDa form (utilising exons 1b, 2,
3, 4, and 7) and a 20 kDa form (containing exons 1b, 2, 3, 4, 6 and 7) in the 
mouse CNS, although it has been suggested that these two isoforms are 
predominantly embryonic (Nakajima et al., 1993). It is also possible that the 
minor MBPs are posttranslationally modified molecules or degradation 
products. Other data suggest that there may be even more alternatively
spliced forms of MBP mRNAs than have been reported. For example in a 
study carried out by Aruga et al. (1991) two myelin basic protein mRNAs 
were identified that had a novel internal exon (5a) that could putatively 
encode a 19.7 kDa and a 21 kDa myelin basic protein utilising exons 1b, 2,
3, 4, 5a, 5b and7 and exons 1 b, 3, 4, 5a, 5b, 6 and 7 respectively. Exon 5a 
encodes 22 amino acid residues, which contain six valines, and forms a 
hydrophobic domain; therefore, the 21 kDa myelin basic protein (including 
exon 5a) might form a similar structure to that of the 18.5 kDa MBP.
Kitamura et al., (1990) also identified an isoform utilising exons 0, 1a, 1b, 3,
4, 5, and 7, which encodes a 14 kDa myelin basic protein.
Complementary DNAs have been isolated that encode two different 
17 kDa MBP isoforms that are so close in molecular mass that the 
corresponding proteins would be indistinguishable by SDS polyacrylamide 
gel electrophoresis. However, from the abundance of the two 17 kDa MBP 
cDNA clones in a cDNA library, it appears that one of the isoforms is present 
in greater abundance than the other at 18 days of postnatal development. Of 
five cDNA clones encoding a 17 kDa mouse MBP isolated in one study one 
was missing exons 2 and 5 and four were missing exon 6 (Newman et al., 
1987a).
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Figure 3. MBP gene and transcript structures.
The alternatively excised exons are shaded.
52 corresponds to the transcriptional start site for embryonic MBP gene 
transcripts.
53 represents the transcriptional initiation site of the ‘classical’ MBP gene 
transcripts.
(AfterZelenika etal., 1993).
The sizes of the exons are exaggerated and are not necessarily
proportional.
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All the MBP mRNA structures published to date contain a relatively 
short 5’ untranslated region (<48 nucleotides) and a very long 3’ 
untranslated region (>1 kb). On Northern blots, the ‘classical’ MBP mRNAs 
migrate as a broad band of approximately 2.0 to 2.4 kb, presumably 
reflecting the heterogeneity of the MBP mRNA population. There are two 
polyadenylation signals near the 3’ end of both mouse and human MBP 
mRNAs. In addition, there is a second AUG codon in the 5’ untranslated 
region 5 bases upstream of the initiator codon, which is immediately followed 
by a termination codon. This structural feature has been postulated to 
explain the poorer translation initiation efficiencies exhibited by MBP mRNAs 
relative to brain mRNAs as a whole (Campagnoni etal., 1987).
1.2. Myelin Basic Protein gene transcription
1.2.1.Transcriptional control of gene expression
The first step in gene expression is RNA synthesis (which takes place 
in the nucleus). RNA polymerase II catalyses transcription of mRNA from the 
5’ to the 3’ direction and uses the non-coding (antiparallel) strand of DNA as 
a template. Transcription can be divided into three stages, initiation, 
elongation and termination. In order for a gene to be expressed it must be 
placed under the control of a promoter. Promoters are relatively short 
sequence elements usually located in the immediate upstream region of the 
gene, relative to the transcription start site, and serve to initiate transcription
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i.e. the site at which RNA polymerase initially binds to the DNA. Initiation of 
transcription requires the binding of protein factors (fra/?s-acting transcription 
factors) to cis-acting regulatory nucleic acid sequences.
The structure of a typical eukaryotic promoter comprising up to four distinct 
transcriptional control regions, the core promoter, upstream promoter 
elements, regulatory elements and enhancer elements is shown 
schematically in Figure 4.
RNA polymerase II is responsible for transcribing the genes encoding
polypeptides and certain species of snRNA genes (important for splicing).
RNA polymerase II is dependent on general transcription factors such as
TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH. In promoters containing a
TATA box TFIID binds to this element and protects a region from -35 to -19
bases upstream of the transcription start site. The binding of TFIID to the
TATA box is the earliest step in the formation of a stable transcriptional
complex, such binding being facilitated by TIIFA. TFIIA may also play a role
in the response to transcriptional activators, acting as a co-activator
molecule linking DNA-bound activators and the basal transcriptional
complex. TFIIB joins the complex by binding to TFIID. This binding of TFIIB
is an essential step in initiation complex formation since TFIIB can also bind
to RNA polymerase II; hence, it acts as a bridging factor allowing the
recruitment of RNA polymerase to the complex in association with TFIIF.
Following the binding of RNA polymerase II, three other transcription factors
(TFIIE, TFIIH and TFIIJ) associate with the complex. At this point TFIIH,
which has DNA helicase activity, unwinds the double-stranded DNA allowing
it to be copied into RNA. Subsequently, the kinase activity of TFIIH
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phosphorylates the C-terminal domain of RNA polymerase II, which converts 
it to the phosphorylated form, which is capable of transcriptional elongation 
to produce the RNA product. This complex of polymerase and general 
transcription factors is known as the basal transcriptional complex, therefore, 
TFIIH via its helicase and kinase activities plays a crucial role in allowing the 
basal transcriptional complex to initiate transcription. Genes are 
constitutively expressed at a minimum rate determined by the core promoter, 
unless altered by additional positive or negative regulatory elements. Core 
promoter elements are usually located close to the transcription initiation 
site, from nucleotide positions -40 to +40, and include elements such as the 
TATA box (consensus sequence TATA(A/T)A(A/T) located at approximately 
position -25). If a promoter does not contain a TATA box (e.g. housekeeping 
genes) an order of bases in the region covering the start site is recognised 
by the transcriptional machinery as the transcription initiator region.
Upstream promoter elements are typically located from nucleotide positions 
-50 to -200 relative to the transcription start site, and include multiple 
recognition sites for some sequence-specific ubiquitous transcription factors 
e.g. GC or Sp1 boxes (consensus sequence GGGCGG) and CCAAT boxes 
(consensus sequence GGCCAATCT typically located at nucleotide position 
-75 and recognised by the protein factor CTF or NF-1). GC and CCAAT 
boxes serve to up-regulate basal transcription of the core promoter.
Regulatory elements function to modulate transcription in response to
specific external stimuli (inducible gene expression) and are located
upstream of the promoter usually within 1 kb of the transcription start site
e.g. glucocorticoid response elements (GRE) or cyclic-AMP response
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elements (CRE). Small hydrophobic hormones e.g. the steroid hormones 
diffuse through the plasma membrane of the target cell and bind to 
intracellular receptors in the cytoplasm or the nucleus. These receptors are 
inducible transcription factors. Following binding of the ligand, the receptor 
protein associates with a specific DNA response element e.g. the 
glucocorticoid response element (GRE) located in the promoter of the target 
gene and activates transcription. In the absence of the ligand, the receptor is 
inactivated by direct repression of the DNA-binding domain by the ligand- 
binding domain or by binding to an inhibitory protein as in the case of the 
glucocorticoid receptor.
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Figure 4. Schematic representation of a typical eukaryotic promoter 
showing distinctive transcriptional control elements.
(After Latchman, 1998)
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The second messenger cyclic-AMP is synthesised from ATP by 
adenylate cyclase (a membrane bound enzyme). Binding of a hormone e.g. 
epinephrine to the cell surface receptor promotes the interaction of the 
receptor with a G protein. This results in the activation of the a subunit of the 
G protein causing it to dissociate and activate adenylate cyclase. The 
increase in intracellular cAMP activates the transcription of specific target 
sequences containing the cAMP response element (CRE). This function of 
cAMP is mediated by protein kinase A. Cyclic AMP binds to protein kinase A 
and activates it by releasing two catalytically active subunits which enter the 
nucleus and phosphorylate a specific transcription factor CREB (CRE- 
binding protein). Activated CREB activates the transcription of genes with 
the cAMP response element.
Enhancers are positive regulatory elements serving to increase the basal 
level of transcription that is initiated through the core promoter irrespective 
of their position and orientation.
Some genes encoding polypeptides are housekeeping genes,
however, a large percentage of genes transcribed by RNA polymerase II
show tissue-specific expression patterns. Since the DNA in different
nucleated cells of an individual is essentially identical, the identity of a cell is
defined by the proteins made by the cell. Therefore, tissue-specific
transcription factors regulate the expression of many genes that encode
polypeptides by recognising and binding specific c/s-acting sequence
elements. Tissue-specificity and developmental-stage specificity of gene
expression are frequently conferred by enhancer and silencer sequences
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and a variety of c/s-acting sequences have been identified which are 
specifically recognised by tissue-specific transcription factors. In addition to 
actively promoting tissue-specific transcription, some c/s-acting silencer 
elements confer tissue or developmental stage specificity by blocking 
expression in all but the desired tissue e.g. the neural restrictive silencer 
element (NRSE) represses the expression of several genes in all tissues 
other then neural tissue (Schoenherr eta l., 1996). A transcription factor 
binding to NRSE and called the neural restrictive silencer factor (NRSF) or 
RE-1 silencing transcription factor (REST) is ubiquitously expressed in non- 
neural tissue and neuronal precursors during early development but 
specifically not expressed in postmitotic neurons.
Transcription factors recognise and bind to short nucleotide 
sequences generally as a result of very specific molecular recognition 
between the surface of the protein and surface features of the DNA double 
helix. In eukaryotic transcription factors two functional domains have been 
identified, one for DNA-binding and one for transcriptional activation, that 
retain their function when removed from their natural context. The DNA- 
binding domains of transcription factors fall into several conserved structural 
motifs e.g. helix-turn-helix, helix-loop-helix, zinc finger and basic DNA 
binding domain. Each of the motifs use a-helices (or occasionally p-sheets) 
to bind to the major groove of DNA. Transcription factors bind to DNA as 
either homodimers or heterodimers, with the DNA-binding region of the 
protein distinct from the region responsible for forming dimers. The activation 
domain functions in activating transcription of the target gene once the
transcription factor has bound to the promoter.
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Zinc finger proteins are so called because of their structure, in which 
an atom of zinc tetrahedrally coordinates the repeated cysteine and histidine 
(or four cysteine) residues that form the base of a loop of twelve amino acids 
containing conserved leucine and phenylalanine residues, as well as several 
basic amino acids. The zinc finger motifs have been shown to constitute the 
DNA-binding domain of the protein, with DNA-binding being dependent on 
their activity. Most notable among the zinc finger proteins are Sp1 and the 
steroid receptor family.
The helix-turn-helix motif is a common motif found in homeoboxes and 
a number of other transcription factors. It consists of two short a-helices 
separated by a short amino acid sequence that induces the turn. It is thought 
that while the HTH motif in general mediates DNA binding, the more C- 
terminal helix acts as a specific recognition element fitting into the major 
groove of the DNA and controlling the precise DNA sequence that is 
recognised.
Leucine zipper proteins derive their name from a helical stretch of
amino acids rich in leucine residues precisely seven amino acids apart.
However, unlike the zinc finger or helix-turn-helix motifs the zipper itself is
not the DNA-binding domain of the molecule and does not directly contact
the DNA. Rather it facilitates DNA binding by an adjacent region of the
molecule, which is rich in basic amino acids and can therefore interact
directly with the DNA. The leucine zipper is believed to serve an indirect
structural role in DNA binding, facilitating dimerisation, which in turn results
in the correct positioning of the two basic DNA-binding domains in the
dimeric molecule for DNA binding to occur. Hence the DNA-binding
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specificity of the leucine zipper-containing transcription factors is determined 
by the sequence of their basic domain with the leucine zipper allowing 
dimerisation to occur. As expected with this notion, the basic DNA binding 
domain can interact with DNA in a sequence-specific manner in the absence 
of the leucine zipper, if it is first dimerised via an inter-molecular disulphide 
bridge. The helix-loop-helix (HLH) motif plays a similar role to the leucine 
zipper family allowing dimerisation of the transcription factor molecule (as 
either homodimers or heterodimers), and thereby facilitating DNA binding by 
the basic domain.
1.2.2. Tissue specific expression of the MBP gene
Non-typical TATA and CAAT boxes are present in the MBP promoter,
located at positions -34 and -85 bp respectively and a non-typical GC box
sequence has been identified at position -92 bp from the transcriptional
initiation site at +1. The TATA box-like sequence is indispensable for the
promoter function. Tamura etal., (1988) suggested that the GC box
functions co-operatively with upstream sequences including the myelin basic
protein transcription element (MBTE) a cis-acting element located between
nucleotide positions -130 to -106 relative to the transcription initiation site.
The MBTE was crucial to direct maximal transcription, and also functioned
with a heterologous promoter in a direction-dependent manner. Tamura et
al., (1988) identified a ubiquitous binding factor, which interacted specifically
with the MBTE and activated transcription. Intensive footprinting studies
(Tamura etal., 1988) demonstrated that the MBTE had an NFI-binding
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sequence. The MBTE was considered to be one of the strongest NFI-binding 
motifs among known cellular genes. Interestingly, similar strong NFI-binding 
motifs are present in the enhancer of JC virus whose genes are expressed, 
like the MBP gene in the nervous system.
By fusing segments from different regions of the 1.3 kb 5’ flanking
region to the chloramphenicol acetyltransferase (CAT) reporter gene it has
been observed that the proximal regulatory sequence from -50 to -14 bp
(which includes the TATA box-like sequence) constitutes the basal
transcription element (Asipu and Blair, 1994; Devine-Beach etal., 1992, and
Tamura et al., 1990). The myelin basic protein promoter also contains a
number of DNA specific c/s-acting elements, which interact with specific
trans-acting factors (DNA binding proteins) present in both oligodendrocytes
(OL) and Schwann cells (SC). The interactions of these factors, with each
other and with the RNA polymerase II initiation complex, directly regulate the
tissue-specific and developmental expression of MBP mRNA. Proof that
specific DNA sequences within the MBP gene can support tissue-specific,
developmentally regulated MBP gene expression has been demonstrated in
vivo by the construction of transgenic mice carrying an MBP transgene.
Kimura etal. (1989) used an MBP transgene consisting of 1.3 kb of the MBP
5’ flanking sequence fused to an MBP cDNA encoding the 14 kDa MBP
isoform to demonstrate that the transgene was expressed predominantly in
the brain in a tissue-specific manner. Tamura et al. (1989) reported specific
transcription from the MBP promoter in brain nuclear extracts. They also
observed that there are no differences between mouse and rat brain nuclear
extracts in specific transcription of the MBP gene. Tamura etal. (1989)
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divided the MBP promoter into two domains referred to as the distal
promoter from -253 to -54, and the proximal promoter from -53 to +60. The
distal region was able to direct tissue-specific transcription when linked to
the heterologous adenovirus type 2 major late core promoter, suggesting
that the distal region contains some tissue-specific c/s-acting elements and
that the brain is rich in the cognate trans-acting factors. The MBP distal
promoter region appears to function in a direction-dependent manner. Only a
native orientation of the distal region linked to the major late core promoter
or the MBP proximal promoter can enhance transcription in brain-derived
nuclear extracts. Cooperative interaction of transcription factors in the distal
and proximal regions may be required for tissue specific transcription.
Alternatively, inhibitory sequences in an upper part of the distal region may
contribute to the different profiles of transcription activation. Transcriptional
inhibitory sequences associated with the distal region may be dominant in
non-expressing tissues. Wrabetz etal. (1993) transfected primary cultures of
both oligodendrocytes and Schwann cells, as well as a number of cell lines
not expressing MBP, with a series of human MBP promoter-CAT reporter
gene constructs and monitored CAT activity as a measure of MBP promoter
activity. They demonstrated in both OL and SC that the 150 bp region
upstream of the MBP cap site is enough to promote CAT expression in a cell
type-specific manner, and that this expression is mediated by multiple
positive and negative acting modules. Wrabetz etal. (1993) also confirms
the results of Tamura etal. (1989) that the MBP distal promoter region
functions in an orientation-dependent manner. These transfection studies
suggested that there are cell type-specific fra/?s-acting factors present in
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both OL and SC that interact with specific DNA sequences within the first
150 bp of the MBP promoter region to increase MBP transcription thereby
contributing to the tissue-specific developmental^ regulated expression of
MBP. Work carried out by Asipu and Blair (1994 and 1998) showed that cell-
type specific transcription of the MBP gene in primary oligodendrocytes (OL)
and Schwann cells (SC) is regulated by c/s-acting regulatory elements both
upstream and downstream of the TATA-like box region of the MBP promoter.
The cell-type specific regulatory elements were defined using constructs
containing varying lengths of the 5’ flanking region and exon 1 of the MBP
gene linked to the CAT reporter gene followed by transfection into several
cell types e.g. primary cultures of differentiated OL, SC, and neuronal and
non-neuronal cell lines. Several upstream cis-acting regulatory elements
were identified, with sequences located between nt -655 to -397(including
the region between nt -609 to -577 studied in this project) and nt -394 to
-54 showing enhancer and repressor effects respectively in
oligodendrocytes. Whereas, in Schwann cells the sequence located between
nt -394 to -253 showed a positive regulatory effect whilst those between nt
-655 to -397 and -253 to -54 showed negative regulatory effects.
Downstream cis-acting regulatory elements were identified between nt
positions +20 to +70 and +70 to +200 showing strong silencer and enhancer
activities respectively, specifically in oligodendrocytes (Asipu and Blair
1994). The expression of MBP is therefore controlled by basal positive
regulatory elements which function in different cell types, but both positive
and negative regulatory elements located on either side of the basal
promoter play an essential role in regulating the transcription of MBP in
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myelin-forming oligodendrocytes (Asipu and Blair 1994). To identify the cell- 
type specific factors binding to the downstream (relative to the transcription 
initiation site) regulatory elements in more detail Asipu and Blair used 
DNase I footprinting analysis and gel retardation assays (EMSA). Two 
regions from nt -17 to +17 and +47 to +58 were protected specifically in 
oligodendrocytes whereas three regions nt +17 to +22, +43 to +49 and +58 
to +64 were protected only with C6 nuclear extracts. Analysis of the 
protected regions for homology with known transcription factor binding sites 
showed the sequence between +47 to +58 and +56 to +68 had extensive 
homology to the negative regulatory element of the mouse rennin gene and 
to the interferon (IFN) consensus sequence of the MHC class I genes 
respectively. Several other frans-acting factors have been identified binding 
to the c/s-acting regulatory elements (both upstream and downstream of the 
TATA-like box region of the MBP promoter) and these include: the thyroid 
hormone a-receptor (TRa) at nt -209 to -169 (Farsetti et al. 1992 and Asipu 
and Blair 1997), the M1 factor from mouse brain and rat liver extracts at nt 
-110 to -97 (Aoyama et. al. 1990), the Ets-consensus sequence at nt +31 to 
+39 (Farsetti et al. 1992), the viral (adenovirus, polyoma) enhancer 
sequences and the human p-interferon regulatory element between nt +41 to 
+48 (Goodbourn et al. 1986). Other regulatory sequences have been 
identified which show homology to previously identified prokaryotic and 
eukaryotic transcription factor binding sites e.g. the PEA3-consensus site 
(AGGAGG) at nt position -283, the E coli MalT binding site and the PER3 
site of the mouse peripherin promoter at nt -216 (Desmaris et al. 1992) and
the AP1 transcription factor binding site at nt -93.
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The golli-mbp gene has multiple promoters; as a result the developing 
brain appears to make use of these multiple promoters to control the 
transcriptional initiation site, to confer tissue-specific and developmental^ 
regulated expression of the MBP gene. Expression initiated by one promoter 
also appears to regulate the expression from a different promoter (Schibler 
and Sierra, 1987). The promoter controlling the transcriptional initiation site 
S3 (Figure 2) located between golli-mbp exons 5a and 5b is active in the 
brain during myelination. Evidence currently available from studies in mice 
suggest the golli-mbp gene is transcribed into at least three primary 
transcripts (Campagnoni etal., 1993), with each primary transcript 
undergoing alternative splicing resulting in three sets of mRNA transcripts. 
Each transcript is of a different length and also differs in spatial and temporal 
expression. For example, the Gi primary transcript undergoes alternative 
splicing of golli-mbp exons G5a, 5b, 6, 9 and 10 with the resulting transcripts 
covering the size range 2.3 to 5.1 kb. These mRNA transcripts are generally 
expressed from the embryonic to the neonatal period. The 5.1 kb mRNA 
transcript is expressed from the embryonic state to the early post-natal 
period. The 2.3 to 2.6 kb mRNA isoforms are expressed post-natally and 
then follow the developmental profile of the 5.1 kb mRNA. Expression of 
these mRNA transcripts is not solely confined to the brain but they are also 
expressed in several other tissues including the bone marrow, thymus, 
spleen, heart, kidney and lung. It is thought that in the case of myelin basic 
protein gene transcription, inhibition may be relieved at the onset of 
myelination when a specific trans-acting factor(s) is activated from the S3 
initiation site.
1.3. Developmental changes in Myelin Basic Protein 
expression
With development, myelin isolated from the brains of mice and rats is 
increasingly enriched in the major myelin proteins relative to the higher 
molecular weight polypeptides. In addition it has been consistently noted 
that the 14 : 18.5 kDa ratio of MBP isoforms increased considerably with age 
(Campagnoni and Macklin, 1988). No clear consensus has emerged with 
respect to changes in the ratio of proteolipid proteins to basic proteins with 
development (Campagnoni and Macklin, 1988).
Developmental studies on the expression of myelin proteins in whole 
brain have largely fallen into two categories:
(a) those measuring changes in the myelin proteins either through 
biochemical isolation of the protein or immunoblot analysis;
(b) those measuring synthesis of the myelin proteins in vivo or in vitro 
(i.e. cell-free synthesis) or by titering the mRNAs with cDNA probes.
Clearly all these techniques reveal important information generally related to 
the expression of the myelin genes, but individual techniques measure 
different aspects of expression.
Investigators have used different criteria to define the order of 
expression of the myelin proteins. Some workers have attempted to rely on 
the earliest age at which a protein could be detected to determine its order of 
expression, however, differences in the sensitivities of the antibodies, or the 
specific activities of cDNA probes could lead to misleading results. Another 
complication is the finding that alternative splicing mechanisms may 
generate related but not identical mRNAs containing common sequences but
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encoding different proteins. Therefore, early detection of mRNAs hybridising 
to myelin protein cDNAs may be detecting structurally related but not 
identical mRNAs. The same problems exist with antibodies that might react 
with related but separate proteins.
The extent of the multiplicity of the MBP isoforms was not fully 
appreciated until immunochemical and recombinant DNA approaches were 
used to study the problem. In the late 1970s, immunochemical techniques 
revealed the presence of four major mouse MBPs with apparent molecular 
masses of 14, 17, 18.5 and 21.5 kDa (Barbarese etal., 1977). Subsequent 
work using immunoblots of the whole brain to measure the different MBP 
isoforms, and cell-free synthesis of brain mRNA to measure the levels of 
individual MBP mRNAs indicated that each isoform exhibited its own 
developmental pattern of expression and accumulation (Carson etal., 1983).
Sequence analysis has proved that the rat 14 kDa MBP was 
structurally similar to the 18.5 kDa bovine and human MBPs except for the 
deletion of a 40- amino acid sequence within the interior of the molecule. In 
retrospect, there was evidence for the presence of other MBP variants 
(Agrawal et al., 1986, and Sorg et al., 1986) but it was difficult to rule out the 
possibility that these were degradation products of genuine MBPs.
From studies carried out during the late 1980s other MBP isoforms
have been identified for example, a second mouse 17 kDa MBP has been
identified (Newman etal., 1987a). This second 17 kDa MBP is apparently
the only form present in humans (Kamholz etal., 1986; Roth etal., 1986;
Roth et al., 1987 and Deibler et al., 1986). A 20 kDa MBP has been
identified in foetal human spinal cord, and immunoblots suggest it exists in
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other species as well (Kerlero de Rosbo etal., 1984) although it may be 
more prevalent in some regions of the CNS than others (Newman et al., 
1987b, Nakajima etal., 1993). In rat brain, Agrawal et a /(1986) have 
identified a 23 kDa phosphorylated protein that is immunologically related to 
MBP. Immunoblots of whole brain homogenate with both polyclonal (Carson 
etal., 1983) and monoclonal (Bansal etal., 1987) anti-myelin basic protein 
antibodies indicate the presence of higher molecular weight immunoreactive 
proteins. The structural relationship among all these proteins and the better- 
characterised MBP isoforms is not clear at the present time.
In the course of studying promoter activity in primary cultures of brain 
cells Nakajima etal. (1993) found that the myelin basic protein gene was 
expressed in brain cells obtained from embryonic mice at a very early stage 
of neural development, i.e., as early as embryonic day 12 (E12). The 
predominant myelin basic protein isoforms in the embryonic stage were 
identified as exon 5-deleted forms, and peaked during the late embryonic 
stage (days E15 to E18) and decreased to very low levels at postnatal day 
18 (P18). The cell type producing the early embryonic myelin basic proteins 
(days E12 to E14) remains to be clarified. If, however, the myelin basic 
proteins are produced in cells of the same cell lineage as those producing in 
the later stage, there may be a group of cells that are committed to generate 
oligodendrocytes later and produce the MBPs. The existence of this type of 
committed cell at this early stage of development has been suggested by 
Luskin et al. (1988).
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1.4. Sites of myelin protein synthesis and transport to the 
membrane
The majority of evidence favours the view that the myelin basic proteins are 
synthesised on free polysomes, (Campagnoni etal., 1980, Campagnoni, 
1985, Brophy etal., 1993) and that the proteolipid proteins are synthesised 
on membrane bound ribosomes (Benjamins and Morell, 1987, Colman etal., 
1982). Neither the MBP nor the PLP are synthesised with “signal” (or 
“leader”) sequences.
The subcellular trafficking pathway for MBP mRNA in the
oligodendrocyte has been defined using micro-injection experiments (Ainger
etal., 1993) and involves three discrete steps: (a) assembly of the RNA into
granules in the perikaryon, (b) transport along cellular processes and (c)
localisation to the myelin compartment. Ainger et al., (1997) have identified
specific regions in the 3’ untranslated region (UTR) of myelin basic protein
mRNA that are required for the latter two steps. The first region is the RNA
transport signal (RTS), which is a 21-nucleotide sequence that is required
for transport of mRNA along oligodendrocyte processes. The second region
is the RNA localisation regions (RLR) and is necessary for localisation of
MBP mRNA to myelin. This region may be implicated in stabilising or
anchoring MBP mRNA in the myelin compartment of the oligodendrocyte
(Ainger etal., 1997). The presence of the RTS in oligodendrocyte process
localised isoforms of myelin oligodendrocyte basic protein (MOBP) 18A RNA
suggests the RTS functions to target the expression of other proteins, in
addition to MBP, in oligodendrocytes (Holz etal., 1996). If the RTS
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represents a cis-acting transport signal, which is conserved in different 
RNAs, it most probably interacts with a cognate trans-acting factor that is 
expressed in different cell types. In vitro binding experiments indicate that 
the RTS sequence specifically interacts with hnRNP A2, a member of a 
family of heterogeneous nuclear ribonucleoprotein (hnRNP) proteins that 
shuttle between the nucleus and cytoplasm (Hoek etal., 1998, Kwon etal., 
1999, Shan etal., 2000). This suggests that hnRNP A2 binding to the RTS is 
required for the transport of RTS containing RNA in oligodendrocytes 
(Ainger etal., 1997). Localisation involves translocation from the 
oligodendrocyte processes to the myelin; this apparently involves 
dissociation from the transport apparatus in the processes and in the case of 
coding mRNAs association with the translational machinery in the myelin 
compartment. Translocation across the boundary between these two 
compartments is RLR dependent for coding RNA and RLR independent for 
non-coding RNA. A possible explanation for this could be that coding RNA 
associates with ribosomes, making translocation RLR dependent, while 
translocation of ribosome-free non-coding RNA is RLR independent (Bacher 
etal., 1996). The RNA localisation regions contain a predicted stable 
secondary structure at a conserved position in rat, mouse and human MBP 
mRNA (Ainger etal., 1997). Endogenous MBP RNA-containing granules in 
oligodendrocytes contain many components of the translational machinery, 
suggesting they also represent the unit of RNA translation. Therefore, the 
granule represents a common unit for transport, localisation and translation 
of RNA (Barbarese et al., 1995).
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1.5. Translational and Post-Translational Events
Cell-free synthesis studies have shown that the myelin basic protein 
mRNAs are poorly initiated during translation relative to the other brain 
mRNAs as a whole, and this appears to be related to the presence of an 
additional translational initiation signal within the 5’ untranslated region of 
the MBP mRNAs which is immediately followed by a termination signal 
(Campagnoni etal., 1987a). The role of post-translational modification such 
as acylation, phosphorylation, methylation, glycosylation, acetylation, 
deamidation, and attachment of fatty acids has been shown to play a 
significant role in directing the function of various proteins. In CNS myelin 
basic protein, these post-translational modifications include: the methylation 
of a specific arginine residue, the phosphorylation of specific serine and 
threonine residues, the acylation of the N-terminal amino acid, the 
deamidation of a glutamine residue and the conversion of arginine residues 
to citrulline by the enzyme peptidyl arginine deiminase.
1.5.1. Methylation
Myelin basic protein has an unusual amino acid at residue-107, a 
mixture of NG-monomethylarginine and NG, N’G-dimethylarginine. The 
formation of these methylarginine derivatives is catalysed by one of the 
protein methyltransferases, utilising S-adenosyl-L-methionine as the methyl 
donor. It is now apparent that each protein methyltransferase with a 
specificity towards any given amino acid residue can be further subclassified
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according to the specific methyl acceptor protein (Kim etal., 1997). Protein 
methylase I is one such enzyme, however, it is only recently that 
unequivocal molecular evidence for the presence of subclasses of the 
enzyme e.g. MBP-specific and nuclear protein/histone-specific has been 
obtained (Ghosh etal., 1988, Rajpurohit etal., 1994). The NG- 
methylarginines occur in nature in a limited number of highly specialised 
proteins such as MBP, nuclear and contractile proteins. The reaction is very 
specific for the amino acid sequence around the methylation site, e.g. among 
18 arginine residues in MBP, only the arginine at residue-107 (in the 
sequence Lys-Gly-Arg-Gly-Leu) is present as a mixture of MMeArg and 
Di(sym)MeArg. Park etal., (1986) demonstrated that the histone specific 
protein methylase I was incapable of methylating MBP and was inhibited by 
MBP. The activity of the MBP-specific methylase has been observed to be 
abnormal in both the jimpy and shiverermouse mutants (Kim etal., 1984, 
and Kim etal., 1986).
Multiple sclerosis is one of the demyelinating diseases in humans and 
as a result of this myelin basic protein is dissociated from the membrane. 
MBP fragments formed by intracellular proteolysis and free amino acids find 
their way into the body fluids (Park et al., 1986). Since methylarginines are 
not reutilised for in vivo protein synthesis, it would appear practicable to 
assess myelin abnormalities by analysing urinary concentrations of these 
methylarginines and MBP-like material in multiple sclerosis patients 
(Whitaker etal., 1993, 1994).
The specific location of methylarginine in MBP (residue-107), together
with the chemical nature of hydrophobicity enhanced by methylation, has
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been implicated in helping to stabilise the myelin structure (Park et al.,
1986). Cells treated with a methylation inhibitor e.g. sinefungin produced a 
membrane structure lacking compactness which resembled vitamin B12- 
deficient myelin with a concomitant reduction in MBP-protein methylase I 
activity (Kim etal., 1997).
It is of interest that the only methylated amino acid residue (residue- 
107) in MBP identified to date lies within the region of the protein encoded 
by exon 5. Therefore, presumably the 20 and the 17 kDa MBP (missing 
exons 2 and 5) and present in the very early stages in the developing human 
spinal cord, are incapable of being methylated.
1.5.2. Phosphorylation
Phosphorylation is a ubiquitous post-translational modification of 
proteins, which is particularly prominent in nervous tissue. Myelin has 
traditionally been regarded as metabolically inert with a wholly structural 
role. However, recent findings indicate it possesses biochemical components 
associated with signal transduction in which protein phosphorylation plays a 
significant part (Eichberg and Iyer, 1996). The myelin basic proteins possess 
multiple consensus sequences for phosphorylation by cyclic AMP-dependent 
protein kinase (PKA) and protein kinase C (PKC). In fact MBP has been 
shown to be a substrate for Ca2+-calmodulin-dependent protein kinase, 
glycogen synthase kinase-3 (known as protein kinase FA) and mitogen 
associated protein (MAP) kinase (Yung, 1986, Yu and Yang, 1994, Hickson
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etal., 1990). Variable phosphorylation is responsible in part for the charge 
microheterogeneity of myelin basic protein e.g. the phosphorylation of thr97 
in bovine MBP has been shown to increase conformational order for the 
protein in aqueous solution which is consistent with the stabilisation of the p- 
pleated sheet structure (Deibler et al., 1990). The dynamic state of the 
phosphate groups suggests that phosphorylated MBP would be 
concentrated in non-compacted areas of myelin with close proximity to the 
cytoplasm (Des Jardins and Morell, 1983).
The introduction of negative charges by phosphorylation of the major 
myelin proteins during deposition may create electrostatic repulsion between 
adjacent proteins or between proteins and neighbouring acidic lipids. 
Phosphorylation of MBP may in part serve this purpose, a notion supported 
by the finding that protein phosphorylation activity is inversely proportional to 
the degree of myelin compaction (Deibler et al., 1990).
In mature myelin, it would be expected that the protein kinases would
be concentrated in the regions of myelin closest to a supply of cytosolic ATP,
i.e. the outer, inner and lateral loops in CNS myelin and the paranodal loops
and Schmidt-Lanterman clefts in PNS myelin. This would suggest that the
fraction of myelin protein molecules undergoing phosphorylation would be
confined to a population resident in these regions, and that in the case of
MBP and P0, this proportion would be small. However, evidence suggests
the turnover of phosphate groups in both these proteins occurs in compact
myelin, suggesting that the myelin structure may be less rigid than generally
assumed so that cytoplasmic components may gain at least limited access
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throughout (Lowery et al., 1989, Ledeen, 1992). In fact, in mature myelin, the 
extent of protein phosphorylation may modulate the penetration of cytosolic 
constituents between myelin lamellae. An indication of a possible functional 
relationship between cell signalling mechanisms and myelin protein 
phosphorylation is provided by the finding that cultured oligodendrocytes 
subjected to hypoxic conditions show evidence of an 80% decrease in MBP 
and CNPase phosphorylation, as well as a failure of agonist stimulated PLC- 
mediated phosphinositide breakdown (Qi and Dawson, 1993). Nevertheless, 
the remaining phosphorylating ability retains its sensitivity to stimulation by 
phorbol esters, suggestive of PKC activity. Eichberg and Iyer (1996) 
therefore conclude that diminished MBP and CNPase phosphorylation may 
result from impaired signal transduction via heterotrimeric GTP binding 
proteins and as a result such a mechanism may contribute to the 
vulnerability of myelination to hypoxia.
1.5.3. Deimination
Deimination of myelin basic protein has been implicated in the
chemical pathogenesis of multiple sclerosis. Degradation of bovine myelin
basic protein by cathepsin D, a myelin-associated protease, was increased
when 6 arginyl residues were deiminated and became even more rapid when
all 18 arginyl residues were deiminated (Pritzker etal., 2000). Myelin basic
protein containing methylated arginine has been shown to increase the
association of lipid vesicles into dimers, signifying that methylated arginine
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may increase the interaction between MBP and the myelin lipids (Young et 
al., 1987). In subacute combined degeneration (SCD) of the spinal cord in 
humans, demyelination results from a deficiency in vitamin B12, which 
decreases the amount of S-adenosyl-L-methionine (the major methyl donor) 
with a subsequent decrease in the methylation of MBP (Surtees, 1993). The 
conversion of arginine to citrulline by the enzyme peptidylarginine deiminase 
has been implicated in demyelination in multiple sclerosis (Moscarello etal.,
1994). In addition, the severity of MS has been correlated with the number of 
arginine residues converted to citrulline in MBP (Wood etal., 1996). Pritzker 
etal., (2000) show that human MBP isolated from normal and MS white 
matter contained greater amounts of citrulline in MBP in which the proportion 
of unmethylated arginine-107 was increased.
1.6. Myelin Protein Gene Expression in Cultured Cells
Myelin protein gene expression has been studied in a variety of
cultured cell systems. Primary cultured oligodendrocytes differentiate to
produce galactosyl ceramide (GC), CNP, MBP, PLP, and other myelin
markers in the apparent absence of any neural signals, their differentiation
process in vitro is somewhat more “plastic” than in vivo, and differences
among studies may result from this plasticity. An important early element of
this plasticity is whether the oligodendrocyte will differentiate from its
progenitor cell. Raff et al., (1983) reported the existence of a cell type in rat
optic nerve primary cultures, which can differentiate into a type 2 astrocyte in
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the presence of foetal calf serum or into an oligodendrocyte in defined media 
with no foetal calf serum. This oligodendrocyte progenitor cell appears to 
stop dividing and begin to differentiate into oligodendrocytes or type 2 
astrocytes within 2 to 3 days in culture whereas in vivo, these progenitor 
cells continue to divide (Raff etal., 1983 Temple and Raff, 1985).
From studies on mixed glial cultures, it has been possible to 
determine that the rat oligodendrocyte progenitor cells (by the late foetal 
period) are committed to express myelin markers two or three weeks later in 
culture. Neurons are not required to induce the synthesis of MBP, PLP,
CNP, GC, or cerebroside sulphotransferase (McCarthy and deVellis, 1980; 
Pfeiffer etal., 1981b, Dubois-Delacq etal., 1986). During the early stages of 
myelination in vivo studies have shown that the 14 kDa MBP is expressed at 
lower levels than the 18.5 kDa MBP. With development, the ratio of the 14 :
18.5 kDa MBP increases significantly until the 14 kDa isoform predominates. 
In contrast in culture the 14 kDa MBP is expressed first, and it remains the 
predominant isoform up to 39 days in culture. However, the other isoforms 
accumulate from 27 - 39 days in culture (Barbarese and Pfeiffer, 1981). 
Conflicting results have been reported on the timing of MBP expression in 
cultured rat oligodendrocytes (Pfeiffer et al., 1981b, Dubois-Delacq etal.,
1986); however, a possible explanation for the differences may provide 
insight into the regulation of MBP expression.
Rat oligodendrocytes in mixed glial cultures express approximately
20-fold more MBP and CNP per oligodendrocyte than do isolated
oligodendrocytes purified away from astrocytes and other cells in the mixed
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culture (Bhat etal., 1981). When the isolated oligodendrocytes are added 
back to the astrocyte-containing cultures, they express the higher levels of 
MBP and CNP. This suggests that the presence of cell(s) and / or factor(s) in 
mixed primary glial cultures plays some role in regulating the expression of 
these two myelin components. Bhat and Pfeiffer (1986) established that a 
soluble astrocyte factor(s), which is non-dialyzable, heat-labile, and trypsin- 
sensitive, enhances MBP and CNP expression in purified oligodendrocytes.
1.7. Gene Expression in Dysmyelinating Mutants
For two of the mutants, shiverer and jimpy, the mutation has been 
localised to the structural genes for the myelin basic protein and the myelin 
proteolipid protein, respectively (Roach etal., 1985, and Sidman etal.,
1985).
1.7.1. Shiverer (shi) and Myelin Deficient (shF!d)
The shiverer mutation (shi) and its allele myelin deficient (shr,d) 
(Doolittle and Schweikart, 1977 and Doolittle etal., 1981) are autosomal 
recessive, and map to the mouse chromosome 18 (Roach et al., 1985 and 
Sidman etal., 1985). These mice exhibit tremors beginning approximately at 
day 12 (postnatally), which become progressively worse. Convulsions 
appear in older animals and these animals do not survive past 90 days
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(Chernoff, 1981). Morphological analyses indicate that many axons have no 
myelin, and those that are myelinated have only low amounts of myelin. A 
striking feature of shiverer CNS myelin is the absence of the major dense 
line but the presence of the intraperiod line (Inoue etal., 1981). This 
suggests there is a greater loss of myelin basic protein in these animals than 
of proteolipid protein or of other proteins expressed on the extracellular 
surface of myelin. Biochemical analysis of shiverer tissue indicates 
essentially the total absence of myelin basic protein in shiverer brain (Bourre 
etal., 1980 and Barbarese etal., 1983). As with shiverer animals, shFId mice 
appear to have a major deficit in MBP. Myelin is poorly compacted, and the 
major dense line of myelin is essentially absent (Matthieu et al., 1980). 
However, more MBP (between 3% and 10% of normal levels) was observed 
in sh rId brains than in shiverer brains. The level of MBP mRNA in shFld mice 
was quite low, approximately 2 - 5% of normal in young animals, (Ginalski- 
Winkelman etal., 1983; Campagnoni etal., 1984; Roch etal., 1986 and 
Popko et al., 1987) but the size of the shFld MBP mRNA was normal, 2.2 - 
2.4 kb (Roch etal., 1986 and Popko etal., 1987).
It has been established that the shiverer and shFld mutations are 
within the structural gene for the myelin basic protein. The alleles map to the 
distal end of mouse chromosome 18, which contains the MBP gene (Doolittle 
and Schweikart, 1977; Roach etal., 1985 and Sidman etal., 1985). When 
the myelin basic protein gene in these mutants was analysed, clear 
alterations in the gene were identified. The shiverer mutation (Figure 5) 
results in a deletion of exons 3 to 7 of the MBP gene (Roach et al., 1983;
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Roach etal., 1985; Kimura etal., 1985 and Molineaux etal., 1986), and the 
production of low levels of MBP-related RNA. This MBP-related mRNA is 
aberrantly spliced and poorly polyadenylated. In contrast, in shFldmice, 
there appears to be a tandem duplication of exons 3 to 7 with the more 
upstream set of exons inverted (Figure 5). There is one complete MBP gene, 
and at least one extra-partial or complete gene that is closely juxtaposed to 
the complete MBP gene (Popko etal., 1987, Popko etal., 1988). Thus, it 
would appear that the partial or complete duplication of the MBP gene near 
a normal gene can reduce the expression of the normal gene to 2% of 
normal and alter the normal developmental expression of the gene.
Readhead etal., (1987) produced transgenic shiverer mice carrying 
one or two copies of the MBP transgene. The transgene is expressed in a 
tissue-specific manner with the correct developmental pattern. Shiverer mice 
carrying the MBP transgene produce more MBP mRNA and protein than the 
original shiverer mice, and they live longer, with a less severe disorder. 
However, shiverer mice carrying a single transgene produced approximately 
12.5% of normal MBP mRNA and 8.5% of normal protein, whereas mice 
homozygous for the transgene produced roughly twice as much mRNA as 
protein. The heterozygous transgenic mice survived longer than the original 
shiverer mice but they still had convulsions and died at approximately 6 
months. Homozygous transgenic mice appeared to be phenotypically closer 
to normal, for example, they had no tremors or convulsions, but some subtle 
behavioural abnormalities were observed. Despite the presence of only 25% 
of normal levels of MBP mRNA in the homozygous transgenic mice, the
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myelination of the optic nerve, spinal cord and cerebellar white matter was 
significantly increased relative to the heterozygous transgenic mice.
These studies with transgenic mice suggest that insertion of a normal 
MBP gene into the genome of mice carrying either a deletion or a duplication 
of the normal gene can produce a tissue-specific and developmental ly 
accurate expression of the transgene. However, the level of expression was 
not normal, since even with two copies of the transgene, only 25% of normal 
MBP mRNA was observed. The fact that the transgene was expressed at 
comparable levels in shiverer and sh rld mice suggests that the deleterious 
effect of the MBP gene duplication on MBP gene expression in sh rId mice is 
cis-acting, not trans-acting. Clearly the production of these transgenic mice, 
and the future use of these mice will provide new insight into myelin gene 
expression.
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Figure 5. Diagrammatic representation of golli-mbp gene structure in 
dysmyelinating mutant mice.
Shi, shiverer mouse where there is a deletion of MBP exons 3 to 7 
and mid, myelin deficient mouse, where MBP exons 3 to 7 are 
repeated with an inversion in the upstream gene, shown as exons 7 
to 3.
(After Asipu and Blair (1997) Regulation of transcription and translation in the central 
nervous system -  from Molecular Biology of Multiple Sclerosis.)
1.7.2. Jimpy (jp) and Myelin Synthesis Deficient {jpmsd)
The Jimpy mutation (/p) and its allele Myelin Synthesis Deficient 
Qpmsd) are recessive X-linked mutations. This is exclusively a central nervous 
system disorder with no PNS involvement. These mice exhibit tremors, which 
become progressively worse, beginning at postnatal day 11. Convulsions 
appear in older animals and these animals do not survive past 25 -  30 days. 
The MBP proteins are significantly reduced in jimpy mice, relative to normal 
animals (Delassale etal., 1981, Kerner and Carson, 1984). Delassale etal. 
(1981), found that the deficit in MBP in jimpy mice ranged from 94 - 98% in 
different regions of the jimpy brain at 25 days of age. When the distribution 
of the four major MBPs was studied, it appeared that in young jimpy mice, 
the deficit of the 21.5 kDa MBP was less than the deficit in the other three 
MBPs. The overall deficit in MBP accumulation in animals in this study was 
92% at all ages (Kerner and Carson, 1984). When MBP accumulation was 
compared in jimpy optic nerve and sciatic nerve, a significant reduction in 
MBP content was observed throughout development in the optic nerve, 
whereas no reduction was apparent in sciatic nerve (Jacque et al., 1983). 
Thus, there are differences in the regulation of the MBP gene in jimpy 
oligodendrocytes and Schwann cells. The level of MBP mRNAs was also 
measured in jimpy mice but with contradictory results Carnow et al., 1984).
In vitro translation studies by Campagnoni et al. (1984) indicated a
reduction in the level of all MBP mRNAs. The mRNAs for the 17, 18.5, and
21.5 kDa proteins were approximately 43 to 48 % of normal, and the 14 kDa
MBP mRNA was approximately 7% of normal. When the level of total MBP
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mRNA was analysed by dot blots, it ranged from 19 to 42 % of normal age- 
matched controls during development (Roth etal., 1985), and these 
reductions were observed for both polysomal and nuclear RNA (Sorg et al.,
1987). Despite differences in MBP mRNA levels measured in these studies, 
the level of detectable protein was significantly below the level of detectable 
mRNA, suggesting that whereas the MBPs may be synthesised to some 
extent, the amount that accumulates is quite low. This would suggest that the 
MBP that is not inserted into an appropriate membrane is “turned over”. This 
would be consistent with the conclusions drawn from experiments on the 
quaking mutant where the synthesis of MBP is significantly above the level 
of accumulation.
1.8. Quaking (qk)
Quaking viable (qkv) is an autosomal recessive mutation resulting in
dysmyelination in the CNS and PNS (Hardy et al., 1998). The quakingv,able
mutant mouse (qk) has a deletion on chromosome 17 (Ebersole etal., 1992).
A candidate gene, qkl, has recently been identified and evidence suggesting
abnormalities leading to diminished expression of the selective RNA-binding
protein QKI in myelin producing cells are involved in the quaking phenotype
(Ebersole etal., 1996, Hardy etal., 1996). QKI contains amino acid domains
characteristic of RNA-binding and interaction with Src homology 3 (SH3)-
containing signalling molecules, and therefore belong to a fast growing
family denoted as signal transduction activators of RNA (STAR) (Vernet and
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Artzt, 1997). Isoforms of the QKI proteins are expressed in myelin-forming
cells, in other CNS glia, as well as in non-nervous tissue; it is therefore
suggested that they are involved in RNA splicing or metabolism (Ebersole et
al., 1996, Kondo etal., 1999, Wolf et al., 1999). The proteins might play
roles not only in myelination but also in embryonic development (Ebersole et
al., 1996). These mice exhibit tremors, which continue throughout their
lifetime beginning at approximately P12. Tonic seizures occur in these
animals, although they have a normal lifespan. The morphologic phenotype
includes thin myelin which often fails to compact, and is thrown into
exuberant loops and whorls. Studies on the accumulation of MBP in different
regions of the quaking nervous system showed that the developmental curve
was different between quaking and normal mice and that there was a delay
in the appearance of MBP in every CNS region tested. Furthermore, the
level of MBP was severely depressed, ranging from 5 -  20 % of normal
(Delassale etal., 1981 and Jacque etal., 1983). Interestingly the
accumulation of MBP in spinal cord myelin did not stop at any particular time
during development, as it normally does (Delassale etal., 1981). Therefore
at day 80 MBP content in the spinal cord was approximately 25 % of normal,
whereas at 1 year it had risen to 35 % of normal. An early study on MBP
biosynthesis in quaking mice suggested the synthesis of the MBPs occurred
at the normal rate, but it was the incorporation of the myelin into the
membrane that was deficient (Brostoff et al., 1977). Both the stability and
localisation of MBP mRNA are potentially coupled with its translation status
(Ueno etal., 1994a, 1994b, Ainger etal., 1997) and QKI has recently been
reported to act as a translation suppressor (Saccomanno et al., 1999),
44
therefore, interactions of MBP mRNAs with QKI may influence MBP 
expression at multiple posttranscriptional levels, including mRNA turnover, 
translation and subcellular localisation (Li et al., 2000).
1.9. TAIEP mutant rat
The name of this mutant is derived from the clinical signs observed in
affected animals, e.g. at 3 weeks old taiep rats show a tremor (t), especially
in the hind quarters, ataxia (a) is seen at 3 to 4 months of age, followed by
immobility Q), epilepsy (e) and a gradually worsening hind limb paralysis Qd)
in animals over 6 months of age. Studies have confirmed an autosomal
recessive mode of inheritance (Duncan etal., 1992). All the myelin proteins
including MBP, PLP, MAG, and CNP are present in the mutant CNS albeit in
reduced levels. This agrees with the finding that taiep myelin sheaths show
positive immunostaining for both MBP and PLP (Duncan etal., 1992). The
microtubule accumulations in the taiep oligodendrocytes are a striking and
unique finding focussing attention on the role of the oligodendrocyte
cytoskeleton in the functioning of this cell. The cytoskeleton of the
oligodendrocyte is likely to influence the transport of both myelin proteins
and their message (Ainger etal., 1993). A close association between MBP
and CNP and the cytoskeleton has been observed in the oligodendrocyte, -
and it would appear that MBP colocalises with tubilin, whereas CNP
associates with microfilaments (Wilson and Brophy, 1989). It has also been
known for some time that the myelin protein mRNAs are spatially segregated
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within the oligodendrocyte (Trapp, 1990). The messages for PLP and MAG 
are found in the perinuclear region, whereas the MBP message is more 
diffusely distributed throughout the cytoplasm. The role of the cytoskeleton 
in the transport of MBP mRNA was demonstrated by Ainger et al., (1993) 
using digoxigenin-labelled MBP mRNA microinjected into cultured 
oligodendrocytes. The mRNA formed granules that were transported from 
the cell body along the oligodendrocyte processes. It would not be 
unreasonable to suggest this transport would be disrupted by the massive 
accumulations of microtubules in the taiep oligodendrocytes. As a result this 
could lead to the inefficient incorporation of myelin components into the 
myelin sheath with the resulting inadequate myelination of the developing 
CNS, and failure of myelin maintenance in the longer term (Lunn et al.,
1995).
1.10. Myelin basic protein is a zinc-binding protein in brain
Zinc is an abundant transition element in the brain that has been 
implicated in a variety of metabolic processes. In humans, zinc deficiency 
has been known to cause many neurological and neuropsychiatric disorders 
(Frederickson, 1989). In the brain zinc, like calcium, is another important 
divalent cation in the CNS, is unevenly distributed with the highest level in 
the hippocampus. As zinc in nervous tissue rarely exists as a free ion but 
usually associated with proteins, it is not known whether this uneven
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distribution in different regions of the brain is related to different 
concentrations of zinc-binding proteins present (Tsang etal., 1997).
Tsang etal., (1997) showed that three major zinc-binding proteins 
(ZnBPs) of molecular weight 53, 42 and 21 kDa were present in porcine 
brain. The 53 and 42 kDa zinc-binding proteins were present in all 
subcellular fractions whereas the 21 kDa protein was mainly found in the 
particulate fractions. It was suggested that of the three major zinc-binding 
proteins in the brain only the 21 kDa protein appears to be brain-specific and 
was later identified as myelin basic protein (Tsang etal., 1997). Since no 
cysteine residues are present in mammalian MBPs the probable zinc binding 
sites in myelin basic protein may consist of imidazole or carboxylate groups 
(Riccio et al., 1995). These groups are fairly abundant in MBP, about 6% 
each of aspartic acid, glutamic acid and histidine. Although the structural 
motif responsible for zinc-binding in MBP is still unknown, studies on other 
ZnBPs have revealed a common structural motif of His-X2l-3-His (Berg,
1986). From the amino acid sequence of porcine MBP, a structural motif of 
His-Ala-Arg-His has been found between amino acid residues 23-26, which 
may be responsible for zinc binding in MBP (Tsang etal., 1997). The 
association of zinc with myelin and the fact that myelin basic protein is a zinc 
binding protein show that zinc plays a structural and/or functional role in 
myelin. Myelin basic protein is located on the cytoplasmic side of the 
multilamellar membrane at the major dense line and is responsible for the 
compaction of the two opposing membrane bilayers. The fact that MBP can 
bind zinc implies that zinc may be involved in myelin compaction by
interacting with MBP. There are developmental studies that showed that 
maternal zinc deficiency caused poor myelination in foetuses and decreased 
amounts of MBP associated with foetal myelin membranes (Liu et al., 1992). 
Furthermore, recent fluorescence studies have confirmed the role of zinc 
ions in the formation of myelin basic protein aggregates (Cavatorta et al., 
1994). In myelin compaction, bimolecular interactions, MBP-membrane, as 
well as MBP-MBP interactions are involved in multilamellar myelin formation. 
Therefore, the effect of zinc on myelin compaction is probably by promoting 
or stabilising the MBP-membrane and/or MBP-MBP interaction (Berlet et al., 
1994). As zinc has been shown to stabilise the binding of macromolecules to 
plasma membranes in peripheral tissues, and that zinc has been shown to 
prevent the dissociation of MBP from membrane, it is not surprising that zinc 
is involved in the stabilisation of MBP in myelin sheath formation (Berlet et 
al., 1994).
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1.11. Aims of the project
The MBP unit is expressed in oligodendrocytes (Central Nervous 
System) and Schwann cells (Peripheral Nervous System) and is regulated at 
the level of transcription by proteins binding in a specific manner to DNA 
sequences located within its promoter region. The identification of these 
proteins and DNA sequences is essential for understanding the 
mechanism(s) that regulate the transcription of the MBP gene.
The major aims of this project were to clone and sequence the 
promoter region of the mouse myelin basic protein (MBP) gene and to 
identify a transcriptional activator(s) (transcription factor(s)) which interact 
with an oligodendrocyte-specific element(s) in the myelin basic protein gene 
promoter. To achieve this the following steps had to be taken:
■ cloning and sequencing of the Hind ill -  Sac I fragment (from the 
plasmid pEX1). This fragment is located between nucleotides -  1319 
and + 227 relative to the transcription start site and comprises the 
promoter region and exon 1 of the mouse myelin basic protein gene.
■ analysis of the interaction of oligodendrocyte specific protein factor(s) 
with the region of the MBP promoter between nucleotides -  609 to
-  577. This region was selected for further study because work 
published by other groups suggested that it contains an 
oligodendrocyte specific transcription activator (Asipu and Blair 1994). 
To achieve this electrophoretic mobility shift assay (EMSA) and 
competition binding with oligonucleotides corresponding to this region 
were performed.
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■ identification using the yeast one -  hybrid system cDNAs encoding 
proteins, which bind to the -609 to -577 region of the mouse myelin 
basic protein promoter. The one-hybrid system is a functional in vivo 
genetic assay used for isolating and studying novel genes encoding 
proteins which bind to target DNA. In this system a reporter construct 
containing at least three tandemly repeated copies of a putative 
binding sequence are inserted upstream of a HIS3 gene minimal 
promoter in a specially designed plasmid. This reporter construct is 
integrated by homologous recombination into a mutated HIS3 gene in 
the yeast host genome to create a yeast reporter strain carrying a 
normal copy of the HIS3 gene. A library of cDNAs encoding GAL4 AD 
fusions is expressed in the reporter strain. If an AD/library protein 
interacts with the target DNA sequence, HIS3 promoter activity is 
increased resulting in increased amounts of histidine produced. 
Therefore, clones expressing histidine at a level higher than the 
reporter strain are selected by growth on medium lacking histidine in 
the presence of 3-aminotriazole (3-AT) for further study.
■ sequencing of cDNAs encoding proteins, which bind to the -609 to 
-577 region of the myelin basic protein promoter.
■ search of nucleotide databases (e.g. EMBL and Genbank) and 
protein databases like Swissprot or Swall for homology with other 
transcription factors using the FastA and Blast sequence alignment 
programs.
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Chapter 2
MATERIALS AND METHODS 
2.1. MATERIALS AND SUPPLIERS
2.1.1. BACTERIAL STRAINS
Escherichia coli strain HB101 (containing plasmid pEX1)
Donated by Arthur Roach, Division of Biology, California 
Institute of Technology, Pasadena, California. 
Escherichia coli strain (DH5a).
2.1.2. CLONING VECTORS
Bluescript SK+ 
pHISi-1
2.1.3. ENZYMES
Hind III 20 U/jliI NEB (104 S)
Sac I 20 U/jliI NEB (156 S)
EcoR 1 20 U/pil NEB (101 XL)
Mlu1 10 U/pil NEB (198 S)
Xho 1 20 U/jil NEB (146 S)
Promega
Clontech
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T4-DNA Ligase (E.C.6.5.1.1.) 400 U/jxl NEB (202 S)
Alkaline, phosphatase (E.C.3.1.3.1.) 10 U/pl NEB (290 S)
Polynucleotide kinase 10 U/pl NEB (201 S)
Lysozyme (E.C.3.2.1.17.) SIGMA (L 6876)
2.1.4. OLIGONUCLEOTIDES
The oligonucleotides used for chain termination sequencing, 
electrophoretic mobility shift assays, PCR amplification were synthesised on 
a Pharmacia Gene Assembler Plus using the phosphoramidite chemistry.
2.1.5. KITS
Mini-Prep Kit Plus 
T7 Sequencing Kit
HYDRO-LINK™ DNA Sequencing System 
Sequenase ™ DNA Sequencing Kit
Pharmacia Ltd.
Pharmacia Ltd.
A.T. Biochem.
United States Biochemical
Corporation.
2.1.6. RADIOCHEMICALS
Deoxyadenosine triphosphate a-thiol (35S) 500 Ci mmol'1 (10 mCi ml'1)
NEN (DUPONT) Hertfordshire. 
Adenosine 5’ triphosphate, tetra (triethylammonium salt) (y - 32P)
>4000 Ci mmol'1 (10 mCi ml'1) ICN Biomedicals Ltd Buckinghamshire.
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2.2. LARGE SCALE ISOLATION OF PLASMID DNA BY A 
MODIFIED CLEWELL AND HELINSKI TECHNIQUE
An overnight culture (4 ml) of Escherichia coli harbouring the pEX1 
plasmid was inoculated into 400 ml of Luria broth (see Appendix II), and 
incubated at 37° C with vigorous shaking until the absorbance at 600 nm 
reached 1.00. Chloramphenicol (4ml of stock solution at a concentration of 
10 mg/ml in 50% ethanol) was added and the incubation continued for a 
further 18 h.
Cells were harvested by centrifugation at 4 krpm for 20 min at 4° C 
using the Sorvall GS3 rotor, and the cell pellet was resuspended by gentle 
agitation in 3.0 ml of ice-cold Buffer I (see Appendix II). After transferring the 
bacterial suspension to a suitable centrifuge tube 500 \i\ of a freshly 
prepared ice-cold lysozyme solution (at a concentration of 10 mg/ml in buffer 
I) were added. Following incubation at 0° C for 4-5 min (for chloramphenicol 
amplified cultures) 1 ml of ice-cold 0.25 M EDTA pH 8.0 was added and the 
4-5 min incubation at 0° C repeated.
Finally 4.0 ml of Triton X-100 lysis solution (see Appendix II) were 
added and the lysis of the cells was monitored by observing the viscosity of 
the mixture. Separation of the chromosomal DNA and cell debris from the 
plasmid DNA was achieved by centrifugation at 18 krpm for 1 h at 4° C using 
the SL50T rotor.
The plasmid DNA was stored at 4° C before purification by 
centrifugation to equilibrium on caesium-chloride density gradients.
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2.3. PURIFICATION OF PLASMID DNA BY
CENTRIFUGATION TO EQUILIBRIUM IN CAESIUM 
CHLORIDE-ETHIDIUM BROMIDE GRADIENT
The volume of cleared lysate prepared as described in section 2.2. 
was accurately measured.
For every 10 ml of lysate, exactly 9.62 g of solid caesium chloride and 
625 pi of a solution of ethidium-bromide (stock concentration 10 mg/ml in 
water) were added, and mixed gently by inversion until all the caesium 
chloride had dissolved, (the final density of the solution being 1.55 g 
t| = 1.3680 and the final concentration of ethidium bromide approximately 
600 jig/ml). It should be noted that in this procedure the furry purple 
aggregates that float to the top of the solution are complexes formed 
between the ethidium-bromide and bacterial proteins.
Centrifugation was carried out at 40 krpm for 40 h at 18° ± 1 ° C 
using a Sorvall T865 rotor. Two bands of DNA were evident in both visible 
light and UV light, the upper band consisting of chromosomal DNA and the 
lower band of plasmid DNA. The lower band of DNA was collected with a 
hypodermic needle, and transferred into a fresh tube.
Ethidium bromide was removed by extraction with caesium chloride 
saturated isopropanol (discarding the top layer each time and re-extracting 
until the bottom layer was colourless, usually six times).
Following dialysis against three changes of TE buffer pH 8.0 (see 
Appendix II), the solution of DNA was extracted three times with phenol 
(transferring the top layer to a fresh tube each time).
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The DNA was precipitated with 0.1 volume 3 M sodium acetate, 2.5 
volumes of ethanol at -70° C for 15 min and pelleted by centrifugation using 
a Sorvall ST-micro rotor. The pellet was dried in vacuo and resuspended in 
400 jul of sterile water. The concentration of the DNA was determined by 
measuring the absorbance at 260 nm (1 A2eo unit of double stranded DNA = 
50 pg/ml).
2.4. ANALYTICAL AGAROSE GEL ELECTROPHORESIS OF 
DNA
Gels were prepared by adding 300 mg of agarose to 30 ml of 1X Tris- 
acetate buffer (1% w/v) (see Appendix II) and heating in a microwave oven 
until all the agarose had dissolved. After cooling to 50° C in a water-bath,
3 pi of ethidium bromide were added to give a final concentration of 
0.5 pg/ml ethidium bromide (stock Et-Br 10 mg/ml stored at 4° C). The 
agarose slurry was then poured into a pre-levelled gel former and allowed to 
set at room temperature for 30 minutes.
Tris-acetate buffer (1X) (see Appendix II) was added to the 
electrophoresis chamber so that the gel was covered to a depth of 1 mm.
Samples (5 pi in loading buffer -  see Appendix II) were loaded below 
the surface of the running buffer into the pre-formed sample wells. The gel 
was electrophoresed at a constant voltage (100 V), until the bromophenol 
blue in the loading buffer was 1 cm from the anode end of the gel.
After electrophoresis the gel was analysed on a UV transilluminator.
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2.5. ANALYTICAL SCALE DIGESTION OF DNA WITH 
RESTRICTION ENDONUCLEASES
Plasmid DNA (2 fig in 5 pi) was mixed in a sterile Eppendorf tube with
1 pi of the appropriate 10X restriction buffer (supplied with each enzyme), 
and 3 pi of sterile deionised water.
For single restriction enzyme digests, 1 pi of enzyme (20 U/pl) was 
added and the digest incubated at 37° C for 1 h after mixing by gentle 
flicking.
For double endonuclease digestions (where the buffer conditions are 
identical), only 5 pi of sterile water were added followed by 1 pi (20 U/pl) of 
the second enzyme, the contents mixed and incubated as above.
The digestion was terminated by the addition of 2 pi of loading buffer 
(see Appendix II) and the products analysed by agarose gel electrophoresis.
2 6 CLONING OF THE Hind I I I -  Sac I FRAGMENT OF pEX1 IN 
pBLUESCRIPT PLASMID 
2.6.1. PREPARATION OF THE Hind III- Sac /FRAGMENT OF 
pEX1 PLASMID FOR CLONING
2.6.1.1. LARGE-SCALE DIGESTION OF THE PLASMID pEX1
Digestion with restriction endonucleases was performed essentially as 
described in 2.5, with the minor modifications indicated below.
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Plasmid pEX1 (37.5pg in 95 pi) was mixed with 35 pi of the 
appropriate 10X restriction buffer, 180 pi of sterile distilled water and 20 pi 
(20 U/pl) of Hind III and 20 pi (20 U/pl) of Sac I. After an incubation for 2h at 
37° C the progress of the digestion was monitored by analytical scale 
agarose gel electrophoresis.
Preparative gel electrophoresis was performed after 3h 45 min of 
digestion.
2 6.1 2 ELECTRO-ELUTION OF THE Hind III-Sac I 
FRAGMENT
The band containing the Hind Ill-Sac I fragment was excised from the 
preparative agarose gel and fastened securely in "pre-wetted" dialysis tubing 
for electro-elution at a constant voltage (100 V). The progress of the elution 
was monitored every 10 min on the UV transilluminator. When the ethidium 
bromide had migrated out of the gel slices the elution of DNA was ended and 
the samples stored at -20° C for subsequent purification and concentration.
2.6.1.3 PURIFICATION AND CONCENTRATION OF THE 
Hind III - Sac I FRAGMENT
An ion-exchange column was plugged with sterile siliconized glass 
wool and filled with approximately 2 ml of DE-52 cellulose matrix. The 
solution containing the Hind Ill-Sac I fragment (produced as described in
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section 2.6.1.2.) was loaded onto the column, the flow-through collected, and 
passed through the column a second time.
After washing the column with "low salt" solution (0.3 M NaCI), the 
DNA fragment was eluted in a small volume (1000 pi) of "high salt" solution 
(1.0 M NaCI), and collected in a Corex tube. Nucleic acid precipitation was 
carried out by the addition of 0.1 volume of 3 M sodium acetate and 2 
volumes of ice-cold ethanol followed by incubation at -20° C for 24h.
The DNA was pelleted by centrifugation at 10 krpm for 1h at 2° C 
using a Sorvall ST-micro rotor. After decanting the supernatant any 
remaining ethanol was evaporated under vacuum and the pellet dried.
Finally the pellet of DNA was resuspended in 170 pi of sterile distilled 
water and stored at -20° C.
2.6.2. PREPARATION OF THE PLASMID pBLUESCRIPT FOR 
CLONING
2.6.2.1. DIGESTION OF pBLUESCRIPT WITH RESTRICTION 
ENDONUCLEASES Hind ill and Sac I
The vector DNA (pBluescript) was cleaved with Sac I and Hind III 
using a similar protocol to that outlined in section 2.5., and the restriction 
enzymes inactivated by heating at 60° C for 10 min. The completeness of the 
digestion was established by running a 2 pi sample on an analytical scale 
agarose gel.
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2.6.2 2. PHOSPHATASE TREATMENT OF pBLUESCRIPT
Digested plasmid pBluescript (20 pg in 20 pi) was treated with 
alkaline phosphatase to remove 5’ phosphate groups. The reaction mixture 
consisted of 20 pi of cleaved vector, 2.5 pi of 1 M Tris pH 8.0 (to give a final 
concentration of 50 mM), 21.5 pi of sterile distilled water and 6 pi of alkaline 
phosphatase (10 U/pl). After mixing the tubes were incubated at 37° C for 45 
min.
The alkaline phosphatase was inactivated by adding an equal volume 
(50 pi) of water-saturated phenol, (discarding the lower layer and repeating 
usually twice). Water-saturated diethyl ether was added, and after removing 
the organic phase (upper layer) the procedure was repeated a further six 
times.
Following the removal of as much of the ether as possible 5 pi of 3M 
sodium acetate and 150 pi of ethanol were added. The DNA solution was 
then incubated at -20° C for 72 h (approx) to precipitate the DNA. The 
dephosphorylated Hind Ill-Sac I cleaved vector DNA was pelleted by 
microcentrifugation at 13 krpm for 20 min at 4° C, the supernatant removed 
and the pellet dried in vacuo.
Sterile deionised water (40 pi) was added to reconstitute the pellet, 
and the recovery of the dephosphorylated vector was checked by agarose 
gel electrophoresis.
2.6.3. LIGATION
Ligation was performed as follows:
2 pi of dephosphorylated vector (0.5 pg/pl) and 5 pi (2 pg) of the 
Hind Ill-Sac I fragment isolated from pEX1 were mixed in a sterile Eppendorf 
tube. This was followed by the addition of 1 pi 10X ligation buffer, 1 pi ATP 
(10 mM) and 0.5 pi (200 U) T4-DNA ligase. After mixing the contents by 
gentle flicking an overnight incubation at 16° C was carried out.
2.6.4 INTRODUCTION OF PLASMID DNA INTO E. coll CELLS
2.6.4.1. PREPARATION OF COMPETENT CELLS
E.coli cells strain DH5a (5 pi) were spread over the surface of an M9
minimal medium plate (see Appendix II) and incubated overnight at 37° C.
If 5 pi proved too large an inoculum to give individual colonies the
procedure was repeated with a 1 pi inoculum. A single colony was then
inoculated into a tube containing 15 ml of L-broth and the culture incubated
overnight at 37° C with vigorous shaking.
Overnight starter culture (1 ml) was inoculated into L-broth (100 ml)
and incubated at 37° C with vigorous shaking to an absorbance at 650 nm of
0.5. Then 50 ml of the culture was centrifuged at 3 krpm for 5 min at 4° C
using the Sorvall SL50T rotor. Following aspiration of the supernatant the
cells were carefully resuspended in 7.5 ml of ice-cold 0.1 M CaCI2 (made
from filter sterilized 2 M stock) and incubated on ice for 15 min before
60
centrifugation at 3 krpm for 5 min at 4° C using the Sorvall SL50T rotor. The 
cells were resuspended in 1.5 ml (0.1 volume) of ice-cold 0.1 M CaCI2, and 
kept on ice until required.
2.6 4.2. TRANSFORMATION
Three transformation mixtures were prepared as follows:
TUBE 1 UNCUT VECTOR: 10 pi of uncut vector (0.1 pg/pl) was added to 
20 pi of 1X SSC. This was followed by 200 pi of competent cells prepared as 
described in section 2.6.4.1. and the contents of the tube mixed well.
TUBE 2 VECTOR AND FRAGMENT: 10 pi of ligation mixture 
(dephosphorylated vector + pEX1 fragment) were added to 20 pi of 1X SSC. 
This was then followed by 200 pi of competent cells and the contents mixed 
well.
TUBE 3 LINEAR VECTOR: 10 pi of dephosphorylated vector (0.1 pg/pl) and 
20 pi of 1X SSC were added to 200 pi of competent cells and the contents of 
the tube mixed well.
After incubation of all three tubes on ice for 30 min, with occasional 
shaking, a heat-shock at 42° C for 2 min was performed. This was followed 
by incubation on ice for a further 15 min.
L-broth (2ml) was added to each sample and incubated at 37° C for
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1 -1.5 h with continuous shaking to allow gene expression. The cells were 
then pelleted by centrifugation at 3 krpm for 5 min at room temperature and 
each pellet was resuspended in a final volume of 100 pi of L-broth.
2.6.4 3. PLATING-OUT OF THE TRANSFORMANTS
L-broth (80 pi) was pipetted into the centre of pre-dried AIX plate (see 
Appendix II) followed by 20 pi of transformed cells. The cells were spread 
over the whole surface of the plate using an "L-shaped" glass rod, kept on 
the bench for a few minutes to let the transformed cells absorb into the agar, 
and then incubated overnight at 37° C.
2.6.5. ANALYSIS OF THE TRANSFORMANTS
Transformants were analysed for the presence of the recombinant 
plasmid by the method of Holmes and Quigley (1981) followed by agarose 
gel electrophoresis. Restriction enzyme digestion (Sac I -  Hind III) was used 
to excise the cloned insert.
2.6 5.1. PREPARATION OF PLASMID DNA ON A SMALL-SCALE 
(HOLMES AND QUIGLEY (1981) METHOD)
White colonies from the vector plus DNA fragment plate were 
resuspended in L-broth containing ampicillin at a final concentration of
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50 pg/ml and incubated at 37° C overnight with constant shaking. Aliquots of 
each culture (2 x 1.5 ml) were pipetted into sterile Eppendorf tubes and the 
cells pelleted by centrifugation in a microfuge for 30 sec. Each pellet was 
resuspended by vortex mixing in 75 pi of STET buffer (see Appendix II) and 
the suspensions combined into one 150 pi suspension in one tube. Freshly 
prepared lysozyme (12 pi at a concentration of 20 mg/ml) was added to each 
tube and the contents mixed by vortexing.
Then the cell lysates were heated in a boiling water bath (40 sec) and 
immediately centrifuged in a microfuge for 15 min at room temperature. The 
supernatant (approximately 100 pi) was carefully removed from the fluffy 
pellet containing chromosomal DNA, and transferred to a fresh sterile tube. 
An equal volume of isopropanol (100 pi) was added to the supernatant and 
the nucleic acids precipitated in an alcohol dry-ice bath for 10 min.
The nucleic acids were pelleted by centrifugation in a microfuge at 12 
to 14 krpm for 15 min in the cold-room. Following the careful removal of the 
supernatant with a sterile Pasteur pipette, the pellet was resuspended in 
100 pi of sterile distilled water and the nucleic acids precipitated with 10 pi of 
3M sodium acetate (pH 6.0) and 300 pi of absolute ethanol (stored at -20° C) 
in an alcohol dry-ice bath for 10 min.
The nucleic acid was pelleted by centrifugation in a microfuge at full 
speed, the supernatant discarded and the pellet washed carefully with 
100 pi of 70 % ethanol (stored at -20° C). The nucleic acid pellets were dried 
under vacuum for 3 to 4 min, resuspended in 30 pi of sterile distilled water 
and stored at -20° C.
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2.6.5 2. CONFIRMATION OF THE PRESENCE OF THE Hind Ill- 
Sac I FRAGMENT IN THE RECOMBINANT PLASMIDS
Plasmid DNA prepared according to the protocol described in section
2.6.5.1. was digested with a combination of Hind III and Sac I restriction 
endonucleases as described in section 2.5.
Agarose gel electrophoresis was used to analyse the products of the 
endonuclease digestion as outlined in section 2.4.
3.0. ISOLATION AND PREPARATION OF PLASMID DNA FOR 
SEQUENCING
3.1.1. ALKALINE LYSIS MINI-PREPARATION USING THE 
PHARMACIA KIT
SB medium (1.4 ml) (see Appendix II) containing the appropriate 
antibiotic was inoculated with a single colony of the recombinant clone of 
interest and incubated overnight at 37° C with constant shaking. The cells 
were pelleted by centrifugation in a microfuge for 1 min at full speed, and the 
medium removed by aspiration to leave the cells as dry as possible.
Solution I (100 pi) (see Appendix II) was added and the cells 
resuspended by vortex mixing. Following incubation on ice for 5 min, 200 pi 
of Solution ll (see Appendix II) were added and the incubation on ice 
repeated. After the further addition of 150 pi of Solution III (see Appendix II) 
and incubation on ice for 5 min the cell lysates were microfuged (Sorvall T21 
with ST Micro rotor) at full speed for 5 min at room temperature. The
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supernatant was transferred to a fresh microfuge tube and 1 volume (450 pi) 
of isopropanol was added, mixed by inversion and incubated at room 
temperature for 5-10 min.
The DNA was pelleted in a microfuge at full speed at room 
temperature for 5 min. Following the removal of the supernatant by 
aspiration the DNA pellet was gently washed in 250 pi of isopropanol, and 
air-dried.
Since the DNA was to be used for sequencing by the dideoxy chain 
termination method the pellet was redissolved in 25 pi of Column Buffer (see 
Appendix II).
3.1.2. ESTIMATION OF THE CONCENTRATION OF DNA 
BEFORE THE PREPARATION OF SINGLE STRANDS
The approximate concentration of plasmid DNA was determined by 
comparing the fluorescence of ethidium bromide-stained DNA with that of 
known amounts of caesium chloride purified DNA. An agarose gel (0.8%) 
was prepared in 1X Tris-acetate buffer (see Appendix II), containing 
ethidium bromide at a final concentration of 0.5 pg/ml.
Redissolved plasmid DNA (1 pi) prepared as described in section
3.1.1. was combined with 4 pi of sample buffer. Aliquots (2, 4 and 8 pi) of the 
pBR322 DNA standard containing 2,4, and 8 pg of DNA respectively were 
loaded into three wells of the agarose gel; duplicate samples of the plasmid 
DNA and a molecular size marker were loaded into adjacent wells.
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The DNA samples were electrophoresed and the amount of DNA in 
the plasmid sample was estimated by comparing the intensity of its 
fluorescence under ultra-violet light with that of the three pBR322 DNA 
samples. The size of the plasmid was estimated from the molecular size 
marker.
3 13. PREPARATION OF SINGLE STRANDED DNA FOR 
SEQUENCING
Plasmid DNA (20 pi at a concentration of 1.5 pg/pl) prepared as 
described in section 3.1.1. was treated with 5 pi of 2 M NaOH at room 
temperature for 5 min. The denatured DNA was purified immediately on 
Sephacryl S-400 columns (prepared as described in Appendix III).
The plasmid solution was slowly applied to the centre of the upper flat 
surface of the compacted bed of Sephacryl S-400. In this procedure careful 
application of the sample to the centre of the bed was essential for good 
separation of the DNA. The column was then centrifuged for 2 min at 
approximately 400 x g in a swing out bucket rotor. The effluent collected in a 
microfuge tube contained the purified single stranded plasmid DNA in 
approximately 25 pi of column buffer.
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4.0. SEQUENCING OF DNA
4.1. PREPARATION OF OLIGONUCLEOTIDE PRIMERS
Oligonucleotide primers were synthesised as described in Appendix 
IV using the phosphoramidite chemistry and prepared by the procedure 
described below. This procedure gives high yields of de-salted 
oligonucleotides which are 20 bases or longer.
The ammonia solution (1 ml) containing the oligonucleotides was 
divided into 3 X 330 pi aliquots in flip-top Eppendorf tubes. The 
oligonucleotides were precipitated by adding 33 pi of 3M sodium acetate 
solution pH 6.0, followed by 915 pi of absolute ethanol (maintained at 
-20° C) to each tube. After overnight incubation at -20° C the tubes were 
microfuged at 13 krpm for 15 min at 4° C. The ethanol was removed by 
aspiration and the pellets resuspended in 500 pi of 80% ethanol (stored at 
-20° C).
After pooling the contents of the three tubes into one conical 
Eppendorf tube and microfuging at 13 krpm for 5 mins at 4° C the ethanol 
was removed and the open tube covered with parafilm. The contents of the 
tube were lyophilised on a freeze-dryer once the parafilm had been 
perforated with a hypodermic needle.
The oligonucleotide primers could be stored indefinitely in this 
lyophilised form, or could be resuspended in 600 pi of buffer (for example 
T.E. pH 7.5 see Appendix II).
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4.2. DNA SEQUENCING USING THE SEQUENASE KIT ™
All sequencing reactions were carried out according to the 
manufacturers instructions in small plastic centrifuge tubes typically 1.5 ml 
Eppendorfs; these were kept capped between manipulations to minimize 
evaporation of the small volumes used.
4.2.1. ANNEALING THE TEMPLATE AND THE PRIMER
For each of four sequencing lanes, a single annealing and labelling 
reaction was used.
Primer (1 pi at a concentration of 0.5 pmol/pl), reaction buffer (2 pi) 
and 7 pi (2.0 pg) of template DNA were combined in a centrifuge tube. For 
the control, 5 pi (0.2pg) of DNA supplied in the kit and 2 pi of water were 
used, this was equivalent to a 1:1 (primer: template) molar stoichiometry.
The capped tubes were held at 65° C for 2 min and then allowed to 
cool slowly to room temperature over a period of about 30 min. Once the 
temperature was below 30° C annealing was complete and the tube kept on 
ice until required.
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4.2.2. THE LABELLING REACTION
For reading sequences up to 500 bases from the primer the labelling 
mix (dGTP) was diluted 5-fold with sterile deionised water. The Sequenase 
Version 2.0 enzyme (13 U/pl) was diluted 1:8 in ice-cold enzyme dilution 
buffer and then stored on ice until required. To the annealed template-primer 
(10 pi) the following additions were made on ice, 1 pi DTT (0.1 M), 2 pi 
diluted labelling mix, 0.5 pi (1 OpCi/pl) [a-35 S] dATP and 2 pi (1.6 U/pl) of 
diluted Sequenase version 2.0. After mixing the contents thoroughly the tube 
was incubated at room temperature for 5 min.
4.2.3. TERMINATION REACTIONS
The ddNTP termination mixes (2.5 pi) were pipetted into their 
corresponding centrifuge tube, capped and pre-warmed to 37° C for at least 
1 min. When the labelling reaction was complete 3.5 pi of the labelling mix 
were removed, added to each of the pre-warmed ddNTP tubes, mixed and 
then returned to the 37° C water-bath for a further 5 min. Stop solution (4 pi) 
was added to each of the termination reactions, mixed thoroughly and stored 
on ice until required.
Just before loading the gel the samples were heated to 75° C for at 
least 2 min and immediately loaded onto the gel. Denaturing gel 
electrophoresis was carried out as outlined in section 4.4.
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4.3 DNA SEQUENCING USING THE T7 DNA POLYMERASE 
KIT
Single-stranded template DNA was isolated as described in section
3.1.1.
4.3.1. ANNEALING THE TEMPLATE AND THE PRIMER
Template (or control) DNA (10 pi containing 2.0 pg of single strand 
DNA), 2 pi primer (at a concentration of 0.5 pmol/pl) and 2 pi annealing 
buffer were pipetted into a sterile Eppendorf tube mixed and incubated at 
60° C for 10 min. Once the annealing reaction was complete the tube was 
kept at room temperature until needed.
4.3.2. THE LABELLING REACTION
Labelling mix (3 pi diluted to a final concentration of 1.5 U/pl),
1 (.if (10nCi/|xl) of [a-35 S] dATP and 2 nl (1.5 U/^l) of diluted T7 DNA 
polymerase were added to the annealed template and primer. The 
components were mixed by gentle agitation and the contents incubated at 
room temperature for 5 min.
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Whilst the incubation was in progress the "read-short" sequence 
mixes were pre-warmed to 37° C for at least 1 min.
4.3.3. TERMINATION REACTIONS
Once the labelling reaction was complete 4.5 pi of this reaction 
mixture was transferred into each of the four pre-warmed sequencing mixes. 
The contents of each tube were incubated at 37° C for 5 min after mixing by 
gentle agitation. Stop solution (5 pi) was added to each tube, mixed by 
gentle agitation and then briefly microfuged to collect the contents at the 
bottom of the tube. An aliquot (3 pi) of each stopped reaction was 
transferred to a separate microfuge tube, heated to 75° C for at least 2 min, 
and 2 pi of this solution was then loaded immediately into an appropriate 
well on a sequencing gel. Denaturing gel electrophoresis was carried out as 
outlined in section 4.4.
4 4. ELECTROPHORESIS OF THE SEQUENCING REACTIONS
4.4.1. PREPARATION OF POLYACRYLAMIDE SEQUENCING 
GELS
A 40% acrylamide solution was prepared in distilled water, and de­
ionised with a small quantity of mixed bed resin (e.g. Amberlite MB1); the
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resin was removed by filtration and the solution stored at 4° C. The 
sequencing plates were prepared as described below.
The notched plate was treated with "Repel" silane solution whilst the 
other plate was treated with diluted "Bind" silane. After inserting the side 
spacers and clamping the two matched plates together the system was 
ready to receive the gel solution, which was prepared as follows:
To 70 ml of 1X TBE gel mix (see Appendix II), 140 pi of 25 % 
ammonium persulphate and 90 pi of TEMED were added. It should be noted 
that 25 % ammonium persulphate solutions were freshly prepared just before 
use. If necessary the gel could be stored overnight at room temperature.
The electrophoresis tank reservoirs were filled with the appropriate 
running buffers; the upper chamber contained 0.5 X TBE and the lower 
buffer chamber contained 1 X TBE. Following the pre-run and before loading 
the samples approximately 0.5 volume of 3 M sodium acetate was added to 
the lower chamber.
The sequencing gel was pre-run at 1200 to 1400 V for 2.5 h before 
loading any samples.
4.4.2. SEQUENCING GELS PREPARED WITH HYDRO-LINK ™ 
DNA SEQUENCING SYSTEM
Both the glass plates were silanized with "Repel" silane and then pre­
assembled in the usual way.
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Hydro-link gel solution (75 ml) and Hydro-link denaturing gel buffer 
(25 ml) were poured directly into a beaker followed immediately by 220 pi of 
TEMED and 500 pi of freshly prepared 20 % ammonium persulphate. After 
gentle mixing the gel solution was poured into the pre-assembled glass 
plates laid on a flat surface, the sample comb was inserted and the gel left to 
polymerise.
Hydro-link SEQ running buffer (50 ml of 20 X concentrate) was made 
up to 1 litre and then both the anode and cathode reaction chambers were 
filled according to the manufacturers recommendations.
Normally for 30 to 300 base extensions the pre-run conditions were 
as follows: constant power (25 to 30 W) for 15 min.
Alternatively, if up to 300 base extensions and the bases close to the 
primer were to be read then the conditions outlined above could still be used 
but the pre-run was extended to 30 min.
The actual sequencing electrophoretic run was carried out at 25 to 
30 W constant power for a period of 2 to 2.5 h. The temperature of the water 
jacket was thermostatically maintained at 45° C.
4 5 AUTORADIOGRAPHY OF SEQUENCING GELS
Upon completion of the electrophoretic run and following the 
separation of the glass plates the gel was fixed in 10 % acetic acid plus 
12 % methanol, washed in water and then dried on a gel-dryer at 80° C.
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X-ray film (Amersham Hyperfilm MP) was placed in direct contact with 
the gel and autoradiographed overnight at -70° C.
Standard X-ray developers (Kodak Industrex developer) and fixers 
(Ilford Hypam fixer) were used to develop the autoradiographs.
However, when using the hydro-link sequencing system the following 
adaptations were made. After separating the glass plates carefully the gel 
was allowed to air-dry for 5 min before transferring it to the support paper. 
The paper and gel were carefully peeled off the glass plate, and then the gel 
was covered with Saran wrap or ordinary cling film and the resulting 
"sandwich" dried on a gel-dryer at 60° C.
Once the gel was dry it was autoradiographed and developed as 
outlined above.
5.0. ELECTROPHORETIC MOBILITY SHIFT ASSAY
5.1. PREPARATION OF OLIGONUCLEOTIDES 
CORRESPONDING TO THE PUTATIVE BINDING SITE
Oligonucleotides corresponding to a putative DNA - protein 
interaction site were synthesised as described in Appendix IV.
Following cleavage and deprotection the oligonucleotides were 
ethanol precipitated, dried and annealed as described in the following 
section.
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5.1.1. ANNEALING OF SYNTHETIC OLIGONUCLEOTIDES
The complementary oligonucleotides were diluted to give a final 
concentration of 200 pg per ml.
To 4 pi (800 ng) of each oligonucleotide, 2 pi of 5X annealing buffer 
were added, mixed thoroughly and incubated at 90° C for 10 min. Then the 
water bath was adjusted to 37° C and the oligonucleotide solution was 
allowed to cool, after 30 min incubation at 37° C, the annealed mixture was 
then allowed to stand at room temperature for 90 min.
5.1.2 5’-END LABELLING OF OLIGONUCLEOTIDES WITH y-32P 
ATP AND POLYNUCLEOTIDE KINASE
To 4 pi of annealed oligonucleotide (section 5.1.1), 2 pi of 10X kinase 
buffer, 10 pi (100pCi) of y-32P ATP, 2pl (10 U/pl) of Polynucleotide kinase 
and 2pl of water were added, mixed and incubated at 37° C for 30 min, 
before adding 40 pi of water, 30 pi of 7.5 M ammonium acetate, 1 pi of 
0.25% linear polyacrylamide as a carrier and 400 pi of ethanol and 
incubating at -20° C for 30 min.
The resulting mixture was microfuged at 14 krpm for 20 min at 4° C, 
and the supernatant removed. The pellet was washed with 70 % ethanol, 
dried on a vacuum dessicator before being resuspended in 100 pi of water
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and frozen until required for the bandshift or electrophoretic mobility shift
assay.
5 2 PREPARATION OF NUCLEAR EXTRACTS
The cells for the preparation of the nuclear extracts were grown on 
90 mm plates, the medium was removed and the cells washed with cold 
phosphate buffered saline (PBS).
The cells were harvested in PBS by scraping with a cell scraper, 
followed by centrifugation in 50 ml Falcon tubes at 2 krpm for 5 min at 4 °C 
using the SL50T rotor, resuspension in 4 ml of cold buffer A (see Appendix 
II), and a 10 min incubation on ice.
Finally the cells were disrupted by 10 strokes with a tight-fitting 
Dounce homogeniser and the nuclei pelleted by centrifugation at 16 krpm for 
20 min at 4 °C using a Sorvall SL50T rotor. The pellet was resuspended in 
4 ml of cold buffer C (see Appendix II) and the nuclei disrupted by 10 strokes 
of a tight fitting Dounce homogeniser.
The nuclear extract was stirred gently on ice for 45 minutes before 
pelleting the chromatin and nuclear membranes by centrifugation at 4 °C for 
20 min at 25 krpm using the Sorvall T865 rotor. Ammonium sulphate was 
then used to precipitate the proteins present in the supernatant. Solid 
ammonium sulphate (0.33 g/ml) was gently stirred into the supernatant 
followed by continual gentle stirring on ice for a further 30 min.
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The nuclear proteins were pelleted by centrifugation at 4 °C for 20 
min at 25 krpm as in the previous step. Finally the protein pellet was 
resuspended in 200 pi of cold buffer D (see Appendix II) and dialysed 
against the same buffer overnight at 4 °C. The following day the nuclear 
extract was snap frozen in liquid nitrogen in aliquots (50 pi) and stored at 
-70 °C.
5.3. ESTIMATION OF THE CONCENTRATION OF PROTEIN IN 
THE NUCLEAR EXTRACTS
A range of protein solutions from 0 to 10 pg/pl were freshly prepared 
from a stock protein solution of 10 gl'1, at the same time an aliquot (15 pi) of 
the nuclear extract was also thawed and dispensed into a sterile Eppendorf 
tube and kept on ice until required. The working solution of Bicinchoninic 
acid (BCA) reagent was then prepared by mixing 200 pi of a 4% copper 
sulphate solution with 9.8 ml of BCA reagent.
The working BCA reagent (200 pi) was pipetted into an appropriate 
number of wells in a microtitre plate, followed by 5 pi of the diluted protein or 
nuclear extract sample. The plate contents were gently mixed, incubated at 
room temperature for 30 min before being read on a microplate reader at 
562 nm
The protein determination experiment was repeated with a standard 
and sample volume of 10 pi because the calibration graph obtained from the
5 pi sample was a curve and not linear as expected.
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5.4. BINDING ASSAY
The annealed oligonucleotide duplex (32P-labelled at the 5’ end to a 
specific activity of approximately 10 x 104 cpm / pg of DNA) was added to 
binding buffer (see Appendix II) and poly[d(IC).d(IC)] (at a final concentration 
of 1 pg per 10 pg of protein) in a reaction volume of 20 pi.
Nuclear extract (10 pg in 10 pi) was added, mixed and incubated at 
room temperature for 30 min. Following incubation, 5 pi of 20 % Ficoll was 
added to the reaction mixture and 5 pi aliquots loaded onto a 7 % non­
denaturing polyacrylamide gel.
Electrophoresis was carried out at 7 Vcrrf1 until the bromophenol blue 
marker loaded in an adjacent well had migrated about 5 cm. The gels were 
dried and autoradiographed as previously described in section 4.5.
5.5. COMPETITION - BINDING ASSAYS
The competition - binding experiments were carried out essentially as 
described in section 5.4, except that each reaction mixture contained a 
100-fold excess of the unlabelled oligonucleotide duplex, in addition to the 
end-labelled duplex.
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6.0. CLONING OF THE PUTATIVE BINDING SITE IN VECTOR 
pHISI-1 FOR USE IN THE YEAST ONE-HYBRID SYSTEM
6.1 PREPARATION OF OLIGONUCLEOTIDES CORRESPONDING
TO THE PUTATIVE BINDING SITE FOR CLONING IN pHISi-1
Complementary strands of the oligonucleotide with four tandem 
copies of the putative binding site corresponding to nt sequence -609 to 
-577 (5’-CACCTTTTGTCAAACGACCGCTTCACATCTGGG-3’) were 
synthesised as described in Appendix IV, except that the 5’ terminal trityl 
group was left on the oligonucleotide to aid purification (see Appendix V). An 
EcoR1 and an Mlu1 overhang were also incorporated to facilitate cloning in 
the reporter vector.
Each oligonucleotide (75 pi at a final concentration of 400 pg/ml) were 
added to 50 pi of 5X Reaction Buffer (from any sequencing kit, see Appendix 
II), mixed thoroughly and heated to 80° C for 10 min before slowly tempering 
down to room temperature before being used in the ligation reaction.
6.2. LIGATION OF THE OLIGONUCLEOTIDES CONTAINING 
THE BINDING SITE TO pHISi-1 PLASMID
The plasmid pHISi-1 (10 pg) was digested with EcoR1 (20 U/pl) and 
M!u1 (10 U/pl) as previously described, however, following each digestion 
the restriction endonucleases were inactivated with TE- saturated phenol (2 
extractions) followed by ether extraction (6 extractions) to remove any 
residual phenol, and subsequent ethanol precipitation and drying of the 
nucleic acid pellet.
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The digested reporter vector (10 pg in 10 pi) and 10 pi (4.0 pg) of the 
annealed oligonucleotide with multiple copies of the binding site were added 
to 3pl 10X ligation buffer, 3pl of ATP (final concentration 2mM) and 4 pi of 
T4 DNA Ligase (400 U/pl), and incubated overnight at room temperature.
Following incubation the ligation mixture was electrophoresed on a 
low melting temperature agarose gel; in order to separate the ligation 
product from unligated vector and excess annealed oligonucleotides. This 
gel slice containing the ligation product was melted in a water bath at 65°C, 
diluted one part to two parts in TE buffer (pH 8.0) (see Appendix II) before 
being used in the transformation protocol already outlined in Section 2.6.4.2.
6.3. SECREENING OF TRANSFORMED BACTERIAL 
COLONIES BY PCR
A master mixture for 15 X 50 pi PCR reactions was prepared as 
described in Table 1:
HIS - RP Primer 15 pi
HIS - 5372 Primer 15 pi
10 X PCR Buffer 75 pi
50 mM Magnesium Chloride 22.5 pi
2 mM dNTPs 75 pi
Water 547.4 pi
Table 1. Components of master mixture
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After mixing the components of the master mixture thoroughly 48 pi 
aliquots were dispensed into labelled Eppendorf tubes and to each was 
added a bacterial colony, followed by 1 pi of Taq Polymerase (5 U/pl). 
Finally 50 pi of mineral oil was added to each tube prior to thermal cycling 
according to the following programme:
STEP 1 94 °C for 7 min
STEP 2 95 °C for 1 min ...... ♦
STEP 3 52 °C for 1 min Cycle Back to step 2 for 34 Cycles
STEP 4 72 °C for 1 min — ► t
STEP 5 72 °C for 10 min
STEP 6 4 °C for oo
Any ‘positive’ clones (i.e. those indicating the presence of the binding 
site ligated to the reporter vector) were cultured in fresh L-broth, the plasmid 
DNA isolated by previously described small-scale procedures, followed by 
digestion with EcoR1 and Mlu1 according to the protocols outlined earlier. 
Further confirmation of the presence of the binding site in the vector was 
obtained from chain termination sequencing using the protocol outlined in 
section 4.2.
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7.0. LARGE SCALE PREPARATION OF YEAST VECTOR
CONTAINING THE BINDING SITE (REPORTER VECTOR)
Representative clones identified by PCR were inoculated into L broth 
(5 ml) containing 5pl of ampicillin (50 mg/ml), and incubated at 37 °C for 18 h 
with constant shaking prior to the inoculation of 200 ml of Terrific broth (see 
Appendix II) containing 800 pi of ampicillin (50 mg/ml) and incubation at 
37 °C for a further 18 - 24 h.
The overnight cell suspension was transferred into 500 ml centrifuge 
bottles and centrifuged at 8 krpm for 15 min at 4 °C using a GS3 rotor, after 
decanting the supernatant the bottles were inverted and allowed to drain 
before resuspending the pellets in 10 ml of solution A (see Appendix II), this 
was followed by 20 ml of freshly prepared solution B (see Appendix II). The 
bottles were swirled for about 1 min until the solution became clear, and then 
incubated on ice for 10 min.
Chilled solution C (10 ml) (see Appendix II) was added and the bottles 
shaken vigorously to mix the contents, following a 5 min incubation on ice 
the bottles were centrifuged at 8 krpm for 15 min at 4 °C using a GS3 rotor. 
After filtering the supernatant, 25 ml of isopropanol was added to each bottle 
followed immediately by centrifugation at 8 krpm for 10 min at 4 °C as above, 
the supernatant was discarded, the bottles inverted and the pellets air dried.
The pellets were resuspended in 2 ml of T.E. buffer (pH 8.0) (see 
Appendix II), 50 pi of RNase A (10 mg/ml) was added to each sample before 
incubation at 37 °C for 30 min. The resulting mixture was then extracted with 
phenol-chloroform twice and chloroform- isoamyl alcohol twice. 500 pi of
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PEG 8000 (20 %) and 25pl magnesium chloride (1 M) were added followed 
by immediate centrifugation in a microfuge at room temperature for 10 min. 
The supernatant was discarded and the pellets washed twice in 70 % 
ethanol prior to air drying and resuspension in 500 pi of T.E. buffer (pH8.0).
Aliquots (10 pi) were removed from each sample diluted to 1 ml with 
T.E buffer pH 8.0 and the concentration of DNA estimated using the 
Pharmacia Gene-Quant. An aliquot (1 pi) was also analysed by agarose gel 
electrophoresis to check the purity and integrity of the DNA isolated.
8.0. PREPARATION OF THE REPORTER STRAIN FOR USE 
IN THE YEAST ONE-HYBRID SYSTEM
The one-hybrid system is an in vivo yeast genetic assay used for 
isolating cDNAs encoding proteins that bind to a short target DNA sequence 
e.g. cis-acting transcription regulatory elements. It is based on the 
interaction between a specific protein DNA-binding domain and the target 
DNA sequence. A cDNA that may encode a DNA-binding domain is 
expressed as a fusion protein with a target independent transcription 
activation domain e.g. GAL4 AD. To carryout a one-hybrid assay at least 
three copies of a putative binding sequence are inserted upstream of the 
HIS3 gene minimal promoter in a specially designed plasmid e.g. pHISi-1, as 
in this case (thus giving a reporter construct). The reporter construct is 
integrated in vivo into a mutated HIS3 gene in the yeast genome to create a 
yeast reporter strain with a normal copy of the Hi S3 gene. A library of cDNAs
encoding GAL4 AD fusions is expressed in the reporter strain. If an 
AD/library protein interacts with the target DNA sequence, HIS3 promoter 
activity is increased resulting in increased amounts of histidine produced. 
Clones expressing histidine at a level higher than the reporter strain are 
selected by growth on medium lacking histidine in the presence of 3- 
aminotriazole (3-AT). In this thesis a rat brain CDNA-GAL4 library was 
screened for cDNA(s) encoding protein(s) binding to the -609nt to -577nt 
region in the mouse MBP promoter.
Diagrams illustrating the procedure are represented in figures 6a to 6d on 
the following pages.
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Putative Binding Site
Amp
pHISi-1
FIGURE 6A. The reporter plasmid pHISi-l, carrying four tandemly repeated 
copies of the putative binding site, was linearised with Xho I 
restriction endonuclease at a unique site located within the 
HIS3 gene before integration by homologous recombination 
into the mutated HIS3 gene locus of yeast strain YM4271 (used 
as the host).
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FIGURE 6B. A diagrammatic representation of the integration of the reporter 
plasmid into the yeast genome to produce a reporter strain 
carrying a normal copy of the HIS3 gene.
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Rat brain cDNA sequences are cloned in the unique EcoRI restriction 
endonuclease site of the multiple cloning site of pGADIO.
FIGURE 6C. A diagrammatic representation of the yeast AD cloning vector.
(Adapted from the Clontech One-hybrid system protocol)
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A sequence consisting of at least three copies of a putative protein-binding 
site (E) is inserted upstream of a reporter gene and integrated into the yeast 
genome (reporter strain). This reporter strain is transformed with a cDNA 
library that comprises a fusion of target specific binding proteins and the 
target-independent GAL4 activation domain. Binding of a cDNA/AD hybrid to 
one of the target elements results in the activation of reporter gene 
transcription.
FIGURE 6D. Diagrammatic representation of the activation of transcription 
following transformation of a cDNA/AD fusion library in the 
yeast reporter strain.
(Adapted from the Clontech One-hybrid system protocol)
8.1. LINEARISATION OF THE TARGET-REPORTER-VECTOR
Target-reporter plasmid containing the binding site was prepared as 
described in 7.0 and digested with Xho1 enzyme. The reaction mixture 
consisted of 20 pi DNA (20 pg), 3 pi of Xho1 buffer (10X), 3 pi (20 U/pl) of 
Xho1 restriction enzyme, and 4 pi of water. After digestion for 2.5 h at 37 °C 
the restriction endonuclease was inactivated with TE - saturated phenol (2 
extractions). This was followed by ether extraction (6 times) to remove 
residual phenol. DNA was precipitated by a standard procedure (as 
described in 2.3).
The DNA pellet was resuspended in 25 pi of sterile water and the 
completeness of the digestion was checked by agarose gel electrophoresis 
using undigested plasmid as a control.
8.2. PREPARATION OF COMPETENT YEAST CELLS
A single colony of Saccharomyces cerevisiae (strain YM4271) was 
inoculated into 1 ml of YPD medium (see Appendix II) and vortexed 
vigorously to disperse the cells. The cell suspension was transferred to 
50 ml of YPD medium and incubated at 30 °C for 18 to 24 h with shaking 
until the culture was saturated.
An aliquot of this culture (10 -  15 ml) was transferred to 100 ml of 
fresh YPD medium to give an initial absorbance at 600 nm of between 0.2 -
0.3 and incubated at 30 °C with shaking for 3 - 4 h.
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The cells were collected by centrifugation in 50 ml tubes at 2.2 krpm 
for 5 min at room temperature using the SL50T rotor, the pellet rinsed in 
25 ml of TE buffer pH 7.5 (see Appendix II) and the centrifugation repeated. 
The cell pellet was resuspended in 1 ml of freshly prepared TE/lithium 
acetate solution.
8.3 TRANSFORMATION OF COMPETENT YEAST CELLS
Linearised reporter vector carrying four copies of the binding site 
(approximately 1pg in 20 pi of TE buffer) was mixed with carrier DNA 
(100 pg in10 pi), and added to 100 pi of yeast competent cells.
As a negative control 100 pg of carrier DNA (sheared and denatured) 
was added to 20 pi (1 pg) of undigested reporter vector carrying the binding 
site, mixed and added to 100 pi of yeast competent cells. The positive 
control consisted of 100 pg of carrier DNA (sheared and denatured) and 
20 pi (1pg) of Xho1 digested p53HIS plasmid containing three tandem 
repeats of the consensus p53 binding site.
Freshly prepared PEG/LiAc solution (600 pi) was added to each 
transformation mixture followed by incubation with shaking at 30 °C for 
30 min to 1 h. 70 pi of DMSO were added to each tube, and a heat shock at 
42 °C for 15 min followed by an incubation on ice for 2 min was performed. 
The cells were spun down at 14 krpm for 5 -  10 sec in a microfuge, the 
supernatant removed and the pellet resuspended in 150 pi of TE buffer.
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The pHISi-1 and the p53HIS transformation mixtures were then plated 
onto SD/-HIS plates, incubated for 4 to 6 days at 30 °C to select for colonies 
with an integrated reporter gene. Colonies containing a functional integrated 
reporter gene were distinguishable by their larger size.
Master stock cultures of the strain containing the integrated target -  
reporter constructs were grown in SD/-HIS medium containing 25 % glycerol 
and kept at -70 °C until required.
8 4. ANALYSIS OF PUTATIVE REPORTER STRAIN 
CONSTRUCTS (THE RAPID ISOLATION OF YEAST 
CHROMOSOMAL DNA)
A culture (10 ml) of the yeast colony to be analysed was grown 
overnight to stationary phase in YPD medium at 30 °C, with shaking.
Following centrifugation at 3 krpm at room temperature the cell pellet 
was resuspended in 500 pi water, and transferred to a sterile Eppendorf tube 
to be pelleted again. The cell pellet was disrupted in 200 pil of breaking 
buffer (see Appendix II), and 200 pi (approximately 0.3 g) of acid-washed 
glass beads and 200 pi of phenol/chloroform/isoamyl alcohol were added 
and vortexed at high speed for 5 min. Following the addition of 200 pi of TE 
buffer pH 7.5 (see Appendix II) and brief vortexing the mixture was 
microfuged at full speed for 5 min at room temperature before and the 
aqueous layer was transferred to a fresh Eppendorf tube.
Absolute ethanol (1 ml) was added to the aqueous phase, mixed by 
inversion before microfuging at full speed for 5 min at room temperature. The
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pellet was resuspended in 400 pi of TE buffer, RNase A (3 pi of a 10 mg/ml 
stock) was added, mixed and incubated at 37 °C for 5 min.
The DNA was recovered by precipitation with 10 pi of 4M ammonium 
acetate and 1 ml of ethanol and microcentrifugation at full speed for 5 min at 
room temperature. The DNA pellet was dried in vacuo, resuspended in 25 pi 
of TE buffer and used in the PCR screening protocol as described 
previously.
8.5. TESTING NEW REPORTER STRAINS FOR 
BACKGROUND HIS3 EXPRESSION
The colonies identified as containing integrated target -  pHISi-1 were 
screened for background HIS3 expression.
A single colony was picked from the SD/-HIS plate and suspended in 
1 ml of TE buffer in a sterile Eppendorf tube. The cell suspension (5 pi) was 
pipetted onto the surface of an SD/-HIS plate containing either 0, 5, 10, 15, 
30, 45, or 60 mM 3 -  Aminotriazole (3 -  AT). The plates were incubated for 4 
to 6 days at 30 °C and the results analysed.
Yeast colonies growing on the SD/-His + >45 mM 3 - AT plates were 
considered to have high (very leaky) background HIS3 expression. Similarly 
if the yeast colony growth was inhibited on the SD/-HIS + < 45 mM 3 -  AT 
plates then the background HIS3 expression was low.
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Colonies of HIS3 reporter strain with the lowest background level of 
HIS3 expression were selected for use in the one-hybrid library screening 
protocol.
Several SD/-HIS/-LEU plates containing the optimal concentration of 
30 mM 3 -  AT were prepared. The 3 -  AT was present to maintain a positive 
selection pressure on the reporter clones. The plates were dried before 
spreading the cells as condensation could cause localised variations in the 
3 -  AT concentration, that could lead to false positive results
9.0. THE SEARCH FOR TRANSCRIPTION FACTORS
9.1. SCREENING OF A cDNA / AD FUSION LIBRARY
The preparation of competent reporter strain cells was carried out 
essentially as described in section 8.2, the only modification being the 
inoculation of reporter strain colonies into liquid SD/-His medium containing 
30 mM 3 -  AT, instead of YPD medium.
cDNA/AD fusion library (approximately 20 pg in 5 pi of water) was 
mixed with carrier DNA (2 mg in 200 pi) and added to 1 ml of competent 
reporter strain cells. Freshly prepared LiAc/PEG solution (6 ml) was added 
to each transformation mix followed by incubation at 30 °C for 30 min to 1 h 
with constant shaking. Then 700 pi of DMSO were added to each tube 
followed by a heat shock at 42 °C for 15 min and an incubation on ice for
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2 min was performed. The cells were pelleted at 2.2 krpm for 5 min, and 
resuspended in 2 X 25 ml of SD/-His liquid medium in two separate 50 ml 
tubes.
After incubation at 30 °C for 1 h with constant shaking, the cells were 
pelleted at 2.2 krpm for 5 min at room temperature and resuspended in 7 ml 
of TE buffer and spread on the SD/-His/-Leu + 30 mM 3 -  AT plates.
It should be noted that immediately after pipetting the cells onto the 
plate they were spread over the surface to prevent localised dilution of the
3 -  AT concentration.
The plates were incubated at 30° C for 4 to 6 days. Large colonies 
resulting from His3 activation were subcultured into fresh SD/-His/-Leu/
+ 30 mM 3 -  AT medium and used to isolate plasmid DNA for further 
analysis.
9.2. ANALYSIS OF PUTATIVE CLONES CARRYING AN AD 
FUSION LIBRARY PLASMID (RAPID ISOLATION OF 
YEAST PLASMID DNA)
Representative clones carrying putative cDNA/AD fusion library
plasmid were inoculated into 5ml of SD/-HIS/-Leu liquid medium containing
30 mM 3 -  AT and incubated at 30° C for 48 h with constant shaking.
The cells were pelleted by centrifugation at 2.2 krpm for 5 min at room
temperature; the pellets were washed with TE buffer and resuspended in
200 jlxI of breaking buffer. Acid-washed glass beads 200 pi (approximately
0.3 g) and 200 pi of phenol/chloroform/iso-amyl alcohol were added, before
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vortexing at high speed for 2 min. After centrifugation at 14 krpm for 10 min 
at room temperature in a microfuge, the supernatant was transferred to a 
clean Eppendorf tube and the plasmid DNA precipitated with 0.1 volume 
sodium acetate (3 M pH 6.0), 1 pi glycogen (at a concentration of 1 mg/ml), 
and 2.5 volumes of ethanol.
After incubation at -70° C for 30 min, the plasmid DNA was pelleted 
by microcentrifugation at 14 krpm for 10 min at room temperature, washed 
with 70 % ethanol, dried in vacuo and resuspended in 20 pi TE buffer.
9.3. ANALYSIS OF PUTATIVE CLONES CARRYING A LIBRARY 
PLASMID BY PCR
An aliquot (2.5 pi) of the plasmid described in section 9.2 was 
analysed by PCR using the library primers,
AD10[S] 5'-CTATTCG AT GAT GAAG ATAC C-3’ (located between 
nucleotides 788 to 808 on the plasmid sequence in Appendix VI), and 
AD10[R] 5’-CACAGTTGAAGTGAACTTGCG-3’ (located between 
nucleotides 903 to 883), essentially as described in section 6.3 except that 
the annealing temperature of the primers to template during thermal cycling 
was reduced to 50° C.
The products of the PCR were analysed by agarose gel 
electrophoresis. Plasmid DNA (10 pi) from positive clones carrying a library 
plasmid identified by PCR was transformed into E. coli strain DH5a using the 
procedure described in section 2.6.4.2.
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It should be noted that plasmid DNA isolated by the technique 
described in section 9.2. is not of suitable quality for sequencing due to 
yeast genomic DNA contamination, therefore, transformation into E. coli cells 
is essential.
9.4 IDENTIFICATION OF DNA -  BINDING PROTEINS BY 
AUTOMATED SEQUENCING AND DATABASE 
SEARCHES
Plasmid DNA was isolated and purified from the transformed E. coli 
cells using the Modified Clewell and Helinski technique and centrifugation to 
equilibrium in caesium chloride-ethidium bromide gradient as described in 
sections 2.2. and 2.3. respectively.
An aliquot of plasmid DNA (20 pi at a concentration of 0.1 pg/jul) was 
sequenced automatically.
From the sequence data obtained comparisons were made with those 
of known nucleotide and protein sequences for transcription factors on other 
databases (e.g. EMBL, Genbank and Swissprot) using the FastA and Blast 
search tool.
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Chapter 3
Results
3.1. Sub -  cloning of the myelin basic protein gene promoter in the 
plasmid pBluescript for the purposes of sequencing and 
functional characterisation
The 6.02 kb plasmid pEX1 (a gift from Arthur Roach Division of 
Biology, California Institute of Technology, Pasadena, California) shown 
schematically in Figure 7 contains the promoter region and a segment 
(including exon 1 which is shown cross-striped in blue) of the mouse myelin 
basic protein gene. On the basis of the restriction map of this plasmid a 
strategy was designed to obtain the fragment of DNA carrying the promoter 
region by excising it with Hind III and Sac I restriction endonucleases. This 
DNA fragment was subsequently used in cloning for further studies.
Analysis of the restriction endonuclease digestion products (Figure 8 
lane 3) shows three distinct bands ranging in size from 1.40 to 2.68 kb. The 
smallest fragment (1.40 kb) represents the Hind III -  Sac I digestion product 
containing the promoter region and segment including exon 1 of the myelin 
basic protein gene. The 2.68 kb digestion product represents the Hind III -  
Hind III fragment of the plasmid pUC13 (shown cross-striped in red in Figure 
7), which was used as the cloning vector, and the third band (1.94 kb) 
represents the Sac I -  Hind III fragment of the myelin basic protein gene.
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Figure 7. Diagrammatic representation of the recombinant plasmid pEX1 
containing the promoter region and segment (including exon 1) 
of the mouse myelin basic protein gene.
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The products of the digestion of pEX1 with Hind III form two bands 
(Lane 1); the slower band corresponds to the larger 3.34 kb fragment, which 
contains the promoter region and segment (including exon 1) of the mouse 
myelin basic protein gene, and the smaller fragment (faster band) containing 
the 2.68 kb part of vector pUC13.
Only a single band corresponding to the linearised 6.02 kb plasmid 
pEX1 after digestion with Sac I can be seen in lane 2.
Uncut pEX1 DNA (0.8 pg) used as a control shows more than one 
band, these represent the supercoiled form (lower band) and the open 
circular form (upper band) of the plasmid (figure 8, Lane 4).
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Figure 8. Analysis by agarose gel (1%) electrophoresis of the restriction 
endonuclease digestion products of the plasmid pEX1 with 
Hind III and Sac I.
Lane M. A X DNA molecular size marker (EcoR1 -  Hind III double digest of X 
phage DNA).
The figures in red represent the molecular size in base pairs.
Lane 1. Digestion of the plasmid pEX1 with Hind III restriction endonuclease. 
Lane 2. Plasmid pEX1 following digestion with Sac I restriction 
endonuclease.
Lane 3. Digestion of the plasmid pEX1 with a combination of Hind III and 
Sac I.
Lane 4. Undigested plasmid pEX1 (0.8 \ig).
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The fragment containing the MBP promoter region was excised from 
the gel, the DNA electro-eluted, and purified by ion exchange 
chromatography on DE-52 cellulose. Following ethanol precipitation the DNA 
was resuspended in sterile deionised water and analysed by agarose gel 
electrophoresis (Figure 9, Lane 2).
The purified 1.40 kb DNA fragment containing the promoter region of 
the mouse myelin basic protein gene was then cloned into the plasmid 
vector pBluescript (a map of this plasmid is given in Appendix VI).
For this purpose, pBluescript was digested with Sac I and Hind III 
restriction endonucleases (data not shown). Two different restriction 
endonucleases were used to prevent religation of the pBluescript vector. The 
restriction endonucleases were inactivated by treating the digestion mixture 
with phenol. Water-saturated ether was then added to remove any residual 
phenol, and the plasmid DNA ethanol precipitated. Following resuspension 
of the plasmid pBluescript in deionised water the purified 1.40 kb fragment 
was added and ligation performed as described in 2.6.3.
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Figure 9. Analysis by agarose gel (1%) electrophoresis of the 1.4 kb
fragment containing the promoter region and segment of the mouse 
myelin basic protein gene after isolation and purification from the 
plasmid pEX1.
Lane 1. A X DNA molecular size marker (EcoR1 -  Hind III double digest of X 
phage DNA).
Lane 2. Purified Hind III -  Sac I fragment containing the promoter region of 
the mouse myelin basic protein gene.
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Competent cells were prepared by growing E coli (strain DH5a) to an 
absorbance of 0.5 (at 650 nm) followed by treatment with ice-cold calcium 
chloride as described in 2.6.4.1. The ligation product consisting of 
pBluescript, with the promoter region and segment of the mouse myelin 
basic protein gene, was mixed with the competent cells. A heat shock at 
42° C followed by an incubation on ice was performed. After incubation at 
37° C for 1 h, to allow for the expression of the p-lactamase gene carried by 
the plasmid pBluescript, the bacteria were spread over the surface of pre­
dried AIX plates (Figure 10).
Many vectors including pBluescript contain the regulatory sequences 
and coding region for the first 146 amino acids (called the a-peptide) of the 
p-galactosidase gene (/acZ). Embedded in this coding region is a 
multicloning site. Vectors of this type are used in host cells that are able to 
synthesise the remainder of the p-galactosidase gene. Neither the plasmid 
nor the host-encoded fragments are active, but they can associate to form an 
enzymatically active protein. This process is called a-complementation. The 
Lac+ bacteria that result from a-complementation are easily recognised 
because they form blue colonies in the presence of the chromogenic 
substrate X-gal. Insertion of a fragment of DNA into the multicloning site of 
the plasmid usually results in the production of an NH2 -  terminal fragment 
incapable of a-complementation (insertional inactivation), so bacteria 
carrying recombinant plasmids will form white colonies.
The chemical analogue of lactose (IPTG), which cannot be cleaved by 
the enzyme p-galactosidase, is used as an inducer of the E.coli lac operon. It
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binds to and inactivates the lac repressor; therefore, incubation with IPTG 
results in the maximum expression of genes cloned into suitable vectors. 
When used in combination with X-GAL, as in this project, it can be used as a 
selection system for recombinant plasmids.
Selection by ampicillin resistance was also used to prevent the growth 
of untransformed host cells.
White colonies were considered putative recombinant clones carrying 
the promoter region of the myelin basic protein gene and analysed further.
Blue colonies resulting from inefficient digestion were considered 
negative since they only contained the plasmid vector.
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Figure 10. Selection of putative recombinant clones carrying the promoter 
region and segment (including exon 1) of the MBP gene using a 
selective medium containing the E. coli lac operon inducer IPTG 
and the chromogenic substrate X-gal.
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Several (five) white colonies were grown in L-broth containing 
ampicillin (50 pg/ml) with vigorous shaking. The plasmid DNA was isolated 
using a small-scale procedure based on the alkaline lysis method of 
Birnboim and Doly (1979).
Analysis of the plasmid DNA by agarose gel electrophoresis (Figure 11) 
showed one band, this represents the supercoiled form of a plasmid of 
approximately 4.4 Kb which corresponds to pBluescript (3.0 Kb) containing 
the 1.4 Kb myelin basic protein gene promoter insert, (Figure 10, Lanes 1 - 
5). pBluescript without the myelin basic protein gene insert was run as a 
control sample and is shown in Figure 11, Lane 6 as a 3.0 Kb band.
An EcoR1 - Hind III double digest of X phage DNA was used as a molecular 
size marker (lane M) to determine the size of the plasmid DNA band 
isolated.
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Figure 11
Lane M. 
Lanes 1 -  
Lane 6.
Analysis by agarose gel (1%) electrophoresis of plasmid DNA 
isolated from putative recombinant clones carrying the 
promoter region of the mouse myelin basic protein gene.
A X DNA molecular size marker (EcoR1 -  Hind III double digest 
of X phage DNA).
5. Plasmid DNA isolated from the putative clones carrying the 
myelin basic protein gene insert.
pBluescript (without the MBP gene insert) run as control.
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To confirm the presence of the 1.4 Kb fragment containing the myelin 
basic protein gene promoter the plasmid DNA was digested with a 
combination of Hind III and Sac I restriction endonucleases, and the 
products analysed by agarose gel electrophoresis (Figure 12).
Two distinct bands can be seen:
i.) a 1.4 kb band putatively corresponding to the Hindlll - Sad 
fragment of the promoter region and segment including the first exon 
of the mouse myelin basic protein gene.
ii.) a 3.0 kb band that corresponds to the vector pBluescript.
The weak band at 4.4kb is the remainder of undigested plasmid product from 
the recombinant plasmid carrying the myelin basic protein gene insert.
Figure 12, Lane 6 shows only a single band of linear pBluescript after 
digestion with Hind III and Sac I restriction endonucleases as expected.
A X DNA molecular size marker (EcoR1 - Hind III double digest of X 
phage DNA) was used to determine the size of the digestion products (Lane 
M).
Plasmid DNA was isolated on a large scale from one of the positive clones 
and used for DNA sequencing studies.
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Figure 12. Analysis of the putative clones carrying the MBP gene
promoter following digestion with a combination of Hind III and 
Sac I restriction endonucleases by agarose gel (1 %) 
electrophoresis.
Lane M. AX  DNA molecular size marker (EcoR1 -  Hind III double digest 
of X phage DNA).
Lanes 1 -  5. Restriction endonuclease digestion products of the plasmid 
DNA isolated from the putative positive clones carrying the 
myelin basic protein gene insert.
Lane 6. Linear pBluescript following digestion with Hind III and Sac I 
restriction endonucleases.
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3.2. Sequencing of the Hind H I- Sac I restriction fragment containing 
the MBP promoter
Single-stranded DNA from a positive clone was prepared using 
alkaline denaturation followed by chromatography on Sephacryl S-400 
columns. DNA obtained by this method is of high enough purity to be used 
directly for sequencing.
Sequencing was done manually using the chain termination method of 
Sanger et a!. (1977), involving the enzymatic synthesis of a new DNA strand 
complementary to the template using a DNA polymerase enzyme (e.g. 
Sequenase). Synthesis of the new DNA strand continues in the presence of 
the deoxynucleoside triphosphates until the incorporation of a 
dideoxynucleotide, at which point the growing chains are terminated, this 
occurs due to the lack of a free 3’ hydroxyl group on the dideoxynucleoside 
triphosphate. The ratio of deoxynucleoside triphosphates (dNTPs) to 
dideoxynucleoside triphosphates (ddNTPs) in the labelling mix is 10 : 1. 
Incorporation of a-35S -  dATP in the growing chains enabled visualisation of 
the sequencing products by autoradiography.
An oligonucleotide primer corresponding to the universal priming site 
(located within the multicloning site) of the plasmid pBluescript SK* (see 
plasmid map in Appendix VI) was synthesised.
Universal primer sequence 5’- TAAAACGACGGCCAGT -3’
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From the sequence determined using the universal primer another 
primer (corresponding to the sequence between nt -1168 to -1154 of the 
MBP gene) was prepared and further sequence data obtained. The 
procedure was repeated until the 1.4 kb Hind III -  Sac I fragment carrying 
the promoter and segment (including exon 1) of the mouse MBP gene had 
been established. The sequences and locations of the primers are shown in 
Table 2.
Similarly sequence data for the reverse (complementary) strand was 
determined using the T3 promoter primer as the starting primer together with 
two other primers, which are represented in Table 2.
T3 promoter primer sequence 5’- AATTAACCCTCACTAAAGGG -3’
An autoradiogram (Figure 13) shows part of the sequence obtained 
(approximately 170 bases) of the 1.4 kb fragment containing the promoter 
region and segment of the myelin basic protein gene. The 93 bases 
identified on the autoradiogram are located between nucleotide positions 
-  832 and -  740. Further autoradiogram showing sequencing data can be 
seen in figures 14 and 15 and represent the myelin basic protein promoter 
region sequence located between nucleotides -1319 and -1244 and -712 
and -666. respectively.
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"E
-1168 0-1154 5’-CAT GGGTGCATAGAT-3’ou_
"D
CO -939 0  - 923 S’-CTAAGGTCAGTAATAGA-S’OUL
T3s_
CO -824 0  - 806 5’-T GTGCTTGGTT GTGGAAGT-3’OH UL
~os_
CO -590 0  - 575 5’-GCTTCACATCTGGGGC-3’oLL.
■o, ! _
CO -442 0  - 425 5’-AGTGGTT CTTTTATT GAG-3’oLL
0)CO
CD> -244 0 - 2 2 8 3’-CCGGGTGTAAGTATAG-5’Q>a:
(DV)(D> -66 0 - 5 1 3’-GGGCTCTACGGGGCCC-5’
CD
DC
Table 2. The sequences of the oligonucleotide primers synthesised in the 
laboratory for determining the sequence of the Hind III -  Sac I 
fragment of the mouse myelin basic protein gene promoter.
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Figure 13. An autoradiogram showing the sequence of the MBP gene 
promoter located between nucleotides -832 and -740.
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Figure 14. An autoradiogram showing the DNA sequence of the MBP
gene promoter located between nucleotides -1319 and -1240. 
Duplicate samples of the sequencing products were loaded 
onto the gel, with the exception of the sequencing product 
labelled universal primer.
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Figure 15. An autoradiogram showing the DNA sequence of the MBP 
gene promoter located between nucleotides -712 and -666. 
Duplicate samples of the sequencing products were loaded 
onto the gel.
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The sequence of the Hind III -  Sac I fragment (located between nucleotide 
positions -1319 and +227) containing the promoter region and segment 
(including exon 1) of the mouse myelin basic protein gene as determined 
from the sequencing gels is outlined as follows:
DNASIS ***** DNA SEQUENCE FILE LIST *****
*** INPUT INFORMATION ***
FILE: MBP_PROMOTER.SEQ
*** SEQUENCE LIST *** (DOUBLE STRANDED)
- 1 3 1 9  - 1 3 1 0  - 1 3 0 0  - 1 2 9 0
AAGCTTTGA GAGAAAAGGG ACCAGATCTT ATTCCTCACC 
TTCGAAACT CTCTTTT CCCTGGTCTAGAA TAAGGAGTGG
- 1 2 8 0  - 1 2 7 0  - 1 2 6 0  - 1 2 5 0
GTGGCTTTAA CACTTAGAGA AAATGCATCC CCTCTAATCA 
CACCGAAATT GTGAATCTCT TTTACGTAGG GGAGATTAGT
- 1 2 4 0  - 1 2 3 0  - 1 2 2 0  - 1 2 1 0
ATAAGTCATC GACAGTGGGT AGATGGAGGA ACGGCAGTCG 
TATTCAGTAG CTGTCACCCA TCTACCTCCT TGCCGTCAGC
- 1 2 0 0  - 1 1 9 0  - 1 1 8 0  - 1 1 7 0
GTAGTAGGAT GCGTGCTAAC GATAGTCTCG T C f B H  
CATCATCCTA CGCACGATTG CTATCAGAGC ACGTACCCAC
116
- 1 1 6 0  - 1 1 5 0  - 1 1 4 0  - 1 1 3 0
f f lg /M c C G  TGGGCAGGTG GACAAGGTGG GGGTGGATAA 
GTATCTAGGC ACCCGTCCAC CTGTTCCACC CCCACCTATT
- 1 1 2 0  - 1 1 1 0  - 1 1 0 0  - 1 0 9 0
AGAAGTGGGT AGATGATTGA TGTTAGGTAA ATATCACTGG 
TCTTCACCCA TCTACTAACT ACAATCCATT TATAGTGACC
- 1 0 8 0  - 1 0 7 0  - 1 0 6 0  - 1 0 5 0
GTGGACAGAT GGGTGGTAGG TGGATGGATG GTTAGAATAG 
CACCTGTCTA CCCACCATCC ACCTACCTAC CAATCTTATC
- 1 0 4 0  - 1 0 3 0  - 1 0 2 0  - 1 0 1 0
TCAGAAGAGG GATGGATTGA TAAGGTGAAC AGATGATAAA 
AGTCTTCTCC CTACCTAACT ATTCCACTTG TCTACTATTT
- 1 0 0 0  - 9 9 0  - 9 8 0  - 9 7 0
TGGGTGATAG ACTGGAAGGG TTGTCAAAAG AGGATAAGGG 
ACCCACTATC TGACCTTCCC AACAGTTTTC TCCTATTCCC
- 9 6 0  - 9 5 0  - 9 4 0  - 9 3 0
TTCACACTCG ATCGGCATAA AGATTCCAGT CATTATCTCA
- 9 2 0  - 9 1 0  - 9 0 0  - 8 9 0
TGGGAGAAGA GGTTAAGTTA CATCCATTTA AACCTCACAC 
ACCCTCTTCT CCAATTCAAT GTAGGTAAAT TTGGAGTGTG
117
- 8 8 0  - 8 7 0  - 8 6 0  - 8 5 0
GAAGCTGAGT GGGAATGGAC TTGCTGCCGT TGGTGAGGAA 
CTTCGACTCA CCCTTACCTG AACGACGGCA ACCACTCCTT
- 8 4 0  - 8 3 0  - 8 2 0  - 8 1 0
TCGCAACGTA AAGGGCACAC GAACCAACAC CTTCACGAGT
- 8 0 0  - 7 9 0  - 7 8 0  - 7 7 0
GGTCCCACAT GAAGCAGTCA GGTTACTGCG GCTTACAGAG 
CCAGGGTGTA CTTCGTCAGT CCAATGACGC CGAATGTCTC
- 7 6 0  - 7 5 0  - 7 4 0  - 7 3 0
GAGCCAGATC CAAATGCCCC GAGTAAGCAC GTCCCCGAGC 
CTCGGTCTAG GTTTACGGGG CTCATTCGTG CAGGGGCTCG
- 7 2 0  - 7 1 0  - 7 0 0  - 6 9 0
CAGAGGCCTC CAGCGGAATC CGGGAGAGGG ATTGCTCAGT 
GTCTCCGGAG GTCGCCTTAG GCCCTCTCCC TAACGAGTCA
- 6 8 0  - 6 7 0  - 6 6 0  - 6 5 0
GCCCTGCTTC CCTGGACTGT AAGCTGCAGA AAGATGTGGG
CGGGACGAAG GGACCTGACA TTCGACGTCT TTCTACACCC
- 6 4 0  - 6 3 0  - 6 2 0  - 6 1 0
AAGTCCTGTT CTCCACTGAG AACACTAAAA GCACCTTTTG 
TTCAGGACAA GAGGTGACTC TTGTGATTTT CGTGGAAAAC
118
- 6 0 0  - 5 9 0  - 5 8 0  - 5 7 0
AGTTTGCTGG CGAAGTGTAG ACCCCGAACA CGTGACCACC
- 5 6 0  - 5 5 0  - 5 4 0  - 5 3 0
CCTTTTAAAC CAGAGACAAC CCACAAGATA CCTAACCTGC 
GGAAAATTTG GTCTCTGTTG GGTGTTCTAT GGATTGGACG
- 5 2 0  - 5 3 0  - 5 2 0  - 5 1 0
GGGGCTCTCT GGTACAGTGA GCAACTCAGG AAATGCTTTG 
CCCCGAGAGA CCATGTCACT CGTTGAGTCC TTTACGAAAC
- 4 8 0  - 4 7 0  - 4 6 0  - 4 5 0
GCTTGATTGC TGTGGGCTCT CAGGCCATCG CCCTCTG G j| 
CGAACTAACG ACACCCGAGA GTCCGGTAGC GGGAGACCTC
- 4 4 0  - 4 3 0  - 4 2 0  - 4 1 0
TGAAGATTGG CCCCTGAGCC 
ACCAAGAAAA TTACTCTTGG ACTTCTAACC GGGGACTCGG
- 4 0 0  - 3 9 0  - 3 8 0  - 3 7 0
ATGTATACCA AGCAAGCTCA ATCCAGGTTA GCTCCCTCTG 
TACATATGGT TCGTTCGAGT TAGGTCCAAT CGAGGGAGAC
- 3 6 0  - 3 5 0  - 3 4 0  - 3 3 0
GTTGGGGCAA GCTAACGTGC TCCTTGGGCC CCGCGCGTAA 
CAACCCCGTT CGATTGCACG AGGAACCCGG GGCGCGCATT
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- 3 2 0  - 3 1 0  - 3 0 0  - 2 9 0
CTGTGCGTTT TATAGGAGAC AGCTAGTTCA AGACCCCAGG 
GACACGCAAA ATATCCTCTG TCGATCAAGT TCTGGGGTCC
- 2 8 0  - 2 7 0  - 2 6 0  - 2 5 0
AAGAAAGCGG CTTTGTCCCC CTCTAGGCCT CGTACAGGCC 
TTCTTTCGCC GAAACAGGGG GAGATCCGGA GCATGTl
- 2 4 0  - 2 3 0  - 2 2 0  - 2 1 0
CACATTCATA TCTCATTGTT GTTGCAGGGG AGGCAGATGC
- 2 0 0  - 1 9 0  - 1 8 0  - 1 7 0
GATCCAGAAC AATGGGACCT CGGCTGAGGA CACGGCGGTG 
CTAGGTCTTG TTACCCTGGA GCCGACTCCT GTGCCGCCAC
- 1 6 0  - 1 5 0  - 1 4 0  - 1 3 0
ACAGACTCCA AGCACACAGC AGACCCAAAG AATAACTGGC
TGTCTGAGGT TCGTGTGTCG TCTGGGTTTC TTATTGACCG
- 1 2 0  - 1 1 0  - 1 0 0  - 9 0
AAGGCGCCCA CCCAGCTGAC CCAGGGAACC GCCCCCACTT
TTCCGCGGGT GGGTCGACTG GGTCCCTTGG CGGGGGTGAA
■80 - 7 0  - 6 0  - 5 0
GATCCGCCTC TTTTCCCGAG ATGCCCCGGG AAGGGAGGAC 
CTAGGCGGAG A A A A | |H j^ B H H H r ~ TTCCCTCCTG
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- 4 0  - 3 0  - 2 0  - 1 0
AACACCTTCA AAGACAGGCC CTCAGAGTCC GACGAGCTTC 
TTGTGGAAGT TTCTGTCCGG GAGTCTCAGG CTGCTCGAAG
+ 1  + 1 1  + 2 1  + 3 1
AGACCATCCA AGAAGACCCC ACAGCAGCTT CCGGAGGCCT 
TCTGGTAGGT TCTTCTGGGG TGTCGTCGAA GGCCTCCGGA
+ 4 1  + 5 1  + 6 1  + 7 1
GGATGTGATG GCATCACAGA AGAGACCCTC ACAGCGATCC 
CCTACACTAC CGTAGTGTCT TCTCTGGGAG TGTCGCTAGG
+ 8 1  + 9 1  + 1 0 1  + 1 1 1
AAGTACCTGG CCACAGCAAG TACCATGGAC CATGCCAGGC 
TTCATGGACC GGTGTCGTTC ATGGTACCTG GTACGGTCCG
+ 1 2 1  + 1 3 1  + 1 4 1  + 1 5 1
ATGGCTTCCT CCCAAGGCAC AGAGACACGG GCATCCTTGA 
TACCGAAGGA GGGTTCCGTG TCTCTGTGCC CGTAGGAACT
+ 1 6 1  + 1 7 1  + 1 8 1  + 1 9 1
CTCCATCGGG CGCTTCTTTA GCGGTGACAG GGGTGCGCCC 
GAGGTAGCCC GCGAAGAAAT CGCCACTGTC CCCACGCGGG
+201 +211 +221
AAGCGGGGCT CTGGCAAGGT GAGCTC 
TTCGCCCCGA GACCGTTCCA CTCGAG
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KEY:
Red Hind III (nt -1319 tO -1314) and Sac I (nt +221 to +226)
restriction endonuclease sites respectively.
Green Restriction endonuclease sites.
Acc I GT/ATAC -398 to -393
Alw44 I G/TGCAC -572 to -567
Bg lll A/GATCT -1297 to -1292
Dra I TTT/AAA -894 to -889
Hae III GG/CCA +89 to +93
Hsp II CATG/ +102 to +108
Sma I CCC/GGG -56 to -51
Stu I AGG/CCT -717 to -712
Xma I C/CCGGG -56 to -51
Blue Primer sequences as shown in table 2.
Yellow Identified protein binding sites as shown in table 3.
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The data obtained from the sequencing gels representing the 
promoter region of the mouse myelin basic protein gene, located between 
nucleotides -1319 and +227, was used as a query or probe sequence to 
carry out a FastA sequence alignment search against the EMBL rodent 
database. A significant alignment was found with a sequence published by 
Miura et al., (1989 and updated March 2000), which showed that the two 
sequences were essentially identical (99.6%).
However, there are three minor discrepancies with the published 
database sequence. These discrepancies are located within the 5’ 
untranslated region at nucleotide positions -1202 to -1201, -1181 to -1180 
and -1152 to -1151 respectively relative to the transcriptional start site. 
Miura et al., (1989) shows the sequence at these positions to be GC yet the 
manual sequencing gels indicate the sequence to be CG. It is possible that 
these differences could be dinucleotide polymorphisms, whereby the 
definition of a polymorphism is applied in its loosest sense i.e. any non- 
pathogenic sequence variant.
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Transcription of many genes begins by the binding of RNA 
polymerase II, mediated by the TFII group of ubiquitous transcription factors, 
to the 'TATA' sequence located at a position upstream of the transcriptional 
initiation site. The MBP promoter, however, does not contain typical TATA 
(consensus TATA(A/T)A(A/T)), CAAT (consensus GGCCAATCT) and GC 
(consensus GGGCGG) boxes, but contains TATA (TTCAAA) and CAAT 
(CACTT) box-like sequences located at positions -34 and -85 respectively. 
It is thought that the myelin basic protein promoter may utilise specific TATA 
and CAAT box factors (Tamura etal. 1989). A GC box-like sequence 
(CCGCCC) has also been identified at position -92 to which a specific Sp1- 
like transcription factor binds (Tamura etal. 1989).
From database searches, published papers by Miura etal. (1989) 
and Tamura etal. (1990) and experimental approaches a number of 
important DNA-binding sites for transcription factors have been identified in 
the mouse myelin basic protein gene promoter (a summary of the positions 
of these binding sites is shown in Table 3).
It has been suggested (Aoyama etal. 1990) that the mouse myelin 
basic protein gene promoter from nucleotide positions -253 to +62 is 
responsible for efficient and tissue-specific transcription, and that this region 
can be further divided into the proximal element (-53 to +62 containing the 
TATA box-like element at -34) which is required for basal transcription and 
the distal element (-253 to -54) which is responsible for brain specificity.
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Nucleotide
Position Nucleotide Sequence Comments Reference
-34 to -28 5-TTCAAA-3’ TATA-like sequence Miura et al. (1989)
-85 to -81 5-CACTT-3’ CAAT box like sequence
Miura et al. 
(1989)
-92 to -87 5-CCGCCC-3’ GC box Miura et al. (1989)
-130 to -93
5’-
AATAACTGGCAAGGCGCCCAC 
C CAGCTGACCCAGGGAA-3 ’
Myelin regulation 
factor-1 (MRF-1)
Haque et al. 
(1994)
-125 to
I -111 5’-CT GGCAAGGCGCCCA-3’ NFI-like binding site
Miura et al. 
(1989) j
-132 to 
-125 5 ’ -C A A AG A AT A AC-3 ’ MEBA
Taveggia et 
al. (1998)
-160 to 
-127
5 -acagactccaagcacaca
gcagacccaaagaata -3 ’
Box I and Box II 
motif
Torron et al. 
(1997)
-183 to 
-168
5’-ACCTCGGCTGAGGACACG-
3’
Thyroid hormone 
response element
Farsetti et al. 
(1992)
-648 to 
-635 5-GATGTGGGAAGTCC-3’
SV40-like enhancer 
core
Miura et al. 
(1989)
-675 to 
-647
5’ GCTTCCCTGGACTGTAA 
GCTGCAGAAAGA -3 ’
Fyn response 
element
Umemori et 
al. (1999)
Table 3: Important protein-binding sites identified in the sequence of the 
Hind III -  Sac I fragment of the mouse myelin basic protein 
promoter region and segment (including exon 1).
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Myelin gene expression factor-2 (MyEF-2) is a protein of 436 amino 
acids isolated from mouse brain that binds specifically to the noncoding 
strand of the proximal regulatory sequence known as MB1 (located between 
nt -50 to -14 relative to the transcription initiation site) and represses 
transcription of the MBP gene in transient transfection assay (Haas et al.
1995). MyEF-2 contains the RNA recognition motif (RRM)-type nucleic acid 
binding motif common to a growing family of proteins that bind single- 
stranded DNA and RNA in a sequence-specific manner (Kenan et al. 1991). 
MyEF-2 mRNA is developmental^ regulated in mouse brain with peak 
expression occurring at post-natal day 7, before the onset of myelin basic 
protein expression. MyEF-2 mRNA expression follows that described for 
SCIP (also called Oct-6 or Tst-1), a POU domain transcription factor that 
represses several myelin -  specific genes notably myelin basic protein and 
P0 glycoprotein expression. The MyEF-2 gene maps to mouse chromosome 
2 (Haas etal., 1995). Muralidharan etal. (1997) using a bandshift assay with 
purified MEF-1/Pura and MyEF-2 demonstrated that the binding of MyEF-2 
to its target sequence is inhibited by MEF-1/Pura. Under similar conditions, 
MyEF-2 enhances the association of MEF-1/Pura with MB1 DNA. MEF- 
1/Pura binds to MB1 in mono- and dimeric forms, and inclusion of MyEF-2 in 
the binding reaction increases the dimeric association of MEF-1/Pura with 
the MB1 sequence. The use of MEF-1/Pura variants in the bandshift assay 
suggested that two distinct regions of this protein may be involved in its 
binding to the MB1 regulatory sequence, and its ability to block MyEF-2 
interaction with the MB1 sequence.
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Steplewski etaf. (1998) reported the isolation of a recombinant cDNA 
clone, termed myelin expression factor-3 (MyEF-3) from a mouse brain 
expression library encoding a novel protein interacting with the MBP 
regulatory domain (MB1) located between nt -50 to -14 relative to the 
transcription initiation site. The MyEF-3 sequence revealed several 
interesting features including four sites for phosphorylation by casein kinase 
II, a transmembrane domain at the N-terminus, a nuclear localisation signal 
and a zinc finger domain at the carboxyl terminus (Steplewski et at. 1998). 
The group also showed that MyEF-3 binds as efficiently to the double­
stranded regulatory region as it does to the single-stranded non-coding 
strand. Northern blot analysis studies demonstrate that expression of MyEF- 
3 is restricted to brain and is developmentally regulated during brain 
maturation.
Functional dissection of the regulatory sequence has led to the
identification of a regulatory motif spanning nucleotides -14 to -50 (named
MB1) with respect to the transcription start site (Tretiakova etal. 1998).
Analysis of nuclear proteins derived from mouse brain identified a 39 kDa
protein that forms a nucleoprotein complex with a DNA fragment containing
the same sequence. Subsequent studies (Tretiakova etal., 1998) showed
the 39 kDa protein, named Pura, recognised the GGC/GGA -  rich
sequences within the MB1 DNA in a single-stranded configuration and has
the ability both in vitro and in vivo to increase transcription of the myelin
basic protein promoter. Pura binding activity to the MB1 regulatory sequence
occurs in a developmental stage-specific manner coinciding with the pattern
of MBP transcription. At the early stage of brain development (days P3 to
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P7) Pura levels associated with MB1 are extremely low, however, during the 
phase of myelination (days P18 to P20) and in adults (day 30) Pura binding 
activity to MB1 dramatically rises. Because a significant amount of Pura is 
detected at an early stage and the association with the MB1 DNA sequence 
is low, then the implication(s) of a cofactor(s) may determine Pura binding 
activity to the DNA molecule. The ability of Pura to interact with a GGN 
repeat in a single-stranded form prompted the examination of its binding 
ability to RNA molecules. Tretiakova etal. (1998) demonstrated that Pura 
obtained from brain extract is associated with RNA molecules that have the 
ability to inhibit its binding activity to the MB1 DNA. This RNA named PU- 
RNA, has significant homology to the 7SL RNA, is expressed during various 
stages of brain development, and is found in association with Pura in 5 day- 
old mouse brain. Therefore, PU-RNA functions as a cofactor by determining 
the binding activity of Pura to the MBP promoter sequence and indirectly 
participate in the developmental activation of the MBP promoter in mouse 
brain.
From the earlier study outlined above, Tretiakova etal. (1999) have 
now found evidence for the binding of the ubiquitous transcription factor 
(Sp1) to the MB1 DNA motif (spanning nucleotides -14 to -50) that partially 
overlaps the Puralpha binding site. They demonstrated that the binding of 
Puralpha to its target sequence is enhanced by the inclusion of Sp1 in the 
binding reaction. Under this condition binding of Sp1 to the MB1 regulatory 
sequence remained unchanged and there was no evidence for the formation 
of a Puralpha:MB1:Sp1 complex. This observation suggested that transient
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interaction of Puralpha and Sp1 might result in the stable association of 
Pura and the MB1 element. Results from immunoprecipitation/Western blot 
studies have established an association of Pura and Sp1 in nuclear extracts 
from mouse brain. Pura appears to bind to the phosphorylated form of Sp1, 
which is developmental^ regulated and coincides with the periods when 
MBP gene expression is at its maximum level. Results from cotransfection 
studies revealed that ectopic expression of Pura and Sp1 synergistically 
stimulates MBP promoter activity in CNS cells (Tretiakova etal. 1999).
Haque etal. (1994) have reported the isolation of a recombinant 
clone, which they named myelin regulatory factor-1 (MRF-1), from a mouse 
brain expression library that encodes a novel protein interacting with the 
distal regulatory domain (MB3) located between nucleotide positions -130 to 
-93. Analysis of MRF-1 by Haque et al. revealed substantial sequence 
homology in the central and the COOH-terminal regions of the protein with 
the splicing factor SC35. Cotransfection studies carried out by the group 
indicated that MRF-1 increases transcription of the MBP promoter in glial 
cells and that the activation requires an intact MRF-1-binding site. The gene 
encoding MRF-1 is located on the distal half of mouse chromosome 11 in a 
region where the human homologue would be predicted to reside on human 
chromosome 17.
Taveggia et al., (1998) describe a DNA sequence flanking and
partially overlapping the NF1 site, which activates the MBP promoter in
oligodendrocytes. This sequence is bound by a unique set of nuclear
proteins enriched in the brain, oligodendrocytes, and Schwann cells,
designated MEBA (myelinating glia-enriched binding activity). The
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appearance of MEBA parallels both myelination in the developing brain and 
myelin basic protein mRNA expression in differentiating oligodendrocytes. 
Mutations within the region of MEBA and NF1 binding distinguish MEBA 
from NF1 and suggest that MEBA consists of at least two proteins. Because 
these binding sites with opposing functions overlap, Taveggia etal., (1998) 
suggested that MEBA might either compete with or alter the NF1 binding of 
the proximal MBP promoter and derepress the MBP promoter in 
oligodendrocytes.
The box 1 and box 2 motif (Torron et al. 1997) of the myelin basic
protein promoter is composed of two DNA sequences 13 and 12 bp long
respectively, separated from each other by nine poorly conserved base
pairs, and are located at -160 to -127 bp from the transcription initiation site
in mouse. The box 1 and 2 motif is flanked at its 5’-end by a thyroid hormone
receptor element (at nucleotides -183 to -168, Farsetti etal. 1992) and at its
3’-end by a nuclear factor 1 (NF1) related site (at nucleotides -130 to -111,
Aoyama etal. 1990 and Zhang and Miskimins, 1993). The evolutionary
conservation, physical location, and structural features of the box 1 and 2
motif suggest that this is a regulatory sequence of the MBP transcription unit
(Fors et al. 1993). The primary structure of box 1 appears to be related to
that of box 2, since both begin with the sequence GAC and contain the
sequence AA near their 3’-ends. The nine non-conserved base pairs
separating box 1 and 2 comprise almost one full-turn of the double helix in
the B-DNA conformation, and could therefore orientate the last base pair of
box 1 and the first base pair of box 2 towards the same face of the molecule.
This molecular configuration may serve as a specific recognition site for the
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binding of transcription regulatory proteins. Torron et al. (1997) used a DNA 
fragment containing the sequence of the motif to identify DNA binding 
proteins. Two proteins MBP32 and MBP38 (of minimum Mr ~ 32 and -  38 
kDa) that are found in nuclear extracts from mouse brain and 
oligodendrocyte-like glioma cells bind to the box 1 and box 2 motif. MBP32 
and MBP38 are also found in other cell types and tissues expressing the 
gollitranscription unit. Therefore, Torron etal., (1997) propose that these 
proteins may participate in the modulation of the MBP transcription unit in 
the context of an active golli unit since exon 5a of the go///-MBP complex also 
contains several other regulatory sequences of the MBP promoter, including 
the TRE, the NF1 -related, M1 and MB1 sites, and the GC, CAAT, and TATA- 
like boxes.
Umemori etal., (1999) have shown that Fyn protein tyrosine kinase
signalling is involved in the initial events of myelination. Fyn, which is
present in myelin-forming cells, is a member of the Src-family nonreceptor
protein tyrosine kinases (PTKs) and is activated by signal transduction
through the stimulation of cell surface receptors such as the large myelin-
associated glycoprotein (L-MAG) to Fyn protein tyrosine kinase (Fyn PTK).
Fyn protein tyrosine kinase then phosphorylates its substrates, which in turn
stimulates transcription factors, resulting in the stimulation of MBP gene
transcription necessary for myelination. The group showed that the
sequence between nucleotides -675 and -647 relative to the transcription
start site included the Fyn response element to which transcription factors
stimulated by Fyn interact. Proteins binding to the region between
nucleotides -675 and -647 were found by EMSA, and the binding activity
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correlated with Fyn activity during myelination thereby suggesting the stage- 
specific regulation of transcription. In a study using 4-week-old Fyn-deficient 
mice Umemori et al., (1999) found that the amount of MBP was significantly 
reduced (by at least 55%), and subsequent electron microscopic analysis 
showed that the myelin was approximately 70% thinner and more irregular 
than in wild-type mice. Umemori etal. (1999) also searched for previously 
known consensus transcription factor response elements and showed that 
the Fyn response region contains the interferon-y response element core 
sequence (consensus C(A/T)(G/T)(G/T)ANN(C/T)) and the NF-IL6 core 
sequence (consensus T(G/T)NNGNAA).
The differentiation of oligodendrocyte and Schwann cell progenitors
into mature myelin producing cells is affected by different growth factors and
hormones. To date not all these factors have been defined, however, it is
evident that increased cyclic AMP levels accelerate the expression of a
differentiated phenotype including the increased expression of myelin
components such as MBP (Mirsky etal. 1980 and Raible etal. 1989). It still
remains to be elucidated what the endogenous factor is that increases cyclic
AMP during differentiation and what signalling pathway(s) lead to
differentiation (Clark etal. 1998). Using the D6P2T cell line the group
investigated the involvement of mitogen-activated protein kinase (MAP
kinase) in the signal transduction cascade initiated by cyclic AMP, which led
to the increased expression of the MBP gene. MAP kinases can be grouped
into three families, which include the extracellular signal-regulated kinases,
Jun N-terminal kinase/stress-activated protein kinases and p38. Activation of
MAP kinases is a rapid cellular response to differentiation and growth factors
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(Marais et al. 1996 and Moriguchi et al. 1996). Phosphorylation of threonine 
and tyrosine residues by dual specificity enzymes like MAP kinase kinase 
(MEK) is the means by which MAP kinases are activated and function within 
the kinase cascade. The D6P2T cell line can be induced to display a 
differentiated phenotype characterised by MBP gene expression in response 
to increased cyclic AMP, similar to the response of oligodendrocytes and 
Schwann cells. Clark et al. (1998) have demonstrated that blocking MAP 
kinase activity with inhibitors of the activating kinase (MEK) blocked the 
activation of the MBP promoter in D6P2T cells. In addition, the group 
showed that blocking MAP kinase activation during differentiation of an 
oligodendrocyte-like cell line (CG4) also led to the inhibition of MBP gene 
expression. Clark et al. (1998) suggest that these findings imply a role for 
MAP kinase in the signal transduction cascade initiated by cyclic AMP and 
leading to the expression of the MBP gene during differentiation.
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3.3. Analysis of DNA -  protein complexes by electrophoretic
mobility shift assay (EMSA) and competition binding assay
Nuclear extracts from rat brains (RBX), glial cell lines (C6 glioma and 
33B oligodendrocytoma) and nonglial cell line (HeLa) were prepared by 
Dounce homogenisation as described in section 5.2. The protein 
concentration in the nuclear extracts was determined before their application 
in the electrophoretic mobility shift assay and competition binding assay.
A microtitre plate method utilising BCA reagent was used and albumin 
served as the protein standard. Data relating to the determination of the 
protein concentration in each of the nuclear extracts can be found in 
Appendix VII.
From a culture typically containing 1.0 x 106 cells, 200 pi of nuclear 
extract was prepared. This produced a protein yield, from the C6 glioma,
HeLa and 33B oligodendrocytoma cell nuclear extracts, ranging from 200 to 
260 pg (1.0 to 1.3 pg/pl), whereas, the rat brain nuclear extract (RBX) gave a 
much higher protein yield of 600 pg (3.0 pg/pl) as expected.
For both the binding assay and the competition binding assay 10 pg 
of nuclear extract per reaction was used.
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Two oligonucleotides corresponding to the putative protein-binding 
site located between nucleotide positions -609 to -577 were synthesised, 
the first corresponding to the sense strand of the binding site,
S’-CACCTTTT GT CAAACGACCGCTT CACAT CTGGG-3’ 
and the second, to the complementary strand
3’-GTGGAAAACAGTTTGCTGGCGAAGT GTAG ACCC-5'.
This region (located between nucleotides -609 and -577) was chosen for 
further investigation because work published by other groups (Asipu and 
Blair 1994) suggested that it contains a cell-type specific transcription 
activation site for oligodendrocytes.
The oligonucleotides were annealed as described in section 5.1.1, 
and an aliquot (10 pi containing approximately 1.5 pg of annealed 
oligonucleotide) analysed by non-denaturing polyacrylamide gel 
electrophoresis. The difference in the mobility between the annealed (Figure 
16 lane 1) and single stranded oligonucleotide (lane 2) can clearly be seen, 
the annealed species being double-stranded does not migrate as far as the 
control sample in lane 2.
The double stranded oligonucleotide was 5’ end-labelled with 
(1 OOpCi) of y-32P ATP to produce a probe with a specific activity of 10 X 104 
counts per minute (cpm) / pg of DNA for use in the electrophoretic mobility 
shift assay and competition binding assay.
For the competition binding assay a 100 - fold excess of unlabelled 
annealed oligonucleotide was used as a specific competitor.
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Figure 16. Analysis by non-denaturing polyacrylamide gel (15%)
electrophoresis of the products of annealing of the strands 
containing a putative transcription factor binding site.
Lane M. A X DNA molecular size marker (BstE II digest of X phage DNA). 
Lane 1. Annealed oligonucleotide (1.5 pg) corresponding to the putative 
protein-binding site.
Lane 2. Single stranded (unannealed) oligonucleotide used as a control 
sample (5’-CACCTTTTGTCAAACGACCGCTTCACATCTGGG-3’).
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The competition binding assay was carried out essentially as the 
binding assay except that unlabelled oligonucleotide probe (100 - fold molar 
excess) was used as a specific competitor. In both cases the binding assay 
and competition binding assay used 1 pg of poly[d(IC).d(IC)] as a non­
specific competitor.
The resulting DNA-protein complexes were separated on 7% native 
polyacrylamide gels. The positions of the complexes are denoted from C1 to 
C4. The fastest migrating bands at the bottom of the gel correspond to the 
free probe (labelled oligonucleotide). Behind the free probe is a group of 
non-specific complexes.
The C e glioma cell nuclear extract (Figures 17 to 19 lanes 1a and 1b) show 
three DNA-protein complexes. C1 the slowest, C2 the intermediate and C4 
with the fastest mobility. The complex represented by C2 shows high 
sequence-specificity since it is sensitive to competition by unlabelled 
oligonucleotide probe and is not present in the competition binding assay 
(lanes 1b).
Only two DNA-protein complexes C1and C3 were detected in the HeLa cell 
nuclear extract (Figure 17, lanes 2a and 2b and Figures 18 and 19 lanes 3a 
and 3b). Neither of these complexes was specific for the putative binding 
site.
RBX nuclear extract (Figure 17, lanes 3a and 3b and Figures 18 and 19
lanes 2a and 2b) revealed three complexes (C1, C2 and C3). Complex C2
appears to be the same mobility and possibly the same protein as that of
complex C2 in the C6 glioma cell line nuclear extract. The competition
binding assay results show this complex to be a sequence specific binding
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protein to the mouse myelin basic protein gene promoter. C3 appears to be 
of the same mobility as the corresponding C3 band in the HeLa cell nuclear 
extract and its binding is not sequence specific.
Two complexes C1 and C3 were detected in the nuclear extract of the 33B 
oligodendrocytoma cells (Figure 17, 18 and 19 lanes 4a and 4b). Both 
complexes were of comparable mobility to the C1 and C3 complexes seen in 
the HeLa and RBX nuclear extracts and neither was a sequence specific 
binding protein to the mouse myelin basic protein gene promoter.
The binding assay and competition binding assay were repeated 
using a binding buffer containing magnesium sulphate (at a final 
concentration of 10 pM) instead of zinc sulphate (at a final concentration of 
10 pM). Four DNA-protein complexes were formed between the proteins of 
the nuclear extracts and the putative DNA binding site, these complexes 
were denoted as C1 to C4 on the autoradiograms shown in Figures 20 and 
21.
Only complex C2 appears to be a sequence-specific binding protein to the 
mouse myelin basic protein gene promoter since this protein is readily 
competed out by a 100 fold molar excess of the unlabelled putative binding 
site in both the C6 glioma cell line and rat brain nuclear extracts (Figure 20 
lanes 1a, 1b and 3a, 3b and Figure 21 lanes 1a, 1b and 2a, 2b respectively). 
Since complex C2 has the same mobility in both nuclear extracts it would 
appear to suggest that the identity of protein in C2 is the same. Protein 
complexes C1, C3 and C4 were not sequence specific binding proteins to 
the mouse MBP gene promoter.
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Figure 17. Gel retardation and competition binding assay analysis of
protein binding to region located between nucleotides -609 to 
-577 of the mouse MBP gene promoter.
Lanes 1a and 1b. C 6 glioma cell nuclear extract.
Lanes 2a and 2b. HeLa cell nuclear extract.
Lanes 3a and 3b. Rat brain extract (RBX) nuclear extract.
Lanes 4a and 4b. 33B oligodendrocytoma cell nuclear extract.
The band labelled free probe represents the labelled oligonucleotide probe 
corresponding to the putative binding site.
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Figure 18. Analysis of proteins binding to the MBP gene promoter
(between nucleotides -609 to -577) by EMSA and competition 
binding assay followed by non-denaturing polyacrylamide gel 
(7%) electrophoresis.
Lanes 1a and 1b. C 6 glioma cell nuclear extract.
Lanes 2a and 2b. Rat brain extract (RBX) nuclear extract. 
Lane Probe. Labelled oligonucleotide probe.
Lanes 3a and 3b. HeLa cell nuclear extract.
Lanes 4a and 4b. 33B oligodendrocytoma cell nuclear extract.
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Figure 19. Electrophoretic mobility shift assay and competition binding 
assay analysis of proteins binding to the region of the MBP 
gene promoter located between nucleotides -609 to -577.
Lanes 1 a and 1b. C 6 glioma cell nuclear extract.
Lanes 2a and 2b. Rat brain extract (RBX) nuclear extract. 
Lane Probe. Labelled oligonucleotide probe.
Lanes 3a and 3b. HeLa cell nuclear extract.
Lanes 4a and 4b. 33B oligodendrocytoma cell nuclear extract.
zf&oW
■iV'MZi
••• V
141
Probe
Figure 20. Analysis of proteins binding to the -609 to -577 region of the 
MBP gene promoter by binding and competition binding assay 
followed by non-denaturing polyacrylamide gel (7%) 
electrophoresis.
Lanes 1a and 1b. C 6 glioma cell nuclear extract.
Lanes 2a and 2b. HeLa cell nuclear extract.
Lanes 3a and 3b. Rat brain extract (RBX) nuclear extract. 
Lanes 4a and 4b. 33B oligodendrocytoma cell nuclear extract. 
Lane Probe. Labelled oligonucleotide probe.
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Figure 21. Gel retardation and competition binding assay analysis of 
protein complexes binding to the region -609 to -577 of the 
MBP gene promoter after non-denaturing polyacrylamide gel 
(7%) electrophoresis.
Lane Probe. Labelled oligonucleotide probe.
Lanes 1a and 1b. C 6 glioma cell nuclear extract.
Lanes 2a and 2b. Rat brain extract (RBX) nuclear extract. 
Lanes 3a and 3b. HeLa cell nuclear extract.
Lanes 4a and 4b. 33B oligodendrocytoma cell nuclear extract.
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3.4. Isolation of cDNA(s) encoding proteins binding to the region 
located between nucleotides - 609 to - 577 of the mouse myelin 
basic protein gene promoter by a yeast one -  hybrid system
3.4.1. Creation of the reporter vector
Complementary oligonucleotides carrying four repeat sequences of 
the putative binding site (-609nt to -577nt) were synthesised and annealed 
as described previously. The ‘sense’ oligonucleotide was synthesised with 
an EcoR1 overhang at the 5’ end, whereas the complementary 
oligonucleotide had an Mlu1 overhang at its 5’ end. These restriction 
endonuclease sites were used to directionally clone the binding site into the 
multicloning site of the pHISi-1 plasmid (see Appendix VI). 
5 ’- a a t t c c a c c t t t t g t c a a a c g a c c g c t t c a c a t c t g g g c a c c t t t t g
3 '  - G T G G AAAAC AG TTTGCTGGC G AAG T G TAG AC C C G T G G AAAAC
TCAAACGACCGCTTCACATCTGGGCACCTTTTGTCAAACGACCGCTTC
AGTTTGCTGGCGAAGTGTAGACCCGTGGAAAACAGTTTGCTGGCGAAG
ACATCTGGGCACCTTTTGTCAAACGACCGCTTCACATCTGGG - 3 '  
TGTAGACCCGTGGAAAACAGTTTGCTGGCGAAGTGTAGACCCACGCG -5’
For this purpose pHISi-1 was digested with EcoR1 and Mlu1
restriction endonucleases. After the enzymes were inactivated by treatment
with phenol followed by ethanol precipitation, the digested vector and the
double stranded oligonucleotide were ligated as described in section 2.6.3.
Competent cells of E.coli strain DH5a were prepared by treating cells, grown
to mid-log phase, with ice cold calcium chloride. The ligation mixture was
precipitated with ethanol and used in the transformation of competent cells.
A heat shock at 42° C followed by an incubation on ice was performed and
the bacterial cells were spread over the surface of L-amp plates. After
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overnight incubation at 37° C samples of the bacterial colonies were 
removed from the plates and analysed by PCR (using the HIS-RP and HIS- 
5372 primers) to confirm the presence of the binding site in the reporter 
plasmid.
Three types of PCR product were obtained as the electrophoretogram (figure 
22) shows. Some of the bacterial colonies chosen for screening show two 
PCR products (lanes 6 and 19), this suggests that these colonies are 
probably mixtures of cells containing the reporter plasmid and the vector 
pHISi-l. The smaller band corresponds to a size of 117 bp (lanes 2, 3, 5, 7,
9, 11, 14,and 17) and is probably the amplification product corresponding to 
the particular region in the original pHISi-l. The putative positive clones 
identified in lanes 1,4,8,10,12, 13,15, 16, 18 and 20 show an amplification 
product corresponding to a size of 255 bp which represents the size of the 
region with the binding site (138 bp) and the flanking region in the original 
pHISi-l plasmid (117 bp). Two representative clones (lanes 4 and 16) were 
selected for large-scale isolation of the reporter plasmid containing the four 
tandem copies of the putative binding site for use in the One-hybrid assay 
system.
A PCR control (negative control) was also run (lane 22); this contains 
all the components of the reaction mixture except a DNA template and is 
used to check for reagent contamination.
A size marker was also included on the gel so that the sizes of the 
PCR products could be determined and compared to the expected products 
determined from the plasmid sequence data (the sequence of plasmid
pHISi-l can be found in Appendix VI).
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Figure 22. Screening of bacterial colonies by PCR and agarose gel (2%)
electrophoresis following transformation into E.coli strain DH5a of 
the ligation product pHISi-1 containing the putative binding site.
Lane M. A DNA molecular size marker (1 kb PCR ladder).
Lanes 1,4,8,10,12,13,15,16,18 & 20. show the 255 bp PCR product
corresponding to the four repeat copies of the putative protein 
binding site and flanking region of plasmid pHISi-l.
Lane 21 was used to run the PCR control (NEGATIVE CONTROL).
Lanes 2,3,5,7,9,11,14,and 17 show the PCR product (117 bp) corresponding 
to the religation of the vector without the binding site insert.
Lanes 6 and 19 show two PCR products.
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Reporter plasmid DNA was isolated on a large scale from one of the 
putative positive clones (clone 4) using the method outlined in section 7.0.
An aliquot (1 pg of plasmid DNA) was analysed by agarose gel 
electrophoresis (Figure 23). In both, the reporter plasmid DNA containing the 
protein binding site which was isolated from clone 4 (Lane 1), and the 
plasmid vector pHISi-1 DNA used as a control sample (lane 2) there are two 
bands, these represent the supercoiled (lower band) and the open circular 
forms of the plasmid (upper band). The difference in size between the two 
plasmid DNA samples resulting from the cloning of four copies of the protein 
binding site (138 bp) into the EcoR1 and Mlu I restriction endonuclease sites 
located in the multiple cloning site (see Appendix VI), upstream of the HIS3 
gene of the vector pHISi-1 were reproducibly seen.
The plasmid pHISi-1 (5.4 kb) is a yeast integrative plasmid, containing 
the yeast HIS3 gene downstream of a multiple cloning site (the map of this 
plasmid is shown in Appendix VI). Pm;nHis is the minimal promoter of the HIS3 
gene. pHISi-1 contains a ColE1 origin of replication (on) and the ampicillin 
resistance gene (AmpR) for propagation and selection in E. coli. The plasmid 
pHISi-1 cannot replicate autonomously in yeast, however, the presence of 
the HIS3 gene allows its integration into the mutated HIS3 gene of the 
YM4271 yeast strain, which was used as the host.
The presence of the binding site in the reporter plasmid was further 
confirmed by digestion of the reporter plasmid with EcoR1 and Mlu I 
restriction endonucleases and analysis of the products by agarose gel 
electrophoresis (Figure 24). Two distinct bands present in the digest
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represent the EcoR1 -  Mlu1 fragment containing the four repeat copies of 
the putative binding site (138 bp) and the linearised vector pHISi-1 (5.4 kb) 
respectively.
Lane 4 shows only a single band corresponding to the digested vector 
pHISi-1, after digestion with EcoR1 and Mlu /, since the second digestion 
product (23 bp) was too small to detect (see the multiple cloning site of the 
vector pHISi-l in appendix VI).
It should be noted that the gel had to be overloaded and over 
exposed to be able to visualise the small 138 bp digestion product (indicated 
in lane 2) corresponding to the putative binding site, and visible towards the 
bottom of the gel. The other diffuse and faint band visible in lanes one to 
four corresponds to a small amount of RNA not removed during the isolation 
procedure. A size marker was also included on the gel so that the sizes of 
the digestion products could be determined (Lane M).
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Figure 23. Analysis by agarose gel (1%) electrophoresis of the reporter
plasmid carrying four repeat copies of the putative binding site 
after large-scale plasmid DNA isolation.
Lane M. A X DNA molecular size marker (BstE II digest of X phage DNA). 
Lane 1. Reporter plasmid DNA isolated from clone 4.
Lane 2. Vector DNA (pHISi-1) used as a control sample.
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Figure 24. Confirmation that the reporter plasmid carries the putative binding 
site.
Lane M. A X DNA molecular size marker (BstE II digest of X phage DNA). 
Lane 1. Undigested reporter plasmid DNA.
Lane 2.Double restriction endonuclease digestion of the reporter plasmid 
with EcoR1 and Mlu I.
Lane 3. Undigested vector DNA (pHISi-l).
Lane 4.Double restriction endonuclease digestion of the plasmid vector 
(pHISi-l) with EcoR1 and Mlu I.
150
The identity of the putative binding site inserted into the pHISi-l 
plasmid was further confirmed by manual (Figure 25) and automated 
sequencing (Figures 26 and 27).
The primer used for manual and automated sequencing in the forward 
direction was HIS -  5372 (which corresponds to the primer located between 
nucleotide positions 5372 and 5392 on the pHISi-l plasmid sequence shown 
in Appendix VI):
5’- TATTATCATGACATTAACCTA -3’
5372 5392
and the primer used for sequencing the complementary strand (automated
sequencing only) was HIS -  RP (where RP means reverse primer located
between nucleotides 99 -  79 on the plasmid sequence):
5’- AT C AC AT T AC T T T AT AT AAT G -3’
99 99
Single stranded template DNA for sequencing was prepared by denaturing
the reporter plasmid DNA with sodium hydroxide (at a final concentration of
0.2 M). Following ethanol precipitation and resuspension in TE buffer the
single stranded DNA was manually sequenced using the method described
in section 4.0. An autoradiogram of the sequencing gel is shown in Figure
25. The sequence GAATTC (highlighted) represents the EcoR1 restriction
endonuclease site synthesised at the 5’ end of the putative binding site and
used for cloning. The binding site sequence is shown in italics.
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Figure 25. An autoradiogram of the manual sequencing results
confirming the presence of the putative binding site in the 
reporter plasmid.
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Figure 26. The automated sequencing results corresponding to the ‘sense’ 
strand of the reporter plasmid confirming the presence of the 
putative protein binding site in the reporter plasmid.
The above data show two I.U.B. base-ambiguity symbols 
represented by the letters V and S at positions 275 and 296 respectively. 
The symbol V represents the bases G, A, or C, and comparison of the above 
sequence with that of the vector pHISi-1 (shown in Appendix VI) indicates 
that the base represented by V should be an A, and that the letter S 
representing bases G or C should be a C base.
These I.U.B. base-ambiguity symbols lie within the reporter vector 
sequence and not within the putative binding site sequence identifiable 
between the restriction endonuclease sites EcoR1 and Mlu I.
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Figure 27. Automated sequencing results of the complementary strand of the 
reporter plasmid confirming the presence of the putative binding 
site.
The sequencing data above contains two I.U.B. base-ambiguity symbols, the 
first represented by an N at position 56 corresponding to a G, A, T or C 
base, and the second a B at position 241 corresponding to either a C, G or T 
base. Comparison of the above sequence to the vector (pHISi-1) should 
show an A and a G at the respective positions.
At position 274 a base misincorporation has occurred during sequencing and 
the T should actually be a G.
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3.4.2. Construction of the reporter strain
To prepare the reporter strain, the reporter plasmid DNA had to be 
linearised. This was achieved by digesting the DNA with Xho I restriction 
endonuclease, which cuts the plasmid DNA uniquely within the HIS3 gene 
downstream from the multiple cloning site.
The completeness of the digestion was confirmed by analysis of the 
digestion mixture on a 1 % agarose gel (Data not shown). Isolation of the 
digestion products was achieved by excising the linearised fragment from 
the gel, and recovering the DNA by microcentrifugation through siliconised 
glass wool into a sterile Eppendorf tube. The ethidium bromide was then 
removed and the DNA precipitated with ethanol, dried in vacuo and 
resuspended in TE buffer for application in the yeast transformation. An 
aliquot of the DNA sample was analysed by agarose gel electrophoresis 
(Figure 28).
The undigested DNA samples of the plasmid pHISi-l used as a 
positive control (lane 3) and the reporter plasmid (lane 1) both show more 
than one band, these represent the different mobilities of the different forms 
of the plasmid. The digested plasmid DNA samples (lanes 2 and 4) show 
only single bands due to the unique Xho 1 restriction site located within the 
HIS3 gene locus.
A BstE II digest of X phage DNA was used as a molecular size marker 
to determine the size of the digestion products.
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Figure 28. Analysis by agarose gel (1 %) electrophoresis of the linearised 
reporter plasmid and positive control DNA before 
transformation into Saccharomyces cerevisiae YM4271 host 
cells.
Lane M. X DNA molecular size marker (BstE II digest of X phage DNA).
Lane 1. Undigested sample of reporter plasmid DNA.
Lane 2. Linearised reporter plasmid following restriction endonuclease 
digestion and purification.
Lane 3. Undigested sample of the positive control DNA (pHISi-1).
Lane 4. Positive control DNA (pHISi-l) following linearisation with Xho 1.
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Positive control experiments for various stages of the transformation and 
integration processes were also carried out. The replicating plasmid YEpmyc 
181 was applied in an experiment, which acted as a control for the 
transformation process. YEpmyc 181 is able to replicate autonomously 
because it contains the origin of replication from a naturally occurring yeast 
plasmid termed a 2pm circle.
The integrating plasmid p53HIS, which carries three tandem copies of the 
consensus p53 binding site, was used in a control experiment for the 
integration process. This plasmid was linearised with Xho 1 restriction 
endonuclease and introduced into competent YM4271 yeast cells in the 
same way as YE pmyc 181.
In order to perform the transformations, competent cells were 
prepared. Saccharomyces cerevisiae strain YM4271 cells were grown to 
mid-log phase represented by an OD6oo of between 0.5 and 0.7, collected by 
centrifugation, washed in TE buffer and treated with fresh TE/LiAc. The 
plasmid DNA was then mixed with the competent cells and after a heat 
shock at 42°C for 15 min followed by an incubation on ice the transformation 
mixtures were spread on appropriate plates (SD/+HIS/-LEU for cells carrying 
YEpmyc 181 and SD/-HIS for cells with p53HIS) and incubated for 4 to 6 
days at 30° C (Figure 29 A and B).
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Figure 29A. Putative clones growing on selective medium following 
transformation of yeast strain YM4271 with the (5.76 kb) 
replicating plasmid YEpmyc 181.
Figure 29B. Putative recombinant clones growing on selective medium after 
transformation of yeast strain YM4271 with Xho 1 linearised 
p53HIS DNA.
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Several of the larger colonies carrying the putatively integrated 
p53H!S DNA were isolated and grown in fresh SD/-HIS at 30° C for 4 to 6 
days with shaking until the cultures were saturated. Chromosomal DNA was 
isolated from each clone using the technique described in section 8.4, and 
an aliquot (1 pi) used to confirm the presence of the consensus p53 binding 
site by PCR. The PCR was carried out essentially as described in section 
6.3 using the HIS-RP primer, (5,-ATCACATTACTTTATATAATG-3,, which is 
located between nucleotide positions 79 -  99 of the plasmid pHISi-l 
sequence shown in Appendix VI), and the HIS-5372 primer, (5’-TATTAT 
CATGACATTA ACCTA-3’ located between nucleotides 5372 -  5392).
The results were analysed by agarose (2%) gel electrophoresis.
Genomic DNA isolated from the wild type yeast strain YM4271 (Figure 
30A Lane 2) shows a single high molecular weight band. The faint diffused 
band at the bottom of this lane is RNA, which was not removed during the 
isolation. Amplification of the wild type chromosomal DNA did not yield a 
PCR product, as expected (Figure 30A Lane 1).
The PCR negative control (Figure 30A Lane 3), containing all the 
PCR components, except a DNA template, and used to check for reagent 
contamination, shows no PCR product(s) as expected.
Genomic DNA isolated from the putative clones carrying the 
integrated p53 consensus binding site (Figure 30A Lanes 4 and 6 and 
Figure 30B Lanes 1 and 3) show high molecular weight DNA bands near the 
sample wells.
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Amplification of the genomic DNA from the putative clones described 
above Lanes 5 and 7 (Figure 30A) and 2 and 4 (Figure 30B) yielded a major 
PCR product of approximately 1000 bp, this corresponds exactly with the 
size of the product obtained in the positive control, (and a minor product of 
approximately 700 bp).
A positive PCR control corresponding to the amplification product of the 
p53HIS plasmid DNA (120 ng) Lane 8 (Figure 30A) and Lane 5 (Figure 30B) 
show one amplification product at approximately 1000 bp.
Lambda phage DNA digested with the restriction endonuclease BstE II (Lane 
M) was also run as a size marker for the identification of the amplification 
products resulting from the PCR.
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Figure 30. Analysis by agarose gel electrophoresis of genomic and PCR 
amplified DNA from the putative clones carrying the integrated 
consensus p53-binding site.
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Lane M. A X DNA molecular size marker (BstE II digest of X phage DNA).
Figure 30A Lane 1. PCR product from the genomic DNA isolated from the 
wild type strain YM4271.
Figure 30A Lane 2. Genomic DNA from wild type strain YM4271.
Figure 30A Lane 3. Negative PCR control.
Figure 30A Lane 4 and 6 Genomic DNA isolated from recombinant yeast
clones.
Figure 30A Lane 5 and 7. PCR product from the genomic DNA isolated from
the putative yeast clones.
Figure 30A Lane 8. Positive PCR control (amplified p53HIS template).
Figure 30B Lane 1 and 3. Genomic DNA isolated from recombinant yeast
clones.
Figure 30B Lane 2 and 4. PCR product from the genomic DNA isolated from
the putative yeast clones 
Figure 30B Lane 5. Positive PCR control (amplified p53HIS template).
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The reporter plasmid, which carries four tandem copies of the putative 
binding site, was linearised with Xho1 restriction endonuclease and 
introduced into competent YM4271 yeast cells in the same way as the 
p53HIS DNA. Cells transformed with the reporter plasmid were spread on 
SD/-HIS plates and incubated at 30° C for 4 to 6 days (Figure 31).
Genomic DNA was isolated from nine of the larger putative reporter 
strain colonies as well as from the wild type yeast host and its integrity 
examined by agarose gel electrophoresis, (Figure 32A). Lanes 1 to 9 
respectively show the DNA isolated from these putative clones and Lane 10 
from the wild type yeast host cells.
An aliquot (1 pi) of this DNA was used to confirm by PCR the presence of 
the putative binding site in the reporter strain (Figure 32B). The PCR was 
carried out essentially as described in section 6.4 using HIS-RP and HIS- 
5372 primers. The location of the two primers used are shown highlighted on 
the pHISi-l plasmid sequence in Appendix VI
The results of the PCR were analysed by agarose (2%) gel 
electrophoresis. A PCR negative control containing all the components 
necessary for PCR except the DNA template was also run (Figure 32B Lane 
1), and was used to monitor any contamination in the reagents.
Chromosomal DNA from the wild type yeast host (YM4271) was amplified by 
PCR (Figure 32B Lane 2), as expected no PCR product was obtained.
A molecular size marker (BstEII digest of lambda phage DNA) and a positive 
PCR control (the reporter plasmid containing the four repeat copies of the
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putative binding site) were used to determine the size of any amplification 
product obtained from the putative reporter strain clones (Figure 32B, Lanes 
M and 12 respectively). Clones were considered positive if a PCR product 
corresponding to a size of 255 bp was obtained as can be seen in Lanes 3 
to 11.
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Figure 31. Putative clones growing on SD/-HIS medium following the 
transformation of yeast host strain YM4271 with the Xho 1 
linearised 5.4 kb plasmid pHISi-1 (carrying four repeat copies of 
the putative binding site). Undigested reporter plasmid served as 
a negative control.
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size (bp)
3675
Figure 32A. Analysis by agarose gel electrophoresis of chromosomal DNA 
isolated from the reporter strain clones carrying the putative
binding site.
Molecular 
Size (bp)
Figure 32B. Analysis by PCR followed by agarose gel (2%) electrophoresis 
of the reporter strain clones carrying the putative binding site.
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Figure 32A. 
Lane M.
Lane 1 - 9 .  
Lane 10.
Figure 32B. 
Lane M.
Lane 1.
Lane 2.
Lane 3 -11 .
Lane 12.
DNA molecular size marker (BstE II digest of X phage 
DNA).
Genomic DNA isolated from putative reporter strain clones. 
Genomic DNA from wild type strain YM4271.
DNA molecular size marker (BstE II digest of X phage 
DNA).
PCR negative control.
PCR product from the genomic DNA isolated from the wild 
type strain YM4271.
PCR products from the genomic DNA isolated from the 
yeast clones
Positive PCR control (amplified putative binding site using 
reporter vector DNA).
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3.4.3. Testing the reporter strain clones for background HIS3 
expression
A small sample of each of the yeast colonies analysed by PCR was 
suspended in TE buffer, and an aliquot (5 jul) pipetted onto the surface of 
pre-dried SD/-HIS plates containing 3 -  AT at the following concentrations,
0, 5, 10, 15, 30, 45, and 60 mM.
It should be noted that the plates were pre-dried to prevent 
condensation causing localised dilution of the 3 -  AT concentration, leading 
to false positive results. The plates were incubated at 30° C for 4 to 6 days, 
and the growth analysed (Figure 33).
All the putative recombinant clones grew on the SD/-His plates in the 
presence of 15 mM 3 -  AT which shows that the background HIS3 
expression is low, and these clones were used for transformation with the 
cDNA/AD Fusion library and further study. However, the only exception to 
this was clone 1 (Figure 33E), which grew in the presence of 45 mM 3 - AT 
indicating that the background HIS3 expression is high, as a result this clone 
was not used for further experimentation.
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AFigure 33A. Testing of reporter strain clones for background expression of 
the HI S3 gene by growth on SD/-HIS medium containing 5mM 
3 -AT.
Figure 33B. Testing of reporter strain clones for background expression of
the HIS3 gene by growth on SD/-HIS medium containing 10mM
3 -A T .
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Figure 33C. Testing of reporter strain clones for background expression of 
the HI S3 gene by growth on SD/-HIS medium containing 15mM 
3 -  AT.
1
Figure 33D. Testing of reporter strain clones for background expression of
the HI S3 gene by growth on SD/-HIS medium containing 30mM
3 -  AT.
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Figure 33E. Testing of reporter strain clones for background expression of 
the HIS3 gene by growth on SD/-HIS medium containing 45mM 
3 -AT.
Mlf9
/w
Figure 33F. Testing of reporter strain clones for background expression of
the HI S3 gene by growth on SD/-HIS medium containing 60mM
3 - AT.
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The search for putative transcription factors was carried out by the 
transformation of yeast reporter strain clones with a rat brain cDNA/AD 
fusion library. To achieve this a culture of the reporter strain (clone 3) was 
grown to mid-log phase in SD/-HIS + 30 mM 3 -  AT and competent cells 
prepared. cDNA/AD fusion library and carrier DNA were mixed with 
competent reporter strain cells, freshly prepared PEG/LiAc solution and 
incubated for 1 h with shaking. A heat shock for 15 min, followed by an 
incubation on ice was performed. After pelleting the cells and resuspension 
in TE buffer (pH 7.5) an aliquot of the transformation mixture (50 jul) was 
spread over the surface of pre-dried SD/-HIS/-LEU plates containing 30 mM 
3 -  AT and incubated for 4 to 6 days at 30° C. Colonies resulting from HIS3 
activation were larger than the colonies resulting from background HIS3 
expression (Figure 34). These larger colonies were cultured in fresh SD/- 
HIS/-LEU medium containing 30 mM 3 -  AT for 4 to 6 days and the plasmid 
DNA isolated as described in section 9.2 (Figure 35).
DNA was isolated from both the wild type host and reporter strain 
clone 3 (Lanes 1 and 2 respectively). No plasmid DNA was isolated from 
these strains of yeast as expected, however, the high molecular weight DNA 
visible in both lanes is chromosomal DNA, a common and unavoidable 
contaminant when isolating plasmid DNA from yeast cells by this method. 
Plasmid DNA was isolated from 7 recombinant yeast clones and varied in 
size from approximately 7.1 to 8.8 kb.
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The yield from the clones shown in lanes 7 and 9 was slightly lower than 
from the other clones. Chromosomal DNA contamination is visible in all 
lanes near the sample wells.
A X DNA molecular size marker (Lane M) was used to determine the size of 
the plasmid DNA isolated.
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Figure 34. Putative clones resulting from the transformation of the reporter 
strain with a cDNA/AD library plasmid growing on selective SD/- 
HIS/-LEU medium containing 30 mM 3-aminotriazole.
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Figure 35. Analysis of the plasmid DNA isolation from the putative positive 
clones transformed with an cDNA/AD fusion library from rat brain 
by agarose gel (1%) electrophoresis.
Lane M. Molecular size marker.
Lane 1. DNA isolated from wild type host.
Lane 2. Reporter strain DNA isolated from the reporter strain clone. 
Lanes 3 to 9. Isolates of plasmid DNA from the putative clones following 
transformation with cDNA/AD fusion library.
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An aliquot (5 pi containing 0.5pg of plasmid DNA) isolated from each 
putative recombinant clone was digested with EcoR1 restriction 
endonuclease and the products analysed by agarose (1 %) gel 
electrophoresis (Data not shown).
The plasmid DNA isolated from the seven recombinant clones was 
further analysed by PCR using the library specific primers AD10[S] 5 ’- c t a t  
tc g a tg a tg a a g a ta c c -3 ’ and AD10[R] S’-c a c a g ttg a a g tg a a c t tg c g -S ’ 
(located between nucleotide positions 788 to 807, and 903 to 893 
respectively on the pGADIO sequence shown in Appendix VI).
Clones 1,5 and 6 (Figure 36 lanes 1,5 and 6 respectively) show a PCR 
amplification product of approximately 0.75 kb. Clone 2 (lane 2) showed the 
smallest PCR product with a molecular size of approximately 0.4 kb. Clones 
3 and 7 (lanes 3 and 7) show an intermediate sized PCR product estimated 
to be 0.6 kb, whereas, recombinant clone 4 showed the largest cDNA insert 
following amplification by PCR of about 1.2 kb.
Plasmid DNA from the positive cDNA/AD fusion library clones was 
purified by agarose gel (1%) electrophoresis and recovered by centrifugation 
through glass wool. Following ethanol precipitation and resuspension in 
deionised water the plasmid DNA was automatically sequenced using the 
AD10[S] primer (Figures 37A to G).
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Figure 36. Analysis by agarose gel (2%) electrophoresis of the library clones 
following amplification by PCR.
Lane M. Molecular size marker (Lambda phage DNA digested with BstE II).
Lanes 1 to 7. PCR amplification products obtained from the plasmid DNA 
isolated from the recombinant library clones.
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1 accaaaccca aaaaaagaga tctctcgagg cggcggtggg41 atccgaattc atggcgcgac cgggctggcc tttccatcgc81 agccccagca gcagcagcag ccgcctcagc cgccgcacca121 cttgccccaa cagatcccgg tgcagcaccc gcggctgcag161 gcgctgaagg aagagccgca gacggtgccg gagatgccgg201 gagagacgcc gcccttgtcc cccatcgaca tggagtctca241 ggagcggatc aaggcggaga ggaagcgcat gagaaaccgc281 atcgctgcct ccaagtgccg gaaaaggaag ctggagcgga321 tcgcccggct agaggaaaaa gtgaaaacct tgaaagcgca361 aaactccgag ctggcgtcca cggccaacat gctcagggaa401 caggtggcac agcttaaaca gaaagtcatg aaccacgtta441 acagtgggtg ccaactcatg ctaacgcagc agttgcaaac481 gttttgagga cagactgtca gggctgaggg gcagtggaag521 aaaaaaataa cagagataaa cttgagaact tgactggttg561 cgacagagaa aaaaaagtgt ccgagtactg aagccaaggg601 tacacaagat ggactgggtt gcgacctgac ggcgccccca641 atgtgctgga gtgggaagga cgtggcgcgc ctggctttgg681 cgaggagcca gagagcagcg gcctgttcgc gacgctttgc721 gaacgggctg tgccgcgacc agaacgatgg acttttcgtt761 aacattgacc aagaactgca tggacctaac attagaattc801 cagatctatg aatcgtagat actgaaaaac
Figure 37 A. Sequencing results of the plasmid DNA from the positive 
cDNA/AD fusion library clone 1.
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1 accaaaccca aaaaaagaga tctctcgagg tttttttttt41 atccgaattc gcgaacagaa ggcgcacctg gaagactact81 actggatgac cggctacccg cagcagctca acccggaggc121 gctgggcttc agcccggagg acgcagtcga ggcgcncatc161 agcaatagcc accagctcca gggtggctnc gvtggctatg201 cgcggggcgc gcagcagctg gccgcggcag cgggggccgg241 cgccggcgcc tccctgggcg gcagcggcga ggagatgggc281 cccgccgccg ccgtggtgtc cgccgtgatc gccgcggcsg321 ccgcgcagag cggcggggca cctcactacc atcaccacca361 ccaccacgcc acggggcacc accaccaccc gacggccggc401 gccccgggag ccgcgggtag cgcgtccgcc tctgcgagcg441 gcgcgggtgg cgcgggcggc ggtggaattc cagatctatg481 actgaaaaac
Figure 37 B. Sequencing results of the plasmid DNA from the positive 
cDNA/AD fusion library clone 2.
1 accaaaccca aaaaaagaga tctctcgagg gtgcctcaaa41 atccgaattc cggagccgag cggctcgccc gtgcacgtcc81 agcttcccca gcaggcggcc ccggtgacag ccgcggcggc121 ggctccggcg gccgcgacat cagcaccggc cccggccccg161 gccccggcgg cgcccgcagc cccggccccg gctccagctg201 cggctccagc cccggccccg gcagctcagg cggtcggctg241 gcccatctgc agggacgcgt acgagctcca ggaggttatc281 ggcagtggag cgaccgccgt ggttcaggca gccctgtgca321 aacccaggca agaacgcgta gccataaagc ggatcaactt361 ggaaaagtgc cagacgagta tggatgaact cttaaaagaa401 attcaagcca tgagccagtg cagccatccc aacgtagtga441 cttattatac ttcctttgtg gtcaaagatg aactttggct481 ggtcatgaaa ttactaagtg gaggttccat gttggatatc521 atcaaataca tcgtcaatcg gggagaaatt cagatctatg561 aatcgtagat actgaaaaac
Figure 37 C. Sequencing results of the plasmid DNA from the positive 
cDNA/AD fusion library clone 3.
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1 accaaaccca aaaaaagaga tctctcgagg gacgactggt41 atccgaattc ggagaacctc tgtcgctggg gctggtccgc81 gggctccgag gaaccgctgc ttcctgagag cgctccgtga121 gtgaccgcga cttttcaaag ctccggatcg cgcgggacca161 accaacgtga gtgcaagcgg tgtcttaacc ctgcgctccc201 tggagcgaac tggggaggag ggcgcagggg ggagcactgc241 ggtctggagc gcacgctcct aaacaaactt tgttactgaa281 gcggggacgc gcgggtatcc cccgcttccc ggcgcgctgt321 tgcggccccg aaacttctgc gcacagccca ggctaacccc361 gcgtgaagtg accgactgtt ctatgactgc aaagatggaa401 acgaccttct acgacgatgc cctcaacgcc tcgttcctcc441 agtccgagag tggcgcctac ggctacagta accctaagat481 tctgaagcag agcatgacct tgaacctggc cgacccggtg521 ggcaatctga agccgcacct ccgagccaag aactcggacc561 ttctcacgtc gcccgacgtc gggctgctca agctggcgtc601 gccggagctg gagcgcctga tcatccagtc cagcaatggg641 cacatcacca ctacaccgac ccccactcag ttcttgtgcc681 ccaagaacgt gaccgacgag caggagggct tcgccgaagg721 cttcgtgcgc gccctagctg aactgcatag ccagaatacg761 ctgcccagtg tcacctccgc ggcacaacct gtcagtgggg801 cgggcatggt cgctcccgct gtggcctcag tagctggcgc841 tggcggcggc ggcggctaca gcgccagcct gcacagtgag881 cctccggtct acgccaacct cagcaacttc aacccgggtg921 cgctgagcag cggcggtggg gcgccctcct atggcgcgac961 cgggctggcc tttccatcgc agccccagca gcagcagcag1001 ccgcctcagc cgccgcacca cttgccccaa cagatcccgg1041 tgcagcaccc gcggctgcag gcgctgaagg aagagccgca1081 gacggtgccg gagatgccgg gagagacgcc gcccttgtcc1121 cccatcgaca tggagtctca ggagcggatc aaggcggaga1161 ggaagcgcat gagaaaccgc atcgctgcct ccaagtgccg1201 gaaaaggaag ctggagcgga tcgcccggct agaggaaaaa1241 gtgaaaacct tgaaagcgca attagaattc cagatctatg1281 aatcgtagat actgaaaaac
Figure 37 D. Sequencing results of the plasmid DNA from the positive 
cDNA/AD fusion library clone 4.
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1 accaaaccca aaaaaagaga tctctcgagg tgggagagca41 atccgaattc ttctgctgcc ctgcctctga gaatgcacca81 cagtgccgct gagggtctcc cagcctccaa ccacgccacc121 aacgtgatgt ccacagcgac aggacttcat tattctgtgc161 cttcctgtca ttatggaaac cagccatcca cctacggagt201 gatggcaggc actttaaccc cttgtcttta caagtttcca241 gaccacaccc tgagtcatgg gtttcctccc ctgcaccaac281 ctctgctggc ggaggaccca acagcctctg aatttaagca321 ggaactcagg cggaaaagta aattggtgga agagccaata361 gacatggact ccccggaaat ccgagaactg gagcagtttg401 ccaacgaatt taaagtgaga agaattaagt taggatacac441 ccagacaaac gtgggcgaag ctctggccgc tgtccacggc481 tccgaattca gtcaaacaac catctgccga tttgaaaact521 tgcagctcag tttcaaaaat gcttgcaaac tgaaagcaat561 tttatccaag tggctggagg aagctgagca ggtcggagct601 ttgtacaatg aaaaagtggg agcaaacgaa aggaagagga641 aacggaggac aactatcagt atcgccgcta aggatgcttt681 ggagagacac tttggagagc acagcaaacc ttcttcgcag721 gagateatgc ggatggctga agaattgaat ctcgagaaag761 aagtagtaag agtgtggttt tgcaagaatt cagatctatg801 aategtagat actgaaaaac
Figure 37 E. Sequencing results of the plasmid DNA from the positive 
cDNA/AD fusion library clone 5.
1 accaaaccca aaaaaagaga tctctcgagg tegttattgt41 atccgaattc tgctgcagga ggcgcaggac ggcgtcctgg81 atctcaaagc ggctgcagat actttggctg tgaggcaaaa121 gegaagaatt tatgatatca ccaacgtctt agaaggaatt161 gatctaattg aaaaaaaatc aaagaacagt atccagtgga201 agggtgtagg tgctggctgt aatactaaag aagttataga241 tagattaaga tgtcttaaag ctgaaattga agatctagaa281 ttgaaggaaa gagaacttga ccagcagaag ttgtggctac321 agcaaagcat caaaaacgtg atggaagact ccattaataa361 cagattttct tatgtaactc acgaagacat ctgcagttgc401 tttaatggtg atacactgtt ggccattcag gcaccctctg441 gtacacagct ggaagtacct attccagaaa tgggacagaa481 tggacaaaag aaataccaga taaatctgaa gagtcactca521 ggaccaatcc atgtgctact tataaataaa gagtccaact561 catctaagcc ggtggttttt cctgtccccc cacctgatga601 cctcacacaa ccttcctccc agtcctcaac ttcagtgact641 ccaccgaaat ccaccatggc tgctcaaaac ctgcccgagc681 agcatgtttc tgaaagaagc cagaatttcc agcagacacc721 agctacagaa atatcttcag gatctattag tggagacatc761 attgatgaac tgatgtcttc tgacgaaatt cagatctatg801 aategtagat actgaaaaac
Figure 37 F. Sequencing results of the plasmid DNA from the positive 
cDNA/AD fusion library clone 6.
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1 accaaaccca aaaaaagaga tctctcgagg gtccagacct41 atccgaattc aaatgcctct agatctgtcc cctcttgcaa81 cacccatcat aagaagcaaa attgaggaac cttctgttgt121 agaaacaact caccaggata gcccgttacc tcaccccgag161 tctactacca atgatgaaaa ggaaatacca ttggcacaaa201 ctgcacagcc cacatcagct atcgttcgtc cagcatcatt241 acaggttccc aatgtgctgc tcacaagttc tgactsaagt281 gtaattattc aacaagcagt accttcacca acctcavgta321 ctgtaatcac ccaggcacca tcctctaaca ggccaattgt361 tcctgtacca ggcccatntc ctcttctatt acatcttcct401 aatggacaaa ccatgcccgt tgctattcct gcatcaatta441 caagttctaa tgtgcatgtt ccagctgcag tcccacttgt481 tcggccagtc accatggtgc ctagtgttcc aggaatccca521 ggccnttcct ctcctgaatt cagatctatg aategtagat561 actgaaaaac
Figure 37 G. Sequencing results of the plasmid DNA from the positive 
cDNA/AD fusion library clone 7.
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3.5. Analysis of the rat brain cDNA library clones for sequence 
homology to other transcription factors
To establish whether the cDNA sequences obtained from the 
recombinant AD/fusion library show homology with known transcription 
factors, sequence alignment searches were performed. To achieve this the 
cDNA sequence was first translated (in all reading frames) into an amino 
acid sequence using the EBI translate programme. The next step was to 
determine the correct open reading frame (ORF), this was deemed to be the 
longest frame uninterrupted by a stop codon (TGA, TAA, or TAG). Usually 
the initiation codon in the coding sequence is that for methionine (ATG), but 
methionine is also a common residue within the coding sequence so its 
presence is not an absolute indicator of an ORF. Therefore, recognition of 
the flanking Kozak sequence (e.g. CCGCCAUGG) may also be helpful in 
pinpointing the beginning of the coding sequence. Once the open reading 
frame was established, the amino acid sequence was used as a query (or 
probe) sequence to search the Swissprot and Swall databases for sequence 
alignments to other known transcription factors using the BLAST sequence 
alignment program. The BLAST (Basic Local Alignment Search Tool) 
algorithm was described by Altschul et al. in 1990. The algorithm itself is 
straightforward, with the important concept being the segment pair. Given 
two sequences, a segment pair is defined as a pair of sub-sequences of the 
same length that form an ungapped alignment. BLAST calculates all the 
segment pairs between the query and the database sequences above a 
scoring threshold. The resulting high scoring pairs form the basis of the
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ungapped alignments that characterise BLAST outputs as shown for each of 
the clones below. Sequences clustered at greater than or equal to 62% 
identity are used to generate the BLOSUM 62 matrix (BLOck Substitution 
Matrix). For each of the searches the ‘identities’ keyword indicates the 
number of identical residue matches in relation to the match length, whereas 
the ‘positives’ keyword considers both identities and similarities.
The following alignments indicate high levels of sequence similarity 
and correspondingly low Expected frequency or E-values (e.g. Clone 1 
shows an E value of 3e -79) indicating that the probability of this match 
having occurred by chance is virtually zero.
After the search summary, the output shows the complete pairwise 
alignment of the high scoring pairs (HSPs) of the query sequence (line 1) 
with that of the database or subject (line 3). The identities for each aligned 
high scoring pairs are indicated with the corresponding amino acid symbol 
shown in line 2.
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The translation of clone 1 in all six reading frames:
Reading frame 1.
GATGLAFPSQPQQQQQPPQPPHHLPQQIPVQHPRLQALKE 
E PQ TVPEM PGETPPLSPIDME S QE RIKAERKRMRNRIAAS 
KCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQ 
LKQKVMNHVNSGCQLMLTQQLQTF*GQTVRAEGQWKKKIT 
EINLRT*LVATEKKKCPSTEAKGTQDGLGCDLTAPPMCWS 
GKDVARLALARSQRAAACSRRFANGLCRDQNDGLFVNIDQ 
ELHGPNIX
Reading frame 2.
MARPGWPFHRSPSSSSSRLSRRTTCPNRSRCSTRGCRR*R 
KSRRRCRRCRERRRPCPPSTWSLRSGSRRRGSA*ETASLP 
PSAGKGSWSGSPG* RKK*KP* KRKT PSWRPRPTCSGNRWH 
SLNRKS*TTLTVGANSC*RSSCKRFEDRLSGLRGSGRKK* 
QR* T * E LDWLRQRKKSVRVLKPRVHKMDWVAT * RRPQCAG 
VGRTWRAWLWRGAREQRPVRDALRTGCAATRTMDFSLTLT 
KNCMDLTLX
Reading frame 3.
WRDRAGLSIAAPAAAAAASAAAPLAPTDPGAAPAAAGAEG
RAADGAGDAGRDAALVPHRHGVSGADQGGEEAHEKPHRCL
QVPEKEAGADRPARGKSEN*ESAKLRAGVHGQHAQGTGGT
A*TESHEPR*QWPTHANAAVANVLRTDCQG*GAVEEKNN
RDKLENLTGCDREKKVSEY*SQGYTRWTGLRPDGAPNVLE
WEGRGAPGFGEEPESSGLFATLCERAVPRPERWTFR*H*P
RTAWT*H*
Reading frame 4.
LMLGPCSSWSMLTKSPSFWSRHSPFAKRREQAAALWLLAK 
ARRA*SFPLQHIGGAVRSQPSPSCVPLASVLGHFFFSVAT 
SQVLKFISVIFFFHCPSALTVCPQNVCNCCVSMSWHPLLT 
WFMTFCLSCATCSLSMLAVDASSEFCAFKVFTFSSSRAIR 
SSFLFRHLEAAMRFLMRFLSALIRS*DSMSMGDKGGVSPG 
ISGTVCGSSFSACSRGCCTGICWGKWCGG*GGCCCCWGCD 
GKAS PVAPX
Reading frame 5.
*C*VHAVLGQC*RKVHRSGRGTARSQSVANRPLLSGSSPK 
PGAPRPSHSSTLGAPSGRNPVHLVYPWLQYSDTFFSLSQP 
VKFSSLSLLFFSSTAPQP*QSVLKTFATAALA*VGTHC*R 
GS* LSV^AVPPVP - ACWPWTPARSFALSRFSLFPLAGRSA 
PASFSGTWRQRCGFSCASSPP*SAPETPCRWGTRAASLPA 
S PAP S AAL P SAPAAAGAAPGSVGAS GAAAE AAAAAAGAAM 
ERPARSRH
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Reading frame 6.
OTRSMQFLVNVNEKSIV*VAAQPVRKASRTGRCSLAPRQS
QARHVLPTPAHWGRRQVATQSILCTLGFSTRTLFFLCRNQ
SSSQVYLCYFFLPLPLSPDSLSSKRLQLLR*HELAPTVNV
VHDFLFKLCHLFPEHVGRGRQLGVLRFQGFHFFL*PGDPL
QLPFPALGGSDAVSHALPLRLDPLLRLHVDGGQGRRLSRH
LRHRLRLFLQRLQPRVLHRDLLGQWRRLRRLLLLLGLRW
KGQPGRAX
Reading frame one is deemed to be the open reading frame.
Program: NCBI-blastp 
Database: Swissprot 
Title: CLONE-1 
SeqLen: 184 
Matrix: -M blosum62 
Filter: -F f
Sequences producing significant alignments: (bits) Value
SW:AP1 RAT P17325 TRANSCRIPTION FACTOR AP-1 (PROTO-ONCOGENE) . 
293 3e-79
SW:AP1 MOUSE P05627 TRANSCRIPTION FACTOR AP-1 (PROTO-ONCOGENE). 
291 1e-78
SW:AP1 HUMAN P05412 TRANSCRIPTION FACTOR AP-1 (PROTO-ONCOGENE). 
275 5e-74
>SW:AP1 RAT P17325 TRANSCRIPTION FACTOR AP-1 (PROTO­
ONCOGENE C-JUN). Length = 334
Score = 293 bits (741), Expect = 3e-79
Identities = 145/145 (100%), Positives = 145/145 (100%)
Q u e r y :3 GATGLAFPSQPQQQQQPPQPPHHLPQQIPVQHPRLQALK 41
S b j c t :1 9 0
GATGLAFPSQPQQQQQPPQPPHHLPQQIPVQHPRLQALK
YGATGLAFPSQPQQQQQPPQPPHHLPQQIPVQHPRLQALK 229
Q u e r y :42 EEPQTVPEMPGETPPLSPIDMESQERIKAERKRMRNRIAA 82
S b j c t :2 3 0
EEPQTVPEMPGETPPLSPIDMESQERIKAERKRMRNRIAA
EEPQTVPEMPGETPPLSPIDMESQERIKAERKRMRNRIAA 270
Q u e r y :83 S KCRKRKLERIARLEEKVKTLKAQNSE LAS TANMLREQVA 123
S b j c t :2 7 1
S KC RKRKL E RIARLEEKVKT LKAQNSE LAS TANMLREQVA 
SKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVA 310
Q u e ry : 124 
S b jc t :  311
QLKQKVMNHVNSGCQLMLTQQLQTF 147 
QLKQKVMNHVNSGCQLMLTQQLQTF 
QLKQKVMNHVNSGCQLMLTQQLQTF 334
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The translation of clone 2 in all six reading frames is shown below.
Reading frame 1.
EQKAHLEDYYWMTGYPQQLNPEALGFSPEDAVEAXISNSH 
QLQGGXXGYARGAQQLAAAAGAGAGASLGGSGEEMGPAAA 
WSAVIAAXAAQSGGAPGQLFLYQAATGKGNTPTAGAPGA 
AGSASASAS GAGGAGGG
Reading frame 2.
ANRRRTWKTTTG*PATRSSSTRRRWASARRTQSRRXSAIA 
T S S RVAXXAMRGARS SW PRQRGPAPAP PWAAAARRWAP P P 
PWCPP*SPRXPRRAAGHLTTITTTTTPRGTTTTRRPAPRE 
PRVAR P PLRAARVARAAV
Reading frame 3.
RTEGAPGRLLLDDRLPAAAQPGGAGLQPGGRSRGXHQQ*P 
PAPGWXXWLCAGRAAAGRGSGGRRRRLPGRQRRGDGPRRR 
RGVRRDRRGXRAERRGTSLPSPPPPRHGAPPPPDGRRPGS 
RG*RVRLCERRGWRGRRW
Reading frame 4.
P P P PAP PAPLAEADAL PAAPGAPAVGWWWC PVAWWWW* W*
* GAP P L CAXAAAITADT TAAAG PIS S P L P P REAPAPAPAA 
AASCCAPRA* PXXP PW SWWLLLMXAS TAS S GLKP SAS GLS 
CCG*PVIQ** SSRCAFCS
Reading frame 5.
HRRPRHPRRSQRRTRYPRLPGRRPSGGGGAPWRGGGGDGS 
EVPRRSARXPRRSRRT PRRRRGPS PRRCRPGRRRRRPPLP 
RPAAARPAHSXXSHPGAGGYC*XAPRLRPPG*SPAPPG*A 
AAGSRSSSSSLPGAPSVR
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Reading frame 6.
TAARATRAARRGGRATRGSRGAGRR*VWPRGVWVVMVV 
RCPAALRGXRGDHGGHHGGGGAHLLAAAAQGGAGAGPRCR 
GQLLRAPRIAXXATLELVAIADXRLDCVLRAEAQRLRVEL 
LRVAGH PWVFQVRLLFX
Reading frame 1 (underlined) represents the open reading frame and was 
used as the query sequence to search the database(s) for homology to other 
known transcription factors.
Title: CLONE-2
The results of the database search show that at present Clone 2 
has not been identified and could possibly be a novel transcription factor.
EQKAHLEDYYWMTGYPQQLNPEALGFSPEDAVEAXISNSH 
QLQGGXXGYARGAQQLAAAAGAGAGASLGGSGEEMGPAAA 
WSAVIAAXAAQSGGAPGQLFLYQAATGKGNTPTAGAPGA 
AGSASASAS GAGGAGGG
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The translation of clone 3 in all six reading frames:
Reading frame 1.
E P S GS PVHVQL PQQAAPVTAAAAAPAAAT SAPAPAPAPAA 
PAAPAPAPAAAPAPAPAAQAVGW PICRDAYE LQE VIGS GA 
TAWQAALCKPRQERVAIKRINLEKCQTSMDELLKEIQAM 
SQCSHPNWTYYTSFWKDELWLVMKLLSGGSMLDIIKYI 
VNRGX
Reading frame 2.
RSRAARPCTSSFPSRRPR*QPRRRLRRPRHQHRPRPRPRR 
RPQPRPRLQLRLQPRPRQLRRSAGPSAGTRTSSRRLSAVE 
R P PW FRQ P CAN P GKNA* P * S G S TWKSARRVWMN S * KK FK P
*ASAAIPT**LIILPLWSKMNFGWS*NY*VEVPCWISSNT 
SSIGEX
Reading frame 3.
GAERLARARPASPAGGPGDSRGGGSGGRDISTGPGPGPGG
ARSPGPGSSCGSSPGPGSSGGRLAHLQGRVRAPGGYRQWS
DRRGSGSPVQTQARTRSHKADQLGKVPDEYG*TLKRNSSH
EPVQPSQRSDLLYFLCGQR*TLAGHEITKWRFHVGYHQIH
RQSGR
Reading frame 4.
SPRLTMYLMISNMEPPLSNFMTSQSSSLTTKEV**VTTLG 
WLHWLMA*ISFKSSSILWHFSKLIRFMATRSCLGLHRAA 
* T TAVAPLPIT S WS S YAS LQMGQ PTA* AAGAGAGAAAGAG 
AGAAGAAGAGAGAGADVAAAGAAAAAVT GAACWGS WT CT G 
EPLGSX
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Reading frame 5.
L P D *R C I**  YPTW NLHLVIS*PAKVHL* PQRKYNKSLRWD 
GGTGSWLEFLLRVHPYSSGTFPS*SALWLRVLAWVCTGLP 
EPRRSLHCR* PPGARTRPCRWASRPPELPGPGLEPQLEPG 
PGLRAPPGPGPGPVLMSRPPEPPPRLSPGPPAGEAGRARA 
SRSAP
Reading frame 6.
SPIDDVFDDIQHGTST** FHDQPKFIFDHKGSIISHYVGM 
AALAHGLNFF*EFIHTRLALFQVDPLYGYAFLPGFAQGCL 
NHGGRSTADNLLELVRVPADGPADRLSCRGRGWSRSWSRG 
RGCGRRRGRGRGRC*CRGRRSRRRGCHRGRLLGKLDVHGR 
AARLX
Reading frame 1 represents the open reading frame (underlined).
Program: NCBI-blastp 
Database: Swissprot 
Title: CLONE-3 
SeqLen: 184 
Matrix: -M blosum62 
Filter: -F f
Sequences producing significant alignments: (bits) Value
SW:SPAK RAT 088506 STE20/SPS1 -RELATED PROLINE-ALA 9.9e-50
SW:SPAK MOUSE Q9Z1W9 STE20/SPS1-RELATED PROLINE-A 6.1e-47
SW:SPAK HUMAN Q9UEW8 STE20/SPS1 -RELATED PROLINE-A 1,2e-43
SW:PAK4 HUMAN 096013 SERINE/THREONINE-PROTEIN KIN 9.4e-06
» S W :SPAK RAT 088506 STE20/SPS1-RELATED PROLINE-ALANINE 
Length =553
Smith-Waterman score: 837; 100.000% identity (100.000% ungapped) in 
164 aa overlap (1-164:3-166)
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Query: 
Sbj ct:
Query: 
Sbjct:
Query: 
Sbjct:
Query:
Sbjct:
Query:
Sbjct:
6 E P S G S P VHVQL P Q QAAP VT AAAAAP AAAT S APAP AE P S G S P VHVQL P QQAAP VTAAAAAPAAAT S APAP A 1 S PAMAE P S G S P VHVQL P QQAAP VTAAAAAPAAAT S APAPA
3 6 PAPAAPAAPAPAPAAAPAPAPAAQAV G W PICRDAYELQEV PAPAAPAAPAPAPAAAPAPAPAAQAVGWPI CRDAYELQEV 41 PAPAAPAAP APAPAAAP AP APAAQAV G W PI CRDAYELQEV
7 6 IGSGATAWQAALCKPRQERVAIKRINLEKCQTSMDELLK IGSGATAWQAALCKPRQERVAIKRINLEKCQTSMDELLK 81 IGSGATAWQAALCKPRQERVAIKRINLEKCQTSMDELLK
116 EIQAMSQCSHPNWTYYTSFWKDELWLVMKLLSGGSMLD EIQAMSQCSHPNWTYYTSFWKDELWLVMKLLSGGSMLD 121 EIQAMSQCSHPNWTYYTSFWKDELWLVMKLLSGGSMLD
156 IIKYIVNRGX IIKYIVNRGX161 IIKYIVNRGXEHKNGVLEEAIIATILKEVLEGLDYLHRNG
35
40
75
80
115
120
155
160
165
200
191
The translation of clone 4 in all six reading frames:
Reading frame 1.
TAKMETTFYDDALNASFLQSESGAYGYSNPKILKQSMTLN 
LADPVGNLKPHLRAKNSDLLTSPDVGLLKLASPELERLII 
QSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAEL 
H S QNT L P S VT SAAQ PVS GAGMVAPAVAS VAGAGGGGG Y S A  
SLHSEPPVYANLSNFNPGALSSGGGAPSYGATGLAFPSQP 
QQQQQPPQPPHHLPQQIPVQHPRLQALKEEPQTVPEMPGE 
T P P L S PIDMES QERIKAE RKRMRNRIAASKCRKRKLERIA 
RLEEKVKTLKAQLXNSELASTANMLREQVAQLKQKVMN tr P
RLFKAPDRAGPTNVSASGVLTLRSLERTGEEGAGGSTAVW 
SARS*TNFVTEAGTRGYPPLPGALLRPRNFCAQPRLTPRE 
VTDCSM
Reading frame 2.
GEPLSLGLVRGLRGTAAS*ERSVSDRDFSKLRIARDQPT* 
VQAVS* PCAPWSELGRRAQGGALRSGAHAPKQTLLLKRGR 
AGIPRFPARCCGPETSAHSPG* PRVK* PTVL*LQRWKRPS 
TTMPSTPRSSSPRVAPTATVTLRF*SRA*P*TWPTRWAI* 
SRTSEPRTRTFSRRPTSGCSSWRRRSWSA*SSSPAMGTSP 
LHRPPLSSCAPRT* PTSRRASPRASCAP*LNCIARIRCPV 
SPPRHNLSVGRAWSLPLWPQ*LALAAAAATAPACTVSLRS 
TPTSATSTRVR*AAAVGRPPMARPGWPFHRSPSSSSSRLS 
RRTTCPNRSRCSTRGCRR*RKSRRRCRRCRERRRPCPPST 
WSLRSGSRRRGSA*ETASLPPSAGKGSWSGSPG*RKK*KP
*KRN*
Reading frame 3.
ENLCRWGWSAGSEEPLLPESAP*VTATFQSSGSRGTNQRE 
CKRCLNPALPGANWGGGRRGEHCGLERTLLNKLCY*SGDA 
RVSPASRRAVAAPKLLRTAQANPA*SDRLFYDCKDGNDLL 
RRCPQRLVPPVREWRLRLQ* P*DSEAEHDLEPGRPGGQSE 
AAPPSQELGPSHVARRRAAQAGVAGAGAPDHPVQQWAHHH 
YTDPHSVLVPQERDRRAGGLRRRLRARPS* TA* PEYAAQC 
HLRGTTCQWGGHGRSRCGLSSWRWRRRRLQRQPAQ*ASGL 
RQPQQLQPGCAEQRRWGALLWRDRAGLSIAAPAAAAAASA 
AAPLAPTDPGAAPAAAGAEGRAADGAGDAGRDAALVPHRH 
GVSGADQGGEEAHEKPHRCLQVPEKEAGADRPARGKSENL 
ESAIX
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Reading frame 4.
LIALSRFSLFPLAGRSAPASFSGTWRQRCGFSCASSPP*S 
APE T PCRWGTRAAS L PAS PAP SAAL P SAPAAAGAAPGSVG 
ASGAAAEAAAAAAGAAMERPARSRHRRAPHRRCSAHPG* S 
C*GWRRPEAHCAGWRCSRRRRQRQLLRPQRERPCPPH*QV 
VPRR* HWAAYSGYAVQLGRARSLRRS PPARRSRSWGTRTE 
WGSV*W* CAHCWT G* S GAPAPAT PA*AARRRAT *EGPSSW 
LGGAASDCPPGRPGSRSCSASES*GYCSRRRHSRTGGTRR 
*GHRRRRSFPSLQS*NSRSLHAGLAWAVRRSFGAATARRE 
AGDTRASPLQ*QSLFRSVRSRPQCSPLRPPPQFAPGSAGL 
RHRLHSRWLVPRDPEIAKVAVTHGALSGSSGSSEPADQPQ 
RQRFS
Reading frame 5.
*LRFQGFHFFL* PGDPLQLPFPALGGSDAVSHALPLRLDP 
LLRLHVDGGQGRRLSRHLRHRLRLFLQRLQPRVLHRDLLG 
QWRRLRRLLLLLGLRWKGQPGRAIGGRPTAAAQRTRVEV 
AE VGVDRRLT VQAGAVAAAAASAS Y ^  GH S GS DHAR P T DRL 
CRGGDTGQRILAMQFS*GAHEAFGEALLLVGHVLGAQELS 
GGRCSGDVPIAGLDDQALQLRRRQLEQPDVGRREKVRVLG 
SEVRLQIAHRVGQVQGHALLQNLRVTVAVGATLGLEERGV 
EGIWEGRFHLCSHRTVGHFTRG*PGLCAEVSGPQQRAGK 
RGIPARPRFSNKVCLGACAPDRSAPPCALLPSSLQGAQG* 
DTACTHVGWSRAIRSFEKSRSLTERSQEAAVPRSPRTSPS 
DRGSX
Reading frame 6.
NCAFKVFTFSSSRAIRSSFLFRHLEAAMRFLMRFLSALIR 
S*DSMSMGDKGGVSPGISGTVCGSSFSACSRGCCTGICWG 
KWCGG* GGCCCCWGCDGKAS PVAP* EGAPPPLLSAPGLKL 
LRLA*TGGSLCRLAL* PPPPPAPATEATAGATMPAPLTGC 
AAEVTLGSVFWLCSSARARTKPSAKPSCSSVTFLGHKN*V 
GVGVWMCPLLDWMIRRSSSGDASLSSPTSGDVRRSEFLA 
RRCGFRLPTGSARFKVMLCFRILGLL* P*APLSDWRNEAL 
RASS*KWSIFAVIEQSVTSRGVSLGCAQKFRGRNSAPGS 
GGYPRVPASVTKFV*ERALQTAVLPPAPSSPVRSRERRVK 
TPLALTLVGPARSGALKSRGHSRSALRKQRFLGARGPAPA 
TEVLX
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Program: NCBI-blastp 
Database: Swissprot 
Title: CLONE-4 
SeqLen:430 
Matrix: -M blosum62 
Filter: -F f
Sequences producing significant alignments: (bits) Value
SW:AP1 RAT P17325 TRANSCRIPTION FACTOR AP-1 (PROTO-ONCOGENE)
591 e-169
SW:AP1 MOUSE P05627 TRANSCRIPTION FACTOR AP-1 (PROTO-ONCOGENE)... 
587 e-167
SW:APINHUMAN P05412 TRANSCRIPTION FACTOR AP-1 (PROTO-ONCOGENE)... 
559 e-159
>SW:AP1 RAT P17325 TRANSCRIPTION FACTOR AP-1 (PROTO­
ONCOGENE C-JUN). Length =334
Score = 591 bits (1507), Expect = e-169
Identities = 293/293 (100%), Positives = 293/293 (100%)
Q u e ry : 129 TAKMET T FYDDALNASFLQSESGAYGYSNPKILKQSMTL 
TAKMETTFYDDALNASFLQSESGAYGYSNPKILKQSMTL
167
S b j c t : 1 MTAKMETTFYDDALNASFLQSESGAYGYSNPKILKQSMTL 40
Q u e ry : 168 NLADPVGNLKPHLRAKNSDLLTSPDVGLLKLASPELERLI 
NLADPVGNLKPHLRAKNSDLLTSPDVGLLKLASPELERLI
207
S b j c t : 41 NLADPVGNLKPHLRAKNSDLLTSPDVGLLKLASPELERLI 80
Q u e ry : 208 IQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAE
IQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAE
247
S b j c t : 81 IQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAE 120
Q u e ry : 248 LH S QNT L P S VT S AAQ P VS GAGMVAPAVAS VAGAGGGGG Y S 
LHSQNTLPSVT SAAQ PVS GAGMVAPAVAS VAGAG G G G G Y S
287
S b j c t : 121 LHSQNTLPSVTSAAQPVSGAGMVAPAVASVAGAGGGGGYS 160
Q u e ry : 288 ASLHSEPPVYANLSNFNPGALSSGGGAPSYGATGLAFPSQ
ASLHSEPPVYANLSNFNPGALSSGGGAPSYGATGLAFPSQ
327
S b j c t : 161 ASLHSEPPVYANLSNFNPGALSSGGGAPSYGATGLAFPSQ 200
194
Query: 328 PQQQQQPPQPPHHLPQQIPVQHPRLQALKEEPQTVPEMPG PQQQQQPPQPPHHLPQQIPVQHPRLQALKEEPQTVPEMPG Sbj ct: 201 PQQQQQPPQPPHHLPQQIPVQHPRLQALKEEPQTVPEMPG
Query: 368 ETPPLSPIDMESQERIKAERKRMRNRIAASKCRKRKLERI ETPPLSPIDMESQERIKAERKRMRNRIAASKCRKRKLERI Sbjct: 241 ETPPLSPIDMESQERIKAERKRMRNRIAASKCRKRKLERI
Query: 408 ARLEEKVKTLKAQ 420 ARLEEKVKTLKAQ Sbjct: 281 ARLEEKVKTLKAQ 293
367
240
407
280
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The translation of clone 5:
Reading frame 1.
SAALPLRMHHSAAEGLPASNHATNVMSTATGLHYSVPSCH
YGNQPSTYGVMAGTLTPCLYKFPDHTLSHGFPPLHQPLIA
EDPTASEFKQELRRKSKLVEEPIDMDSPEIRELEQFANEF
KVRRIKLGYTQTNVGEALAAVHGSEFSQTTICRFENLQLS
FKNACKLKAILSKWLEEAEQVGALYNEKVGANERKRKRRT
TISIAAKDALERHFGEHSKPSSQEIMRMAEELNLEKEWR
VWFC
Reading frame 2.
FCCPASENAPQCR*GSPSLQPRHQRDVHSDRTSLFCAFLS
LWKPAIHLRSDGRHFNPLSLQVSRPHPESWSSPAPTSAG
GGPNSL*I*AGTQAEK*IGGRANRHGLPGNPRTGAVCQRI
*SEKN*VRIHPDKRGRSSGRCPRLRIQSNNHLPI*KLAAQ
FQKCLQTESNFIQVAGGS*AGRSFVQ*KSGSKRKEEETED
NYQYRR*GCFGETLWRAQQTFFAGDHADG*RIESRERSSK
SW LQX
Reading frame 3.
LLPCL*ECTTVPLRVSQPPTTPPT*CPQRQDFIILCLPVI 
METSHPPTE*WQAL*PLVFTSFQTTP*VMGFLPCTNLCWR 
RTQQPLNLSRNSGGKVNWWKSQ*TWTPRKSENWSSLPTNL 
K*EELS*DTPRQTWAKLWPLSTAPNSVKQPSADLKTCSSV 
SKMLAN*KQFYPSGWRKLSRSELCTMKKWEQTKGRGNGGQ 
LSVSPLRMLWRDTLESTANLLRRRSCGWLKN*ISRKK**E 
CGFAX
Reading frame 4.
LAKPHSYYFFLEIQFFSHPHDLLRRRFAVLSKVSLQSILS
GDTDSCPPFPLPFVCSHFFIVQSSDLLSFLQPLG*NCFQF
ASIFETELQVFKSADGCLTEFGAVDSGQSFAHVCLGVS*L
NSSHFKFVGKLLQFSDFRGVHVYWLFHQFTFPPEFLLKFR
GCWLRQQRLVQGRKPMTQGWWKLVKTRG*SACHHSVGG
WLVSIMTGRHRIMKSCRCGHHVGGWGGWETLSGTWHSQ
RQGSRX
Reading frame 5.
LQNHTLTTSFSRFNSSAIRMISCEEGLLCSPKCLSKASLA 
A ILIW LR FLFLSFAPTFSLYKAPTC SASSSH LD KIAFSL 
QAFLKLSCKFSNRQMW* LNSE PWTAARAS PT FVWVY PNL 
ILLTLNSIANCSSSRISGESMSIGSSTNLLFRLSSCLNSE 
AVGSSASRGWCRGGNP*LRVWSGNL*RQGVKVPAITP*VD 
GW FP**QEGTE**SPVAVDIT LVAWLEAGR PSAALWCILR 
GRAAE
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Reading frame 6.
CKTTLLLLLSRDSILQPSA*SPAKKVCCALQSVSPKHP*R
RY**LSSVSSSFRLLPLFHCTKLRPAQLPPATWIKLLSVC
KHF*N*AASFQIGRW LFD*IRSRGQRPELRPRLSGCILT*
FFSL*IRW QTAPVLGFPGSPCLLALPPIYFSA*VPA*IQR
LLGPPPAEVGAGEETHDSGCGLETCKDKGLKCLPSLRRWM
AGFHNDRKAQNNEVLSLWTSRWWRGWRLGDPQRHCGAFSE
AGQQX
Reading frame 1 (underlined) is deemed to be the open reading frame.
Program: NCBI-blastp 
Database: Swissprot 
Title: CLONE-5 
SeqLen:249 
Matrix: -M blosum62 
Filter: -F f
Sequences producing significant alignments: (bits) Value
SW:HMP1 MOUSE Q00286 PITUITARY-SPECIFIC POSITIVE TRANSCRIPTION 
494 e-139
SW:HMP1 RAT P10037 PITUITARY-SPECIFIC POSITIVE TRANSCRIPTION 
487 e-137
SW:HMP1 HUMAN P28069 PITUITARY-SPECIFIC POSITIVE TRANSCRIPTION 
481 e-136
SW:HMP1 BOVIN P10036 PITUITARY-SPECIFIC POSITIVE TRANSCRIPTION 
470 e-132
>SW:HMP1 RAT P10037 PITUITARY-SPECIFIC POSITIVE 
TRANSCRIPTION FACTOR 1 (PIT-1)
(GROWTH HORMONE FACTOR 1) (GHF-1).
Score = 487 bits (1239), Expect = e-137
Identities = 244/272 (89%), Positives = 246/272 (89%), Gaps = 26/272 (9%)
Q u e ry : 1 SSAALPLRMHHSAAEGLPASNHATNVMST------------------------  30
S AAL PLRMHHS AAE GL PASNHATNVMS T 
S b j c t :  18 DASAALPLRMHHSAAEGLPASNHATNVMS TVPSILS L IQ T  57
Q u e ry : 31 ----------------------------------- ATGLHYSVPSCHYGNQPSTYGVMA 54
ATGLHYSVPSCHYGNQPSTYGVMA 
S b j c t :  58 PKCLHTYFSMTTMGNTATGLHYSVPSCHYGNQPSTYGVMA 97
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Query: 55 GTLTPCLYKFPDHTLSHGFPPLHQPLLAEDPTASEFKQELGTLTPCLYKFPDHTLSHGFPPLHQPLLAEDPTASEFKQEL 94Sbj ct: 98 GTLTPCLYKFPDHTLSHGFPPLHQPLLAEDPTASEFKQEL 137
Query: 95 RRKSKLVEEPIDMDSPEIRELEQFANEFKVRRIKLGYTQTRRKSKLVEEPIDMDSPEIRELEQFANEFKVRRIKLGYTQT 134Sbjct: 138 RRKSKLVEEPIDMDSPEIRELEQFANEFKVRRIKLGYTQT 177
Query: 135 NVGEALAAVHGSE FSQTTICRFENLQLS FKNACKLKAILS NVGEALAAVHGSE FSQT TICRFENLQLS FKNACKLKAILS 154Sbjct: 178 NVGEALAAVHGSE FS QT TICRFENLQLS FKNACKLKAILS 217
Query: 155 KWLEEAEQVGALYNEKVGANERKRKRRTTISIAAKDALER KWLEEAEQVGALYNEKVGANERKRKRRTTISIAAKDALER 194Sbjct: 218 KWLEEAEQVGALYNEKVGANERKRKRRTT IS IAAKDALER 257
Query: 195 HFGEHSKPSSQEIMRMAEELNLEKEWRVWFC 246 H FGEHS KP S S QEIMRMAEELNLEKEVVRVWFCSbjct: 258 HFGEHSKPS S QE IMRMAEELNLEKEWRVWFC 289
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The translation of clone 6:
Reading frame 1.
LQEAQDGVLDLKAAADTLAVRQKRRIYDITNVLEGIDLIE
KKSKNSIQWKGVGAGCNTKEVIDRLRCLKAEIEDLELKER
ELDQQKLWLQQSIKNVMEDSINNRFSYVTHEDICSCFNGD
TLLAIQAPSGTQLEVPIPEMGQNGQKKYQINLKSHSGPIH
VLLINKESNSSKPWFPVPPPDDLTQPSSQSSTSVTPPKS
TMAAQNLPEQHVSERSQNFQQTPATEISSGSISGDIIDEL
MSSDX
Reading frame 2.
CCRRRRTASW ISKRLQILW L*GKSEEFMISPTS*KELI*L 
KKNQRTVSS G R V*VLA VILKK L* ID *D V L K L K L K I*N *R K  
ENLTSRSCGYSKASKT*WKTPLITDFLM*LTKTSAVALMV 
IHCWPFRHPLVHSWKYLFQKWDRMDKRNTR*I*RVTQDQS 
MCYL*IKSPTHLSRWFFLSPHLMTSHNLPPSPQLQ*LHRN 
PPWLLKTCPSSMFLKEARISSRHQLQKYLQDLLVETSLMN 
*C LLTX
Reading frame 3.
AAGGAGRRPGSQSGCRYFGCEAKAKNL*YHQRLRRN*SN* 
KKIKEQYPVEGCRCW L*Y*RSYR*IKMS*S*N*RSRIEGK 
RT*PAEW ATAKHQKRDGRLH**QIFLCNSRRHLQLL*W * 
YTVGHSGTLWYTAGSTYSRNGTEWTKEIPDKSEESLRTNP 
C ATYK*R VQ LI+AGGFSCPPT^'PHTTFLPVLNFSDSTEI 
HHGCSKPARAACF*KKPEFPADTSYRNIFRIY*WRHH**T 
DVF*R
Reading frame 4.
SSEDISSSMMSPLIDPEDISVAGVCWKFWLLSETCCSGRF
*AAMVDFGGVTEVEDWEEGCVRSSGGGTGKTTGLDELDSL 
FISSTW IGPE*LFRFIW YFFCPFCPISGIGTSSCVPEGA* 
MANSVSPLKQLQMSS*VT*ENLLLMESSITFLMLCCSHNF 
CWSSSLSFNSRSSISALRHLNLSITSLVLQPAPTPFHWIL 
FFDFFSIRSIPSKTLVIS*ILRFCLTAKVSAAALRSRTPS 
CAS CSX
Reading frame 5.
RQKTSVHQ* CLH* *  IL K IF L *  LVSAGNSGFFQKHAARAGF 
EQPWWISVESLKLRTGRKW*GHQVGGQEKPPA*MSWTLY 
L*VAHGLVLSDSSDLSGISFVHSVPFLE*VLPAVYQRVPE 
WPTVYHH*SNCRCLRELHKKICY*WSLPSRF*CFAVATTS 
AG Q VLFPSILDLQ FQ L*DILIYL*LL*YYSQ HLHPSTG YC 
SLIFFQLDQFLLRRW*YHKFFAFASQPKYLQPL*DPGRRP 
APPAA
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Reading frame 6.
VRRHQFINDVSTNRS*RY FCSWCLLEILAS FRNMLLGQVL 
SSHGGFRWSH*S*GLGGRLCEVIRWGDRKNHRLR*VGLFI 
YK*HMDWS*VTLQIYLVFLLSILSHFWNRYFQLCTRGCLN 
GQQCITIKATADVFVSYIRKSVINGVFHHVFDALL*PQLL 
LVK FS FLQ F*IFN FSFKTS*S IYN FFS ITA STYTLP LD TV 
L*FFFN *IN SF*D VG D IIN S SLLPH S Q SIC S R FE IQ D AVL 
RLLQX
Reading frame 1 (underlined) was deemed to be the open reading frame.
Program: NCBI-blastp 
Database: Swissprot 
Title: CLONE-6 
SeqLen:245 
Matrix: -M blosum62 
Filter: -F f
Sequences producing significant alignments: (bits) Value
SW:E2F5 RAT Q62814 TRANSCRIPTION FACTOR E2F5 CE2F 
1.2e-111
(300) 1246 401
SW:E2F5 MOUSE Q61502 TRANSCRIPTION FACTOR E2F5 (E 
1.8e-108
(335) 1213 391
SW:E2F5 HUMAN Q15329 TRANSCRIPTION FACTOR E2F5 fE 
4.5e-103
(346) 1156 373
» S W :E2F5 RAT Q62814 TRANSCRIPTION FACTOR E2F5 (E2F-5) 
Length=300
Smith-Waterman score: 1246; 100.000% identity (100.000% ungapped) in 
244 aa overlap (1-244:21-264)
Q u e ry : 21 LQEAQDGVLDLKAAADTLAV 4 0
LQEAQDGVLDLKAAADTLAV 
S b j c t :  1 GGSSRHEKSLGLLTTKFVSLLQEAQDGVLDLKAAADTLAV 4 0
Q u e ry : 41 RQKRRIYDITNVLEGIDLIEKKSKNSIQWKGVGAGCNTKE 8 0
RQKRRIYDITNVLEGIDLIEKKSKNSIQWKGVGAGCNTKE 
S b j c t :  41 RQKRRIYDITNVLEGIDLIEKKSKNSIQWKGVGAGCNTKE 8 0
Q u e ry : 81 VIDRLRCLKAEIEDLELKERELDQQKLWLQQSIKNVMEDS 12 0
VIDRLRCLKAEIEDLELKERELDQQKLWLQQSIKNVMEDS 
S b j c t :  81 VIDRLRCLKAEIEDLELKERELDQQKLWLQQSIKNVMEDS 12 0
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Query: 121 INNRFSYVTHEDICSCFNGDTLLAIQAPSGTQLEVPIPEM 160 INNRFSYVTHEDICSCFNGDTLLAIQAPSGTQLEVPIPEM Sbjct: 121 INNRFSYVTHEDICSCFNGDTLLAIQAPSGTQLEVPIPEM 160
Query: 161 GQNGQKKYQINLKSHSGPIHVLLINKESNSSKPWFPVPP 200GQNGQKKYQINLKSHSGPIHVLLINKESNSSKPWFPVPP Sbj ct: 161 GQNGQKKYQINLKSHSGPIHVLLINKESNSSKPWFPVPP 200
Query: 201 PDDLTQPSSQSSTSVTPPKSTMAAQNLPEQHVSERSQNFQ 241 PDDLTQPSSQSSTSVTPPKSTMAAQNLPEQHVSERSQNFQ Sbjct: 201 PDDLTQPSSQSSTSVTPPKSTMAAQNLPEQHVSERSQNFQ 241
Query: 241 QTPATEISSGSISGDIIDELMSSD 264QTPATEISSGSISGDIIDELMSSD Sbjct: 241 QTPATEISSGSISGDIIDELMSSDVFPLLRLSPTPADDYN 280
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The translation of clone 7:
Reading frame 1.
QMPLDLSPLATPIIRSKIEEPSW ETTHQDSPLPHPESTT
NDEKEIPLAQTAQPTSAIVRPASLQVPNVLLTSSDXSVII
QQAVPSPTSXTVITQAPSSNRPIVPVPGPXPLLLHLPNGQ
TMPVAIPASITSSNVHVPAAVPLVRPVTMVPSVPGIPGXS
SP
Reading frame 2:
KC L*ICPLLQ HPS*EAKLRNLLL*KQ LTRIARYLTPSLLP 
MMKRKYHWHKLHSPHQLSFVQHHYRFPMCCSQVLTXV"LF 
NKQYLHQPXVL*SPRHHPLTGQLFLYQAHXLFYYIFLMDK 
PCPLLFLHQLQVLMCMFQLQSHLFGQSPWCLVFQESQAXP 
LL
Reading frame 3.
NASRSVPSCNTHHKKQN*GTFCCRNNSPG* PVTSPRVYYQ 
**KGNTIGTNCTAHISYRSSSIITGSQCAAHKF*XKCNYS 
TSSTFTNLXYCNHPGTIL*QANCSCTRPXSSSITSS*WTN 
HARCYSCINYKF*CACSSCSPTCSASHHGA*CSRNPRXFL 
SX
Reading frame 4:
QERXGLGFLEH*APW*IA.EQVGLQLEHAH*NL*LMQE*QR 
AWFVH*EDVIEEXMGLVQEQLAC*RMVPG*LQYXRLVKVL 
LVE*LHXSQNL*AAHWEPVMMLDER*LMWAVQFVPMVFPF 
HHW* * TRGEVTGYPGELFLQQKVPQFCFL*WVLQEGTDLE 
AF
Reading frame 5:
RRGXAWDSWNTRHHGDWPNKWDCSWNMHIRTCN*CRNSNG 
HGLSIRKM* * KRXWAWYRNNWPVRGWCLGDYSX*GW* RYC 
LLNNYTXVRTCEQHIGNL**CWTNDS*CGLCSLCQWYFLF 
IIGSRLGVR*RAILVSCFYNRRFLNFASYDGCCKRGQI* R 
HX
Reading frame 6:
GEEXPGIPGTLGTMVTGRTSGTAAGTCTLELVIDAGIATG 
MVCPLGRCNRRGXGPGTGTIGLLEDGAWITVXEVGEGTA 
C*IITLXSELVSSTLGTCNDAGRTIADVGCAVCANGIS FS 
SLWDSG*GNGLSW*WSTTEGSSILLLMMGVARGDRSRG 
IX
Reading frame 1 (underlined) was deemed to be the open reading frame.
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Program: NCBI-blastp 
Database: Swissprot 
Title: CLONE-7 
SeqLen:162 
Matrix: -M blosum62 
Filter: -F f
Sequences producing significant alignments: (bits) Value
SW:ATF2 RAT Q00969 CYCLIC-AMP-DEPENDENT TRANSCRIPTION FACTOR 
312 2e-85
SW:ATF2 MOUSE P16951 CYCLIC-AMP-DEPENDENT TRANSCRIPTION FACTOR 
310 1e-84
SW:ATF2 HUMAN P15336 CYCLIC-AMP-DEPENDENT TRANSCRIPTION FACTOR 
308 5e-84
SW:ATF2 CHICK 093602 CYCLIC-AMP-DEPENDENT TRANSCRIPTION FACTOR 
302 3e-82
>SW:ATF2 RAT Q00969 CYCLIC-AMP-DEPENDENT TRANSCRIPTION 
FACTOR ATF-2 (ACTIVATING TRANSCRIPTION FACTOR 2)
(CAMP RESPONSE ELEMENT BINDING PROTEIN CRE- BP1). 
Length = 487
Score =3 1 2  bits (791), Expect = 2e-85
Identities = 157/161 (97%), Positives = 157/161 (97%)
Q u e ry : 1 MPLDLSPLATPIIRSKIEEPSW ETTHQDSPLPHPESTTN 40
MPLDLSPLATPIIRSKIEEPSW ETTHQDSPLPHPESTTN 
S b j c t :  89 MPLDLSPLATPIIRSKIEEPSW ETTHQDSPLPHPESTTN 128
Q u e ry : 41 DEKEIPLAQTAQPTSAIVRPASLQVPNVLLTSSDXSVIIQ 8 0
DEKEIPLAQTAQPTSAIVRPASLQVPNVLLTSSD S V IIQ  
S b j c t :  129 DEKEIPLAQTAQPTSAIVRPASLQVPNVLLTSSDSSVIIQ 168
Q u e ry : 81 QAVPSPTSXTVITQAPSSNRPIVPVPGPXPLLLHLPNGQT 
QAVPSPTS TVITQAPSSNRPIVPVPGP PLLLHLPNGQT
120
S b j c t : 169 QAVPSPTSSTVITQAPSSNRPIVPVPGPFPLLLHLPNGQT 208
Q u e ry : 121 MPVAIPASITSSNVHVPAAVPLVRPVTMVPSVPGIPGXSSP 
MPVAIPASITSSNVHVPAAVPLVRPVTMVPSVPGIPG SSP
161
S b j c t : 209 MPVAI PASITSSNVHVPAAVPLVRPVTMVPSVPGIPGPS S P 249
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From the results of the database searches clones 1 and 4 both show 
sequence homology to the transcription factor AP-1 (proto-oncogene c-jun), 
therefore, the next step was to search for an overlapping sequence between 
the two clones. To achieve this it was necessary to use the BLAST2 multiple 
sequence alignment tool. This tool produces the alignment of two given 
sequences using the BLAST2 search engine for local alignment (Tatusova 
T.A. and Madden T.L. 1999).
Interestingly the DNA sequence of the MBP promoter region located 
between nucleotides -609 to -577 resembles the AP-1 binding site.
-609 -577
5 ' CACCTTTTGTCAAACGACCGCTTCACATCTGGG 3 '
5 ' TGAGTCAG 3 AP-1 binding site
BLAST 2 SEQUENCES: RESULTS [VERSION BLASTP 2.1.2]
Sequence 1 lcl|seq_1 Length 252 (1 .. 252)
Sequence 2 lcl|seq_2 Length 433 (1 .. 433)
Sequence 2
Sequence 1
Score = 139 bits (351), Expect = 2e-32
Identities = 104/104 (100%), Positives = 104/104 (100%)
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Query: 2 GATGLAFXXXXXXXXXXXXXXXXXXXXXXXXXXRLQALK 42GATGLAF RLQALKSbj ct: 317 YGATGLAFPSQPQQQQQPPQPPHHLPQQIPVQHPRLQALK 356
Query: 42 EE PQTVPEMP GE T P P L S PIDMES QERIKAERKRMRNRIAA 81EEPQTVPEMPGETPPLSPIDMESQERIKAERKRMRNRIAA Sbjct: 357 EEPQTVPEMPGETPPLSPIDMESQERIKAERKRMRNRIAA 396
Query: 82 SKCRKRKLERIARLEEKVKTLKAQ 105SKCRKRKLERIARLEEKVKTLKAQ Sbjct: 397 SKCRKRKLERIARLEEKVKTLKAQ 420
GappedLambda K0.318 0.133
GappedLambda K0.267 0.0410
Matrix: BLOSUM62 Gap Penalties: Existence: 11, Extension: 1 Number of Hits to DB: 711 Number of Sequences: 0 Number of extensions: 47 Number of successful extensions: 1 Number of sequences better than 10.0: 1 Number of HSP’s better than 10.0 without gapping: 1Number of HSP’s successfully gapped in prelim test: 0Number of HSP's that attempted gapping in prelim test: 0Number of HSP’s gapped (non-prelim): 1
length of query: 252 
length of database: 187,523,045 
effective HSP length: 56 
effective length of query: 196 
effective length of database: 145,851,261 
effective search space: 28586847156 
effective search space used: 28586847156
The results of the BLAST2 search above show that clones 1 and 4 
contain an overlapping sequence, and since the alignment indicates a high 
level of sequence similarity and a correspondingly low E-value (Expect = 2e- 
32) this would imply that the alignment is unlikely to be a random match. In
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H0.389
H0.140
the data shown above the program SEG has been implemented as part of 
the BLAST routine. The purpose of the SEG program is to mask out low 
complexity regions (i.e. regions within a sequence which have high densities 
of particular residues, e.g. psqpqqqqqppqpphhlpqqipvqhp), which would 
otherwise result in large numbers of spurious high-scoring matches 
swamping the ‘hitlist’. Regions masked by SEG are denoted by strings of Xs 
in the query sequence.
Clones 1 and 4 have been identified as the transcription factor c-jun,
which is capable of stimulating transcription via an AP-1 site. The AP-Mjun
family of transcription factors bind to the consensus nucleotide sequence
TGAGTCAG found in the enhancers of many cellular and viral genes, c-jun
is a proto-oncogene which when mutated becomes an oncogene. Implicit in
the growth functions of all oncogenes is the potential to induce abnormal cell
growth and cancer as a result of deregulated gene expression (Vogt and
Bos, 1990). As well as Jun, purified preparations of AP-1 contain several
different proteins e.g. Jun-related proteins, c-fos and Fos-related proteins
known as fras (fos-related antigens) (Karin et al., 1997). Unlike Jun, which
can form a DNA-binding homodimer, Fos cannot bind to the AP-1 site as a
homodimer. Flowever, Fos can bind (with approximately 30 fold greater
affinity than the Jun homodimer alone) to AP-1 sites in the presence of
another nuclear protein, p39, which has been identified as Jun (Rauscher et
al., 1988). The p39 protein is also identical to yeast protein GCN4 (Hattori et
al., 1988). The strong homology of the Jun and GCN4 proteins suggests
they recognise very similar DNA-binding sequences (e.g. GCN4 binds to the
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consensus sequence 5'-TGA(C/G)TCA-3' and Jun binds to the consensus 
sequence 5’-TGAGTCAG-3’ respectively). It has been proposed by Vogt and 
Bos (1990) that the C-terminus of the Jun protein (located between amino 
acid residues 260 to 311) is the DNA-binding domain. Within this region two 
features stand out: the basic domain located between amino acid residues 
260 to 279) and the leucine zipper (located between amino acid residues 
283 to 311). The zipper itself consists of a periodic repetition of leucine 
residues at every seventh position, and regions containing them appear to 
span 8 turns of alpha-helix. The leucine side chains that extend from one 
helix interact with those from a similar helix, thus facilitating dimerisation, 
which in turn results in the correct positioning of the two basic DNA-binding 
domains in the dimeric molecule for DNA binding to occur. Leucine zippers 
are present in many gene regulatory proteins, including the CREB proteins, 
Jun, Fos oncogene and Fos-related proteins (Fras), C-myc, L-myc and N- 
myc oncogenes. Promoters containing the AP-1 binding site sequence are 
inducible by treatment with phorbol esters which appear to increase DNA 
binding of Jun by activating protein kinase C. However, it has been shown 
that increased DNA-binding of Jun is mediated by a dephosphorylation at 
three specific sites (one threonine and two serine) following phorbol ester 
treatment (Boyle etaf., 1991). This indicates protein kinase C acts by 
stimulating a phosphatase enzyme, which in turn dephosphorylates Jun.
Such an inhibitory effect of phosphorylation on the activity of a transcription 
factor is not unique to Jun. Interestingly, there are two amino acid residues 
(both serine) located at amino acid positions 63 and 73 respectively which
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can be modified by phosphorylation by JNK1 which inhibits transcriptional 
activity (Boyle etal., 1991).
Clone 3 has been identified as the PASK protein (jDroline-alanine rich 
STE20-related kinase). It is thought that this protein may act as a mediator of 
stress-activated signals (Ushiro etal., 1998). The PAPA box (proline-alanine 
repeats) may target the kinase to a specific subcellular location by 
facilitating the interaction with intracellular proteins such as actin or actin-like 
proteins. Sequence homology puts the PASK protein into the serine / 
threonine family of protein kinases (STE20 subfamily). According to the 
Ushiro group PASK is preferentially expressed in cells rich in Na+, K+- 
ATPase and active in ion transport (i.e. those cells maintaining an 
electrochemical sodium and potassium gradient across the plasma 
membrane). Sodium-coupled active transport relies on these gradients within 
the cell (e.g. in neurons, Na+, K+-ATPase is active to maintain their resting 
membrane potential (Albers etal., 1994).
Clone 5 has been identified as the pituitary specific positive
transcription factor 1 (Pit-1), growth hormone factor-1 (GHF-1) or general
transcription factor 2i. The transcription factor Pit-1 plays a crucial role in
pituitary-specific gene expression, and belongs to the homeobox / POU
family of transcription factors. The POU-domain located between amino acid
residues 154 to 224 is a 70 to 75 amino acid region found upstream of a
homeobox domain in some transcription factors. Such proteins bind to
specific DNA sequences to cause spatial and temporal regulation of the
expression of genes, many of which are involved in the regulation of
neuronal development in the central nervous system of mammals (Johnson
208
and Hirsh, 1990). Other genes are also regulated by the POU-domain, 
including those for the immunoglobulin light and heavy chains (Oct-2) 
(Petryniak et al., 1990), and trophic hormone genes, such as those for 
prolactin and growth hormone (Pit-1). The POU-domain may also be 
involved in protein-protein interactions (Mathis etal., 1992). The 3- 
dimensional structure of the POU-domain has been determined by 
multidimensional nuclear magnetic resonance (Assa-Munt etal., 1993) and 
X-ray crystallography (Klemm et al., 1994).
The homeobox (DNA-binding domain) located between residues
240 to 299 is a 60 amino acid region, first identified in a number of
Drosophila segmentation and homeotic proteins, is known to be well
conserved in many other species (Gehring, 1992). Proteins containing
homeobox domains are likely to play a vital role in development and most
are known to be sequence-specific DNA-binding transcription factors. The
homeobox domain binds DNA through a helix-turn-helix (HTH) structure. The
HTH motif is characterised by two a-helices, which make intimate contacts
with the DNA and are joined by a short turn. The first helix helps to stabilise
the structure. The second helix binds to the DNA via a number of hydrogen
bonds and hydrophobic interactions, which occur between specific side
chains and the exposed bases and thymine methyl groups within the major
groove of the DNA (Schofield, 1987). Interestingly there is also an
alternative splicing site located between amino acid residues 48 to 73 which
gives rise to two functionally distinct homeodomain proteins (Theill et al.,
1992). This transcription factor is implicated in the specification of the
lactotrope, somatotrope and tyrotrope phenotypes in the developing anterior
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pituitary. It activates the growth hormone and prolactin genes by specifically 
binding to the consensus sequence TAAAT (Ingraham et al., 1988).
Clone 6 was identified as the transcription factor E2F5. The EF 
transcription factor family are transcriptional activators that bind to E2F sites, 
these sites are present in the promoters of many genes whose products are 
involved in cell proliferation and therefore play an important role in 
regulating the expression of genes that are required for passage through the 
cell cycle. It is also thought they may mediate growth factor-initiated signal 
transduction, and may participate in differentiation processes (Itoh etal., 
1995). Multiple E2F family members have been identified that bind to DNA 
as heterodimers, interacting with proteins known as dimerisation partners 
(DP).
Clone 7 has been identified as the cyclic-AMP-dependent
transcription factor atf-2 (activating transcription factor 2). This protein factor
belongs to the basic DNA-binding/leucine zipper and zinc finger families of
transcription factors. The zinc finger motif is located between residues 7 to
31 and is of the two cysteine-two histidine type. The motif is referred to as a
zinc finger because of its proposed structure i.e. a loop of twelve amino
acids project from the surface of the molecule which is anchored at its base
by the cysteine and histidine residues which tetrahedrally co-ordinate a zinc
atom (Kadonaga et al., 1987). The zinc finger motif has been shown to
constitute the DNA-binding domain of the protein. The basic DNA-binding
domain is located between amino acid residues 333 and 356, and the
leucine zipper between residues 362 to 390 respectively. Interestingly there
are two tyrosine residues at positions 51 and 53 that are susceptible to
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modification (phosphorylation) by MAP kinase. This protein factor is thought 
to function as a constitutive transcriptional activator binding to the cyclic 
AMP response element (CRE) a sequence that is present in many cellular 
and viral promoters (Kageyama etal., 1991).
Comparison of the basic DNA binding and leucine zipper motifs of the 
clones have revealed some interesting similarities, e.g. comparison of the 
basic DNA binding domain of the clones encoding the AP-1 transcription 
factor (clones 1 and 4) with that of the ATF-2 transcription factor clone 
(clone 7) showed a 10% amino acid sequence similarity.
AP-1 RKRMRNRIAAS KCRKRKLE R: : 10% Similarity
ATF-2 PDEKRRKFLERNRAAASRCRQKRK
However, comparison of the leucine zipper motifs of the respective clones
showed an amino acid sequence similarity of 45%.
AP-1 LEEKVKTLKAQNSELASTANMLREQVAQL:: : : : : : :: :::: 45% Similarity
ATF-2 LEKKAEDLSSLNGQLQSEVTLLRNEVAQL
The identification of c-jun is very interesting as there is a site in the 
-609 and -577 region of the MBP promoter which resembles an AP-1 
binding site. However further investigations including EMSA with 
recombinant c-Jun and labelled ds oligonucletide corresponding to this site 
are required. Cross-linking studies using nuclear extracts from 
oligodendrocyte cell lines and this oligonucleotide followed by protein micro­
sequencing would be also useful. Work on the unidentified clone, possibly
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representing a novel transcription factor, should be extended by screening a 
brain cDNA library in order to isolate a full-length copy of the corresponding 
cDNA. Expression of this protein in heterologous systems combined with 
established approaches applied in studies of transcription factors would 
permit the determination of a role, if any, of this protein in transcription of 
MBPs. Possible investigations which could be based on this thesis are also 
described in the section entitled Future Work (p 230). Surprisingly, several 
known transcription factors have been also detected in the one-hybrid 
system. Their cognate DNA sequences are not present in the studied region 
therefore they might represent false positives.
It should be noted that one of the limitations of the yeast one-hybrid 
system is the frequent occurrence of false positive results (e.g. clone 3) 
which reflect non-specific interactions between the cDNA (encoding the 
protein) and the target DNA-binding sequence. However, to reduce the 
frequency of such spurious results, most one-hybrid systems make use of 
dual reporters, typically HIS3 and LacZ. Since the minimal promoter of the 
HIS3 gene (PminHis3) is different from that of the LacZ gene (P Cy c i), non­
specific interactions fail to activate the expression of both reporter genes. 
Therefore, the first genetic selection can be achieved using the HIS3 
reporter gene, and the second selection can be performed by measuring 
LacZ expression with a p-galactosidase assay. From published data (Chen 
and Zack, 2000) it has been shown that up to half the HIS3 positives from a 
library screen are LacZ negative, suggesting these represent false positive 
results. False positive results can also be due to condensation caused whilst
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the SD medium solidifies resulting in localised dilution of the 3 -  
aminotriazole thus enabling colony growth due to the background expression 
of the HI S3 gene.
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Chapter 4
DISCUSSION
4.1.Discussion and Conclusions
A study has been undertaken to identify new protein factor(s) that 
could be involved in the expression of the mouse myelin basic protein gene. 
To achieve this the promoter region of the mouse myelin basic protein gene 
was cloned in the vector pBluescript and manually sequenced by the chain 
termination method of Sanger et al. (1977). The Hind III -  Sac I fragment 
which corresponds to the region between nucleotides -1319 and +227 
relative to the transcriptional start site of the MBP gene was used for this 
purpose (Roach etal., 1985). The data obtained from the sequencing gels 
was used to carry out a FastA sequence alignment search against the EMBL 
rodent database. A significant alignment was found with a sequence 
published by Miura et al., (1989 and updated March 2000) which showed 
that the two sequences were essentially identical (99.6%). The analysis of 
the sequence allowed the identification of putative binding sites for many 
known transcription factors e.g. MyEF2 (Haas etal., 1995), MEBA (Taveggia 
etal., 1998), Pura (Tretiakova etal., 1998), MRF-1 (Haque etal., 1994) and 
others. The region -  609 to -  577 was selected for further studies because 
work published by other groups suggested that it contains cell-type specific 
transcription activator for oligodendrocytes (Asipu and Blair 1994). To 
establish if specific protein factor(s) bind to this region, the electrophoretic 
mobility shift assay was performed using nuclear extracts from several cell 
lines and rat brain extracts. A protein complex (C2) has been identified in the
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C6 glioma cell and rat brain nuclear extracts (Figures 17 to 21) which was 
absent in HeLa cells and 33B oligodendrocytoma cells. The binding of the 
protein factor(s) to this region of the promoter is highly specific, as the 
competition binding assay results show. When a 100 - fold molar excess of 
unlabelled oligonucleotide corresponding to the binding site is added to the 
reaction mixture, protein complex 2 is competed out in both the Ce glioma 
cell and rat brain nuclear extracts. Once the specificity of the binding had 
been established the next step was to identify the protein factor(s), this was 
achieved using the yeast one-hybrid assay (Clontech Laboratories). The 
one-hybrid system is an in vivo genetic assay used for the isolation of novel 
genes encoding proteins that bind to a target, c/s-acting regulatory element 
(or any other short DNA biding site).
The one-hybrid assay is based on the notion that many eukaryotic
transcriptional activators are composed of physically and functionally
independent DNA-binding domains and transcription activation domains.
This allows the creation of various gene fusions carrying a cDNA that
encodes the protein of interest, when expressed in yeast the fusion protein
can simultaneously bind to a target sequence and activate transcription. The
one-hybrid system is centred on this interaction between a target -
independent activation domain and a target -  specific DNA binding domain.
To create the yeast reporter strain it was first necessary to construct a
reporter plasmid by cloning the putative binding site in the multiple cloning
site (MCS) of a yeast vector (pHISi-l). The vector pHISi-1 (5.4 kb) is a yeast
integrative plasmid, containing the yeast HIS3 gene downstream of a
multiple cloning site (see the map of this vector in Appendix VI). pHISi-1
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cannot replicate autonomously in yeast (as it does not have the yeast 2 jum 
origin of replication or an autonomously replicating sequence (ARS) which 
allows its propagation in those yeast cells), however, the presence of the 
HIS3 gene allows its integration into the mutated HIS3 gene of the YM4271 
yeast host strain. Integration was achieved by digesting the reporter plasmid 
with the restriction endonuclease Xhol, which cuts uniquely within the HIS3 
gene, since DNA ends are the favoured substrate for the recombination 
enzymes (Guthrie and Fink, 1991). To carry out the integration linear 
reporter plasmid carrying the putative binding site was introduced into 
competent yeast sphaeroplasts (a diagrammatic representation of the 
integration process can be seen in the materials and methods chapter). 
Integration of the plasmid DNA resulted in a stable duplication of the target 
gene into the yeast genome. This yeast reporter strain was then used as a 
host for the screening of a rat brain cDNA/AD fusion library to isolate the 
protein factor(s).
The cDNA/AD fusion library (Clontech Laboratories) is centred on RT-
PCR products (from mRNA isolated from whole rat brains), to which EcoR1
adapters were ligated, before being cloned via the EcoR1 restriction
endonuclease site located in the MCS of the plasmid pGADIO which
comprises of the target -  independent GAL 4 activation domain and the
target -  specific cDNA binding domain (a diagrammatic representation of the
cDNA/AD fusion library is shown in Figure 6c). The cDNA/AD fusion hybrid
then interacts with the target element (binding site) resulting in the
expression of the HIS3 reporter gene, which allows colony growth on
minimal medium lacking histidine. Also incorporated into the growth medium
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was 3-Aminotriazole (3-AT), which is a competitive inhibitor of the yeast 
HIS3 protein (H/S3p), and was used to inhibit low levels of HIS3p expressed 
in a background (or leaky) manner in the reporter strain.
The plasmid DNA encoding the protein factor(s) was sequenced 
automatically, and following conversion of the nucleotide sequence to a 
protein sequence the results were compared to other protein factor(s) by 
FastA and BLAST searches in the Swissprot database. The protein factor(s) 
have been identified as follows :
Clones 1 and 4 both contain protein sequence homology to the rat c-jun 
transcription factor which belongs to the basic DNA-binding domain / leucine 
zipper family of transcription factors. Using the BLAST2 sequence alignment 
tool a significant sequence overlap between the two clones was also found. 
From the expected probability value (E) it is highly unlikely these alignments 
had occurred by chance. The reason the AP-1 Ic-jun transcription factor is 
binding to the region -  609 to -  577 may be explained by the fact that this 
region contains a partial homology to the AP-1 binding site (consensus 
sequence TGAGTCAG). This may also explain the quite high background 
expression of the HIS3 gene in the reporter strain since yeast also have a 
transcriptional activator GCN4 which binds to the consensus sequence 
TGA(C/G)TCAG (Hattori etal., 1988). Such similarities imply that the c-jun 
product acts in the nucleus as a transcription factor, and that the high 
structural identity with GCN4 suggests that the two proteins may recognise 
similar DNA sequences (Latchman, 1998).
Clone 2 carries a sequence that at present has not yet been identified and
could possibly be a novel transcription factor.
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Clone 3 carries a sequence identified as the PASK protein. The PASK 
protein is a groline-alanine rich STE20-related kinase.
Clone 5 belongs to the homeobox / POU family of transcription factors and 
has been identified as the pituitary specific positive transcription factor 1 
(Pit-1), growth hormone factor-1 (GHF-1) or general transcription factor 
(GTF2.i). The homeobox is a highly conserved 180 nucleotide segment of 
DNA encoding a 60 amino acid homeodomain, which was first identified in 
several Drosophila genes important for controlling early development 
(McGinnis etal., 1984). The observed homology of the homeodomain with 
the helix-turn-helix DNA-binding motif found in prokaryotic repressors led to 
the notion that homeodomain-containing proteins are sequence-specific 
DNA-binding proteins (Mihara and Kaiser, 1988). POU proteins, like the 
homeobox proteins, occur in a wide variety of organisms and play an 
extremely important role in the regulation of gene expression during 
development. These proteins may also be of particular importance in the 
development of the central nervous system (Latchman, 1998).
Clone 6 has been identified from BLAST sequence alignment searches as 
belonging to the EF transcription factor family, which are transcriptional 
activators binding to E2F sites.
BLAST alignment searches have identified clone 7 as the protein factor 
known as ATF-2 (the activating transcription factor 2), and like clones 1 and 
4, ATF-2 belongs to the basic DNA-binding/leucine zipper family of 
transcription factors. Both of these protein factors mediate their effects by 
binding to the basic DNA-binding domain as either a homodimer or as a 
heterodimer.
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In order to confirm the DNA-binding activity of the protein isolated 
from the clones it would be necessary to carry out an electrophoretic mobility 
shift assay (EMSA) using the purified protein (transcription factor) and the 
labelled binding site as probe.
Since the region (between nucleotides -  609 to -  577) lies outside the 
distal promoter region (which is located between nucleotides -  254 to -  53 
as described by Tamura et al., 1989 and Aoyama et al., 1990) of the mouse 
myelin basic protein gene it may have some other function, for example, 
acting as an enhancer.
A characteristic feature of eukaryotic gene expression is the existence of
sequence elements located some distance away from the transcriptional
start site, which also influence the level of gene expression. These elements
can be located upstream, downstream or within the transcription unit itself,
and function irrespective of orientation relative to the transcription start site
(Figure 38). Enhancers act by increasing the activity of the promoter,
although they lack promoter activity (Hatzopoulos et al., 1988 and Muller et
al., 1988). Some enhancers are active in all tissues increasing the activity of
the promoter in all cell types, however, others function as tissue-specific
enhancers which activate a particular promoter only in a specific cell type as
it has been proposed for the region located between nucleotides -609 to
-577 of the myelin basic protein promoter. The tissue-specific activity of
such enhancer elements plays a fundamental role in mediating the observed
tissue-specific pattern of expression of the corresponding gene. As with the
promoter elements, enhancer elements also contain multiple binding sites for
transcription factors which interact together (Carey 1998). In many cases
219
these elements are identical to those immediately upstream of gene 
promoters, for example the immunoglobulin heavy-chain enhancer contains 
a copy of the octamer sequence found in the immunoglobulin promoters. 
Enhancers, therefore, are made up of sequence elements that are present in 
similarly regulated promoters and may also be found within the enhancers 
associated with other control elements. Mutation of conserved sequences 
within the tissue-specific enhancers abolish the tissue-specific pattern of 
expression of those genes.
Models involving the binding of protein factors to the enhancer 
followed by direct interaction with proteins of the transcriptional apparatus 
are more difficult to resolve with the action at some distance, characteristic 
of most enhancers. Models hypothesising this suggest that the enhancer 
serves as a site of entry for a regulatory factor, this factor would then make 
contact with the promoter -  bound transcriptional apparatus by one of three 
ways:
(a) sliding along the DNA
(b) via a continuous scaffold of other proteins, or
(c) by ‘looping’ out of the intervening DNA.
Of these possibilities, both the continuous scaffold and sliding models are
difficult to square with the large distances over which enhancers act. It has
also been shown that an enhancer can act on promoters located on two
different DNA molecules linked only by a protein bridge. This would totally
disrupt the scaffold or sliding molecules model (Muller et at. 1989). A more
explicable model is one in which the proteins bound at the promoter and
enhancer have an affinity for one another and make contact by looping out
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of the intervening DNA, and such a model can also explain the critical 
importance that DNA structure has on enhancer action, for example, using 
the SV40 enhancer it has been shown that removing multiples of 10 bases 
(one helical turn) has no effect on enhancer activity. However, deletion of 
five DNA bases (corresponding to half a helical turn) does severely disrupt 
enhancer activity (Takahashi etal. 1989).
Enhancers have been considered to act in a positive manner, 
however, some enhancers produce specific patterns of gene expression by 
relieving a negative effect. In these cases it appears the enhancer binds a 
protein factor, which inhibits the promoter, following induction, or in the case 
of a specific tissue, this negative factor is inactivated and falls off the 
enhancer allowing a positive-acting factor to bind and activate gene 
expression. This positive acting factor may be present in all cell types, but 
cannot normally bind to the DNA because of the presence of the negative 
repressor factor (Goodbourn et al., 1986). The most extreme example of an 
enhancer-like sequence acting in a totally negative way is a silencer. 
Silencers can act in either orientation to inhibit the activity of distant 
promoters without binding a regulatory protein, hence appearing to have a 
negative effect. To sum up, whether acting positively or negatively, 
enhancers play a key role in regulating eukaryotic gene expression, and 
often act together with related regulatory elements located adjacent to the 
promoter itself.
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Figure 38. Characteristics of an enhancer element activating a promoter at:
a) a distance from the promoter
b) in either orientation relative to the promoter
c) or when positioned upstream, downstream or within a transcription 
element.
KEY E = Enhancer. P = Promoter
(Adapted from Latchman D.S. 1990)
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Awatramani etal. (1997) have investigated the patterns of postnatal
brain expression and DNA binding of Gtx (a homeodomain transcription
factor). The accumulation of Gtx mRNA parallels that of the RNAs encoding
the major structural proteins of myelin, for example, the myelin basic protein
and the proteolipid protein during postnatal brain development. Gtx mRNA
decreases in parallel with MBP and PLP in the brains of myelin deficient
rats. Gtx mRNA is expressed in differentiated, post-mitotic oligodendrocytes
but not in oligodendrocyte precursors, astrocytes or other glia. Using a
maltose-binding protein-Gtx fusion protein produced in E.coli Awatramani et
al. (1997) have established that Gtx is a sequence-specific DNA-binding
protein, which binds DNA sequences containing a core AT-rich
homeodomain. Immunoprecipitation of labelled DNA fragments encoding the
myelin basic protein or proteolipid protein promoter regions with the fusion
protein have identified several Gtx-binding fragments, which have been
confirmed by electrophoretic mobility shift assay. In this way four Gtx binding
sites have been identified within the first 750 bp of the myelin basic protein
promoter, three sites are located between nucleotides -  598 and -  656, and
the fourth site is located between nucleotides -  304 and -  331 .The site
between nucleotides -  598 and -  621 binds Gtx with the highest affinity of
the four MBP sites. Four Gtx binding sites in the first -  1.3 kb of the
proteolipid protein promoter, the site located between nucleotides -  644 and
-671 binds Gtx with the highest affinity. The sites located between -  409
and -  434, and -  1128 and -1214 bind with a lesser affinity and the site
located between -  259 and -286 binds with the least affinity. The locations
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and DNA sequences of the Gtx binding sites located in the MBP and PLP 
promoters are shown in Table 4. Further analysis of the first kilobase of the 
PLP promoter sequence has since revealed the presence of an additional six 
putative Gtx binding sites. These data suggest that Gtx is important for the 
function of differentiated oligodendrocytes and may be involved in the 
regulation of myelin-specific gene expression.
Although Gtx is a regulator of oligodendrocyte development and
myelin-specific gene expression it is not expressed in Schwann cells, which
are the myelinating cells of the peripheral nervous system (PNS), whereas,
both the major CNS proteins, MBP and PLP, are also expressed in
myelinating Schwann cells. Comparison of the known mechanisms of
development and regulation of myelin-specific gene expression in both
oligodendrocytes and Schwann cells demonstrate several differences. Firstly
the transcription factors necessary for normal Schwann cell maturation and
PNS myelination, SCIP and Krox-20, are not required for normal
oligodendrocyte maturation or myelination, and the developmental
expression profile of these proteins is different in the two cell types e.g. SCIP
is expressed in promyelinating Schwann cells committed to myelination, but
it is also found in oligodendrocyte precursors and undifferentiated
myelinating cells. Krox-20 is not expressed in oligodendrocytes. Secondly,
different regions within the myelin basic protein promoter region have been
shown to be required for oligodendrocyte and Schwann cell gene
expression, e.g. myelin basic protein promoter sequences up to 3.2 kb are
sufficient to drive developmental^ regulated, oligodendrocyte-specific
transgene expression but do not support transgene expression in Schwann
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cells. (Gow etal., 1992). Thirdly, comparison of the oligodendrocyte and 
Schwann cell nuclear proteins that bind to the proximal MBP promoter 
(Wrabetz etal., 1993) demonstrates a number of significant differences, 
suggesting there is a unique set of transcriptional activators present in the 
two cell types. The data suggests that the molecular mechanism underlying 
the regulation of Schwann cell and oligodendrocyte development are 
different, and as a result the presence of Gtx in oligodendrocytes but not in 
Schwann cells is further proof of this suggestion.
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Type Location of site Sequence
MBP -327 to -320 CATATTCT
MBP -606 to -613 GTTAAATA
MBP -630 to -623 AATAAATG
MBP -650 to -643 ACTAAAAA
PLP -262 to -269 TGTAATTG
PLP -284 to -277 CTTAATTT
PLP -428 to -421 GGTAATAT
PLP -662 to -669 ATTAATGA
PLP -1194 to -1201 AATAATTC
PLP -10 to -17 TGTAATCT
PLP -245 to -252 TATAAATG
PLP* -296 to -303 CTTAAATC
PLP* -331 to -324 TTTAAATG
PLP* -559 to -566 AATAATTT
PLP* -1020 to -1013 GATAATCC
A putative Gtx binding site identified by homology to a known binding site.
Table 4. Gtx binding sites located within the MBP and PLP Promoter 
regions.
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In many respects the myelin basic protein gene is unique, it is among 
a relatively small group of genes > 100 kb in length and represent an 
example of both a gene within a gene as well as two overlapping genes, and 
in that respect it bears some resemblance to the neurofibromatosis gene in 
that both genes are large transcription units encompassing smaller genes. 
However, they are different in that the smaller myelin basic protein gene 
portions are not simply included within an intron of the larger gene but share 
alternatively spliced exons in common.
Another unusual feature of the myelin basic protein gene is its
regulation. The MBP transcription start site (S3), shown in Figure 2, is under
very tight developmental control and is only expressed in myelin-forming
cells. Most of this regulation resides within the exon 5a region upstream of
transcription start site S3. The golli-mbp transcription start site S1 is under
less specific regulation, therefore, there appears to be a gradient of cell and
tissue specificity amongst the three promoters of the gene, with the most
downstream promoter being the most specific to myelin forming cells and the
most upstream promoter exhibiting the least cell and tissue specificity. This
combination of structure and expression significantly changes the notion of
the myelin basic protein gene, which has generally been thought to be
specific for myelin-forming cells. The genomic region encompassing exon 5A
has been used by many workers to target transgenes specifically to
oligodendrocytes. It is now suggested that this “myelin” gene is expressed in
many neuronal cell populations, some of which are important in establishing
the structure of the cerebral cortex. In addition, it has been suggested that
increased expression of this gene within the immune system may be
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responsible for the relapsing disease phase of experimental autoimmune 
encephalomyelitis, an animal model of multiple sclerosis (MacKenzie- 
Graham et a/., 1997). Therefore, it has become clear that the myelin basic 
protein gene is important to neurons and immune cells as well as 
oligodendrocytes and must therefore perform a function that is not solely 
associated with myelination.
The work of Landry et al., (1998) has also contributed to the evolving 
notion that the myelin basic protein gene is one with broader functions in 
neurons and in myelin-forming cells in the nervous system than was first 
thought. They have identified a region upstream of the first transcription start 
site (S1), shown in Figure 2, that can target transgenes to a very limited 
number of neurons, including the very earliest-forming (pioneer) neurons in 
the cortex, the Cajal-Retzius cells and preplate neurons.
Since the early nineties there has been a shift away from the
traditional notion that the MBP and PLP genes were expressed solely in
myelin-forming cells, and their products were thought to be structural
components of myelin. It has now been shown that the products of these
genes have been identified in nonmyelinating cell types including the
immune system and nervous system (Givogri etal., 2000). In the nervous
system golli is produced in oligodendrocytes and specific subsets of
neurons, however there is no evidence of golli expression in astrocytes or
microglia (Landry etal., 1996). Neuronal expression of golli is prominent in
the following regions: the spinal cord (interneurons of the anterior and
posterior grey horns), the developing cortex (embryonic cortical neurons,
presubplate and subplate neurons, Cajal-Retzius cells), the hippocampus
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(pyramidal cells, granule cells of dentate gyrus), the cerebellum (Purkinje 
and granular cells), the olfactory system and the dorsal root ganglia (Landry 
etal., 1996). Golli products of the MBP gene are expressed in the immune 
system (Campagnoni etal., 1993). In the mouse thymus, golli appears to be 
expressed in the thymic epithelial cells and macrophages and to a lesser 
extent in the thymocytes (Campagnoni etal., 1993). Expression of the MBP 
gene in the thymus might have an important role in influencing tolerance 
development (by influencing the positive and negative selection of the T-cell 
repertoire) which could lead to the opening of new research to 
understanding autoimmune diseases like experimental autoimmune 
encephalomyelitis (EAE) (Voskhul, 1998).
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4.2. Future Work
Future work would involve further studies on the role of the putative
transcription factors, which were identified in this project, in the expression of
the myelin basic protein gene in oligodendrocytes. To achieve this the
activity of the promoter in HeLa cells ( control) and oligodendrocytes in the
presence and absence of the cDNA clone expressing the studied
transcription factor would be compared. For this purpose it would be
necessary to obtain the mouse myelin basic protein gene promoter in a
vector containing a reporter gene e.g. chloramphenicol acetyl transferase
(pBLCAT) or luciferase (pGL2-Basic vector), both vectors lack eukaryotic
promoter and enhancer sequences (the reporter plasmid). A full length copy
of the cDNA for a putative transcription factor in a plasmid vector containing
a ubiquitously active promoter e.g. CMV promoter (pcDNA 3.1) would be
also required. Experiments involving the co-transfection of the reporter
plasmid and the plasmid containing the transcription factor cDNA into HeLa
cells (control) and glial (oligodendrocyte) cells would be performed. If the
CAT assay were used to assess activity of the promoter, it would be
performed as follows: cell lysates would be incubated with 14C-labelled
chloramphenicol and acetyl-CoA. In this reaction the acetyl group from the
acetyl-CoA is transferred by the CAT enzyme to the 2- or 3- position on the
chloramphenicol. The products of this reaction are detected by thin layer
chromatography (TLC) followed by autoradiography. The TLC separates the
acetylated chloramphenicol from the unreacted substrates, as a result the 2-
and 3- acetylated chloramphenicol migrate at slightly different rates
producing two spots if the promoter were active. The presence and intensity
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of the spots reflects the activity of the promoter as the CAT enzyme is 
present only when active promoter is upstream of the reporter gene in the 
reporter plasmid.
Studies of how mutations in the region -609 to -577 affect the 
expression of the reporter gene in the presence of putative transcription 
factors could also be undertaken. To achieve this it would initially be 
necessary to transfect a plasmid with the wild type binding site (enhancer) 
linked to a promoter and a reporter gene (e.g. pBLCAT2 vector which has 
the tk HSV promoter upstream of the CAT gene or pGL2-promoter vector 
which has SV40 promoter upstream of the luciferase gene) into HeLa and 
glial (oligodendrocyte) cell lines to investigate further the biological function 
and the cell type-specificity of the binding site (enhancer). Similar 
experiments would be performed using co-transfection experiments with 
cDNA for the putative transcription factor. An increase in the expression of 
the reporter gene in the presence of a cDNA encoding a putative 
transcription factor is expected in an appropriate cell line.
Subsequently constructs with point mutations in the -609 to -577 nt 
region linked to a reporter gene would be prepared. These constructs would 
be transfected with and without the transcription factor cDNA into 
oligodendrocytes (and HeLa cells as control). In this case no increase in 
reporter gene transcription as determined by the CAT enzyme activity would 
be expected.
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APPENDIX I.
EQUIPMENT SUPPLIERS.
Mini-Gel Submarine Electrophoresis Units.
Biometra Ltd, P.O. Box 42, Sale, Manchester.
Gallenkamp Ltd. (Fisons Pic Scientific Equipment Division), 
Bishop Meadow, Loughborough, Leicester.
DNA Sequencing Gel Apparatus.
Biometra Ltd, P.O. Box 42, Sale, Manchester.
Mini-Gel Submarine Electrophoresis Units.
Gallenkamp Ltd. (Fisons Pic Scientific Equipment Division), 
Bishop Meadow, Loughborough, Leicester.
Mini-Gel Electrophoresis Power Supply.
Biometra Ltd, P.O. Box 42, Sale, Manchester.
Gallenkamp Ltd. (Fisons Pic Scientific Equipment Division), 
Bishop Meadow, Loughborough, Leicester.
Sequencing Power Supply.
Pharmacia Ltd, 351 Midsummer Boulevard, Milton Keynes, 
Buckinghamshire.
PCR Machines.
Biometra Ltd, P.O. Box 42, Sale, Manchester.
MWG Biotech Ltd,
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APPENDIX II.
MEDIA AND BUFFER COMPOSITION.
2.2. Large scale isolation of plasmid DNA by a modified Clewell and 
Helinski technique.
Luria Broth:
Tryptone 10 g
Yeast Extract 5 g
Sodium Chloride 5 g
GLUCOSE 2 g
Water make up to 1 litre.
Buffer I:
Glucose 50 mmol 1-1
Tris-HCI (pH 8.0) 25 mmol 1-1
EDTA (pH8.0) 10 mmol 1-1
SOLUTION I can be prepared in batches of 100 ml, autoclaved for
15 min at 10 Ib/in^ and stored at 4^  C.
3X Triton X-100 Lysis Solution:
Triton X-100 (10%) 300 pi
EDTA (2.5 M) 750 pi
Tris-HCI (pH 8.0) (1M) 1500 pi
WATER 700 pi
2.3. Purification of plasmid DNA by centrifugation to equilibrium in 
caesium chloride-ethidium bromide gradient.
T.E. Buffer (pH8.0):
Tris-HCI (pH 8.0) 10 m mol f ]
EDTA (0.5M) 1 m mol I"1
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2.4. Analytical agarose gel electrophoresis of DNA.
10X Tris acetate buffer:
Tris (SIGMA 7-9) 
EDTA
Glacial Acetic Acid 
WATER
32.3 g 
2.48 g 
11.7 ml 
make up to 1 litre.
Loading Buffer:
Glycerol
Xylene Cyanol FF 
Bromophenol Blue
25 %
0.02 % 
0.05 %
2.6.3. Ligation.
Tris-HCI 200 mmol I1-1
Magnesium Chloride 100 mmol I1-1
Dithiothreitol 100 mmol I1-1
WATER (Sterile) 600 pi
Dispense into 200 pi aliquots and store frozen until required. 
Fresh A.T.P. is added (from a 10 mmol M stock) just before use.
Incubation Buffer:
Tris-HCI 20 mmol l"1
Magnesium Chloride 10 mmol l"1
Dithioerythritol 10 mmol l"1
A.T.P. 0.6 mmol |-1
Adjust the pH TO 7.6
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2.6.4. Introduction of plasmid DNA into E. coli cells.
M9 Minimal Medium:
5X M9 Salts:
Disodium hydrogen orthophosphate (7H20) 64 gl'1
Potassium dihydrogen orthophosphate 15 gl'1
Sodium chloride 2.5 gl'1
Ammonium chloride 5.0 gl'1
The salt solution is divided into 200 ml aliquots prior to sterilisation by 
autoclaving at 15 psi for 15 min.
To 750 ml of sterile deionised water cooled to 50° C the following was 
added aseptically:
200 ml of 5X M9 salts 
20 ml of 20 % Glucose (filter sterilised)
Make up to 1 litre with sterile deionised water added aseptically.
20X SSC Buffer:
Sodium Chloride 175 g
Tri-sodium Citrate 88.2 g
Dissolve in 800 ml of water, adjust the pH to 7.0 with 10 normal 
sodium hydroxide and then make up to volume (1 litre).
Sterilize by autoclaving.
AIX Medium:
Allow L-B agar to cool to 50 °C before adding:
I.P.T.G. (1M) 300 pi
X-GAL (10%) 80 pi
Ampicillin (1%) 2.5 ml
for each 100 ml OF L-B agar.
L-B Agar:
Tryptone 10 9Yeast Extract 5 gSodium Chloride 10 gAgar 10 g
Add 900 ml of water, adjust the pH TO 7.5 with sodium hydroxide and then 
make up to volume (1 litre).
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Stock I.P.T.G. (1 M):
Dissolve 1 g I.P.T.G. in 4.2 ml of sterile distilled water and 
store frozen until required.
Stock X-GAL (10%):
Dissolve 100 mg X-GAL in 1000 pi of Dimethylformamide.
2.6.5.1.Preparation of plasmid DNA on a small-scale.
STET Buffer:
Sodium Chloride 
Tris-HCI (pH 8.0)
EDTA (pH 8.0)
Triton X-100
1 0 0 mmol 1-1
1 0 mmol I1-1
1 mmol I1-1
5 %
3.1.1. Alkaline lysis mini-preparation using the Pharmacia kit.
SB Medium:
Tryptone 
Yeast Extract
Dissolved in 900 ml of distilled water.
Prepare 0.9 mol l"1 Potassium Phosphate buffer (pH 7.3) by 
dissolving 2.3 g of KH2 PO4  and 12.5 g of K2 HPO4  in 100 ml of water, 
sterilize both solutions separately by autoclaving and mix them 
aseptically together and add 4 ml of sterile glycerol.
Add ampicillin to a final concentration of 50 pg/ml for selection of the 
plasmid of interest.
1 2  g 
24 g
Solution I:
Tris-HCI (pH 8.0) 50 mmol 1-1
Glucose 50 mmol 1-1
EDTA 1 0 mmol I1-1
KATHON® CG/ICP 0.15%
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Solution II:
Sodium Hydroxide 
Triton X-100
0 . 8  mol M 
4 % (v/v)
It should be noted that before using solution II for the first time, 75 ml of 
sterile distilled water should be added, this will bring the final concentration 
to 0.2 mol 1-1 NaOH and 1% TRITON X-100.
Solution III:
Sodium Acetate (pH 4.8) 3 mol M
Column Buffer:
Tris-HCI (pH 8.0) 10 mmol M
EDTA 1 mmol M
4.0. Sequencing of DNA.
T.E. Buffer pH 7.5 (for reconstitution of oligonucleotides only) 
Tris-HCI pH7.5 10 m mol \
EDTA 1 m mol I
4.2. DNA sequencing using the Sequenase kit.
Sequenase Buffer (5X concentrate).
Tris-HCI pH7.5 200 mM
Magnesium chloride 100 mM
Sodium chloride 250 mM
Dithiothreitol 0.1 M
Enzyme Dilution Buffer.
Tris-HCI pH7.5 10 mM
DTT 5 mM
BSA 0.5 mg/ml
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Stop Solution.
Formamide 95 %
EDTA 20 mM
Bromophenol Blue 0.05 %
Xylene Cyanol FF 0.05 %
4.4.1. Preparation of polyacrylamide gels.
40 % Acrylamide Solution:
Acrylamide 114 g
Bis-acrylamide 6 g
Make up to 300 ml with deionised water.
When dissolved stir gently with 6 g of amberlite MB-1 mixed bed 
resin. Filter through glass wool to remove resin and store solution at 
4 O C until required.
10XTBE Buffer:
Tris 54 g
Boric Acid 27.5 g
EDTA (0.5 mol M STOCK) 20 ml
Make up to 500 ml with sterile distilled water.
1XTBE Gel Mix:
10XTBE 20.8 ml
Acrylamide (40%) 31.2 ml
Urea (Ultrapure Grade) 100 g
Make up to 208 ml with sterile distilled water.
6% Acrylamide Sequencing Gel:
1XTBE GEL MIX 70 ml
Ammonium Persulphate (25%) 140 pi
TEMED 90 pi
The gel should set within 15 min otherwise the whole procedure must 
be repeated.
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5.0. Electrophoretic mobility shift assay.
5X Annealing Buffer:
100 mM Sodium chloride
10 mM Tris.CI (pH 7.8)
1 mM EDTA
100 mM Magnesium chloride
5 mM DTT
Binding Buffer-
25 mM Hepes.KOH (pH 8.0) 
0.5 mM EDTA 
10 % (v/v) Glycerol 
0.01 mM zinc chloride 
0.5 mM dithiothreitol
5.2. Preparation of nuclear extracts.
Buffer A:
10 mM Hepes (pH 7.9)
1.5 mM magnesium chloride 
10 mM potassium chloride 
0.5 mM PMSF 
0.5 mM dithiothreitol
Buffer C:
20 mM Hepes (pH 7.9)
0.42 mM sodium chloride
1.5 mM magnesium chloride 
0.2 mM EDTA 
0.5 mM dithiothreitol 
25 % v/v Glycerol
Buffer D:
20 mM Hepes (pH 7.9) 
100 mM potassium chloride 
0.2 mM EDTA 
0.5 mM PMSF 
0.5 mM dithiothreitol 
20 % v/v Glycerol
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It should be noted that DTT and PMSF were added fresh at the time
of use.
7.0. Large scale preparation of yeast vector containing the binding 
site.
Terrific broth:
Tryptone 12 g
Yeast extract 24 g
Glycerol 4.0 ml
Water 900 ml
Autoclave to sterilise, when cooled to room temperature aseptically 
add 100 ml of phosphate salt solution.
Phosphate salt solution:
Potassium dihydrogen orthophosphate 2.31 g
Dipotassium hydrogen orthophosphate 12.54 g
Water 100 ml
Autoclave to sterilise
Solution A:
Glucose 9.0 g
1M Tris (pH 8.0) 12.5 ml
0.5 M EDTA 10.0 ml
Water 475 ml
Autoclave to sterilise.
Solution B: (Prepared fresh just prior to use)
10M Sodium hydroxide 1.6 ml
10% SDS 8.0 ml
Water 70.4 ml
Solution C:
Potassium acetate 147 g
Acetic acid 58 ml
Make up to a final volume of 500 ml 
Autoclave to sterilise, and store at 4° C
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PEG 8000
Dissolve 5 g of Polyethylene glycol 8000 in 15 ml of water then make 
up to a final volume of 25 ml.
8.2. Preparation of yeast competent cells.
YPD Medium (For Liquid Cultures):
20 gl'1 Difco Peptone 
10 gl'1 Difco Yeast Extract
Adjust the pH to 5.8 and make up to a final volume of 950 ml. 
Autoclave to sterilise.
Cool to 55 °C prior to aseptically adding 50 ml of filter sterilised 40% 
glucose
YPD Medium (For Plates):
20 gl'1 Difco Peptone 
10 gl'1 Difco Yeast Extract 
20 gl'1 Difco Agar
Adjust the pH to 5.8 and make up to a final volume of 950 ml. 
Autoclave to sterilise.
Cool to 55 °C prior to aseptically adding 50 ml of filter sterilised 40% 
glucose
10XTE Buffer:
0.1 M Tris.CI 
10 mM EDTA
Adjust the pH to 7.5 and make up to 100 ml with distilled water. 
Autoclave to sterilise.
10 X LiAc:
Lithium Acetate 10.2 g
Adjust the pH to 7.5 with dilute acetic acid and make up to 100 ml with 
distilled water.
Autoclave to sterilise.
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1 X TE/LiAc Solution (prepare fresh just before use): 
Water 8 ml of Sterile Water
TE Buffer 1mlo f10XTE
LiAc 1 ml of 10 X LiAc
50 % PEG 4000:
Polyethylene glycol (avg. mol. wt. = 3,350) 50 g
Make up to 100 ml with distilled water.
Autoclave to sterilise.
1 X PEG/LiAc Solution (prepare fresh just before use): 
PEG 4000 8 ml of 50 % PEG
TE Buffer 1mlo f10XTE
LiAc 1 ml of 10 X LiAc
TE Buffer:
1M Tris.CI (pH 8.0) 1000 pi
500 mM EDTA (pH 8.0) 200 pi
Make up to 100 ml with sterile distilled water.
SD Medium (For Liquid Medium):
6.7 gl*1 Difco yeast nitrogen base without amino acids
Adjust the pH to 5.8 and make up to a final volume of 850 ml. 
Autoclave to sterilise.
Cool to 55 °C prior to aseptically adding:
100 ml of 10X dropout medium 
50 ml of filter sterilised 40% glucose
SD Medium (For Plates):
6.7 gl"1 Difco yeast nitrogen base without amino acids 
20 gl"1 Difco agar
Adjust the pH to 5.8 and make up to a final volume of 850 ml. 
Autoclave to sterilise.
Cool to 55 °C prior to aseptically adding:
100 ml of 10X dropout medium
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50 ml of filter sterilised 40% glucose
For medium containing 3 - AT, powdered 3 - Aminotriazole was added 
to the appropriate concentration after the medium had cooled and 
before the plates were poured.
10X Dropout Medium:
L-lsoleucine 300 mg I'
L-Valine 1500 mg I'
L-Adenine hemisulphate salt 200 mg I'
L-Arginine HCI 200 mg I’
L-Leucine 1000 mg I'
L-Lysine HCI 300 mg f
L-Methionine 200 mg I*
L-Phenylalanine 500 mg I'
L-Threonine 2000 mg I"
L-Tryptophan 200 mg I'
L-Tyrosine 300 mg I"
L-Uracil 200 mg I'
Make up to a final volume of 1000 ml. 
Autoclave to sterilise.
Keep refrigerated until required.
3 - AT Concentrations:
For each 100ml of SD medium add:
Concentration (mM) Amount 3 - AT 
(g/100 ml of medium)
5 mM 0.043 g
10 mM 0.086 g
15 mM 0.13 g
30 mM 0.25 g
45 mM 0.38 g
60 mM 0.5 g
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8.4. Screening of putative reporter strain constructs (rapid isolation 
of chromosomal DNA).
Breaking Buffer:
2% (v/v) Triton X-100 
1 % (v/v) Sodium Dodecyl Sulphate (SDS)
100 mM NaCI
10 mM Tris.CI (pH 8.0)
1 mM EDTA (pH 8.0)
Can be stored at room temperature for up to 1 yr.
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APPENDIX III.
PREPARATION OF SEPHACRYL S-400 COLUMNS.
Each spun column was prepared as follows:
The column was inverted several times to resuspend the Sephacryl S- 
400 gel and then set upright in a rack to allow the gel to settle to form a 
continuous bed.
The Column was allowed to drain prior to the addition of 2 ml of 
Column Buffer.
The column was placed in a 15 ml Corex tube and centrifuged for 
2 min at approximately 400 x g in a swinging bucket rotor and the eluted 
buffer discarded from the tube.
An uncapped 1.5 ml Eppendorf tube was placed in the bottom of the 
Corex tube, the column was replaced inside the Corex tube with the tip 
inside the Eppendorf tube.
The column was then used for DNA purification.
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APPENDIX IV.
OLIGONUCLEOTIDE SYNTHESIS.
The procedure used for the synthesis of oligonucleotides was the 
phosphoramidite version of the phosphite triester method carried out on a 
solid phase support. The support material was inert towards all the reagents 
and solvents used in the synthesis cycle.
Four fully protected nucleotides corresponding to the bases A, C, G 
and T, (the basic building blocks in the synthesis), and referred to as 
amidites, were required,. An example of the structure of a fully protected 
amidite is shown in Figure 39. The complete reaction cycle itself consisted of 
four main steps, each separated by column washing as shown in Figure 40:
a. DEPROTECTION.
This is the removal of the dimethoxytrityl (DMTr) group to expose the 
hydroxyl group at position 5 of the 2-deoxyribose unit, and the subsequent 
activation of the phosphoramidite by tetrazole.
b. COUPLING.
The formation of an internucleotide bond between the 5' hydroxyl group and 
the phosphorous containing group at the 3' position on the incoming 
protected nucleotide.
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c. CAPPING.
The termination of any unreacted 5' hydroxyl groups,
d. OXIDATION.
The phosphite linkage is oxidised to phosphate by iodine.
Each time this procedure is repeated one nucleotide is added to the 
growing chain, until an oligonucleotide of the required sequence and length 
has been synthesised.
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Amidite
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FIGURE 39: The structure of a fully protected amidite.
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FIGURE 40: The complete synthesis cycle.
COUPLING
The phosphite triester method makes use of the great reactivity of the 
trivalent phosphorous, in this state it will be electron deficient and therefore 
readily accepts electrons from an electron donating group such as the 5'- 
hydroxyl group of the deoxyribose unit. Unfortunately any other similarly 
donating group(s) would interfere with the efficiency of this reaction. 
However, the group of most concern is the hydroxyl group found in water 
and as a consequence all coupling reactions were carried out under totally 
anhydrous conditions. All reagents and solvents used in this reaction were 
also stored under anhydrous conditions.
The first step was the removal of the dimethoxytrityl (DMTr) protecting 
group from the 5' hydroxyl of the initial nucleoside (as illustrated in Figure 
41). The absorbance value of the orange DMTr ion produced was monitored 
at 436 nm and used to calculate the efficiency of coupling in the previous 
cycle. Obviously, no such calculation could be performed for the first 
detritylation.
The acidic conditions used in detritylation can also cause 
depurination, (this is the cleavage of the purine base from its deoxyribose at 
the glycosidic bond). Such a detrimental reaction would not be picked up by 
the DMTr assay since normal release of the DMTr cation would have taken 
place at the same time.
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FIGURE 41: The detritylation reaction.
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POST-SYNTHETIC PROCEDURES
Three further steps were needed before the final oligonucleotide was 
ready for use:
(a.) Deprotection.
(b.) Cleavage of the oligonucleotide from its support.
(c.) Purification.
It was at this stage that the advantage of the p-cyanoethyl group 
became apparent for it allowed both deprotection and cleavage to be carried 
out at the same time.
Deprotection is the removal of the protecting amide groups from the 
bases and the p-cyanoethyl group from the phosphorous, this process would 
normally take 16 h at 50° C, however, the use of PAC amidites and supports 
allows total deprotection and cleavage in 1 h at 70° C.
Ammonia cleaves the oligonucleotide from its support by breaking the 
ester linkage between the spacer arm and the 3' hydroxyl group of the initial 
nucleoside, thus leaving the cleaved DNA with a free 3' hydroxyl group.
During the synthesis cycle all 5' hydroxyls, which did not undergo 
successful coupling, were capped as acetates. These were now removed by 
the ammonia to leave a free hydroxyl group. The full length molecule, which 
of course was not acetylated, has its 5' hydroxyl protected by a DMTr group. 
Usually this DMTr is cleaved automatically as the final step in the synthesis
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cycle but it may have been left uncleaved if reverse phase HPLC or other 
purification methods requiring its presence were to be employed.
This deprotected and detritylated synthetic oligonucleotide DNA has 
free 5' and 3' hydroxyls and is biologically active. Ion-exchange FPLC, 
reverse phase HPLC or PAGE electrophoresis are the usual methods of 
purification, but as the majority of oligonucleotides produced are less than 
30 bases in length then nothing more complicated than desalting is usually 
required. This can be accomplished by size exclusion chromatography on a 
Sephadex column (for example NAP-10) or by ethanol precipitation.
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APPENDIX V.
COP PURIFICATION OF 5’ TRITYL-ON OLIGONUCLEOTIDES
The COP purification cartridges separate molecules using the same 
principle as reverse phase chromatography, that is the less hydrophobic the 
molecule the quicker it will elute from the column.
Since the desired oligonucleotide product possesses the hydrophobic 
dimethoxytrityl (DMTr) protecting group on the 5’ hydroxyl group, and the 
truncated sequences did not, it gives the desired product more 
hydrophobicity and therefore enabled purification on the COP cartridge.
Following synthesis the trityl-ON oligonucleotide was deprotected as 
previously described in section 2.13.3.
After removing the plunger from a 5 ml disposable syringe the main 
body of the syringe was then connected to the COP cartridge and using the 
graduations 2  ml of acetonitrile was passed through the column at a rate of 1 
to 2  drops per second using the plunger.
The cartridge was then flushed with 2 ml of 2.0 M triethylamine 
acetate (pH 7.0). Prior to loading the oligonucleotide onto the column 3 ml of 
water was added to the ammonium hydroxide solution containing the 
deprotected trityl-ON oligonucleotide.
The oligonucleotide solution was passed through the column, the 
eluate collected and then repassed through the column a second time.
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Dilute ammonium hydroxide (3 ml) was flushed through the column 
followed by 2  ml of deionised water, 2  ml of 2  % trifluoroacetic acid to 
detritylate the support-bound oligonucleotide and a further 2  ml of water.
Recovery of the oligonucleotide was achieved by flushing the column 
with 2  ml of 2 0  % (v/v) acetonitrile/water.
The absorbance units recovered was determined at 260 nm from a 
dry sample resuspended in water.
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APPENDIX VI
Vector Maps and Sequences.
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FIGURE 42.Map and multiple cloning site of plasmid pBluescript.
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FIGURE 43. Map of pHISi-l and multiple cloning site.
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E e o R I  SmaX Sac I H r u l  C laX
. Xfcal SsfcXT 
SacXX
< y^ATTC^CGGGGAGCTCACGC3tTC<SCGrAATCGATCOKX3QTCTlW3A-ftAT?CCT^GCATTATCACATAAT 
i 3TAAGGK30CCCTCGAGT50C:Oa^ acarrTaaCTA<3GDXCAC^ TCTTTJiAQ3RCa5T?*ATAaTGmTTA 
* * " 1  30 40 * 50 1 n r  IT
G^TTATjkCATTATATAAAGTAATGTGATX'TCTTCGA^AATATACTAAAAAATGAGCAGGCAAGATAAA CTTAA'XA^ TAATATATGTCATTACACTA^ AAGCTTC^ ATAXGA’rriTrrACTCGTCCGTrcmTTT 
" " "  "*55 ~"Tm? 110 120 130 1*0
Cm?W30CAAAGATGACAG^W3CAaAAA(KXXTAGTAMGCGTATTACAMTx3AAACCAAaATTCAGATTGC 
GCTTCCtrri^CTACTGTC,T C G ^ frTrCGGGATCAlvrrCGCATAATGTTTACTTTGGTTCTAAGTCTAACG 
150 160 170 ISO ISO 200 213
Oral
GATCTCTTTAAAGGGTGGTCCCCTAOCGA^AjGUWCACTCGATCTTCCC^AAAAAGAGGCAGAAGCAGTA CTAGAGA.%ATTTCCCACCA^3<^ATCGCTATC?CGTaAGGTAGAAGCrGrCTTTl^ CTCCGTCTTCGTCAT 
220 230 240 ISO 260 270 280
KriteXIGCAGAACAaGCCACA.CA.\TCGCAAs9TGATTAACGTCCACACAGG'TATAGGGTTTCTGGACCA.?ATGATAC CaKTrTGTCCGXSTGTGT^AGCG^mCTM.TTiGCJySGTGl^ GCATATCCCAAAGACClXJGX'ATACmTG 
290 200 318 320 330 340 3SS
A T 3C T C TO S C C A A  SGATGCCGGCTGGTCGCTAATCGTT'GAGXSCATTGGT^ACTTAC ACATnGACGACCA  
T A C G A G A C C ^ T T C G T A A C ^ C C G A C C m C G A r f l^ m C T C A C O T A A C G A C ^ A A X G T G T A T C T G C T G ^ r  
380 373 3SO 390 400 4X0 420
D r a XHindi XI SglXi I i2 .^CACCACTOAAGACTGCGGGATTGCTCTCGGTCAA<KriTTTAAAGAGGCCCTACTQGCGCGTGaA©TA 
A C ^ T G G T G A C T rC T C A C G C C C T A ^ G A G A G C C A G rrC a A A A A T T T C T C O S G G A P G A C G G C G C A C C I^ A T  
430 440 450 460 470 480 4S0
B g l l X  
{   _AAAn^TTTC'CATCAQGAJTl^ GCGOCJ'TTQGATGAi^ CZhCTTTCCAQAGCGQTQGTAGATCTTTCGAACA 
lrTITCC AAA C CTAG TC C TA A A C G C G 3A A A C CTA C TC C G XG A A AG G TC niC G C C A C CA TC TA G A A A a7TTG T  
SOO 5X0 520 §30 540 §50 550
B s iW I  B g l X II 1G ^X G TAG G C AG 'rTG TC G AAC TTG G TTTG C A AA G G G AG A AAG TA G G AG ATCTCTC TTCC G AG AX’G A'fCCC  Ct^ GCATGCGTCAACAGCTTGAACCAAAaSTTTCCCTCTTTCATCCTCTAGAGAaAACGCTCTACTAOaa 
$70 580 590 600 610 620 630
H in d iX XIG C ATTTTCTTGAAAGCTTTGCAGAQGCTAGCAG AA'TTACCCTCCACG TTG ATTGTCTGCGAGGCAAGAAT  
C G T A > J \A G /m C 1 1 T C G A A A C G ? C ^ :C G A T C G T C rrA A T G Q 3 A ® 7 I^ C A iirT /^ G A G A C G C rc C G T T C T T A  
64S 653 660 670 680 690 700
281
PH1SI-1,TXT: 5429 bases {linear) P 0 3 0  g
S e l l!
GATCATCACC3TAGIGAGAQT^STTCAAGGCTCTTGCGGTTGCCATAAGAGAAGCCACCTCGCCCAAT3CTAGTAGTCGCArCACTCrCACrfCAAGTTCCSAGAACGCCAACGGTATTCTCTTCCGTGGAGCGGGTTAC
710 720 730 740 750 760 770
K p n l E r a !  P s t l
i I IGTACCAACGATGTTCCCTCCACCAAAGGTGTTCTTATGO'AGTGACACCGATTAXTTAAAGCTGCAGCATA 
CATQGTTGCTACAAGGGAGG7GGTXTCCACAAGAATACATCACTGTGGCTAATAAATTTCGACGTCGTAT 
780 750 §00 810 S2Q 820 840
CGATATATATACATGTGTATATATGTATACCTATCiAATGTCACrrAAaTATGTATACGAACAGTATQATAC
GCTATATATATGTACACATATATACATATOSATACTTACACTCATTCATACATATGCTTtSTCATACTATG
850 £6-0 870 880 850 SCO 910
N s i l!TGAAGATGAW^TAA7GCATCATTCTATACGTCriOTlCrGAACGA<^ GCQCTT?CCnTrTTCTTT
ACTTCTACTtn^CATTACGTACTAAGATATGCACAG7AJlGACTTGXr?CCGCflCGAAAGGAAAAAA6AAA
520 950 940 950 563 970 980
KholITTGCTTTTTCTTTTTITXTCTCTTGAACr0CAaAAAAAAAATATAAAACASATGGA<WAACX»35AAAAAG 
AACGAAAAAGAAAAftAAAftGAGAACTTGAGCTCTTTTTTTTATATTTrCTCTACCrCCTTGCCCTTTTTC 
990 1000 1010 1020 1030 1040 1QS0
TTAOTTGTCGTGATAG^TGGC^GTGSTATTCCGTAAGAACAACAAaAAAAGCATTTCATATTATGGCTG
AATCAACACCACTATCTACCGTTCACCATAJl5GCAT7CT73TTGTTCTTTTC3TAnA6TATAArACCGAC
1050 1070 1080 1090 2100 1110 1120
AACTGAGCGAACAAGTGCAAAA,TT7,AAGCATCAACGACrtACA^,CGAGAATGGTTATGTrCCTCCTCACTT 
•ITGACTCGCTTGTTCACGTTTTAJA.TTCGTAGTTGCTG'rTGTTGCTCTTACCAATACAAGGAGGAGTGAA 
1130 1140 1150 1160 1170 1180 1150
AAGAGGAMACCAAGAAGTGCCAGMATAACATGAGCAACTACMTMCMCAACGGaS^CTACARCGGT 
T T C T C C T iri^ 3 T T C T IC ? iC&GTCTXTA?TGTACTCGTTCATGT'rA7TG7TGTT'GCCGCCGA'I>GTTG*CCA 
2200 1210 1220 1230 1240 1250 1260
<^OGTGGCGGT©3CAGCTTCriTAXX^a^CCGTCGTGGTGGTTAC»GCAAC<35TGGTTTCTTCQGTG
CCGGCACCGCCACCGTCGAA'GAAATCGTTGTIGGCAGCAXCACCAA1,G<XGTTGCCACCAAAGAAGCCAC 
1270 1280 1250 1300 1310 1320 1330
B g llX  C l a l! !GAAACAACC^G30\&2AGATCTAnCGGCCGTTCTGGTGGTAGAT<KSATCGATGGCAAACATGTCCCAGC: 
CXTTGTIGCCACCGTCG-I'CTAGATTGCCGG'CAA.GACCACCATCTACCTAGCTACCG'rT'TGTACAGGGTCG 
1340 1353 1360 1370 2350 1390 1400
282
PHlSi-1.TXT: 5429 bases (linear) Pago 3
S «n H II
TCC^GAAACGAAJUGqCCSAa2.TCGCCATA'rTTG3TGTCCCCi5AGGATCC'rCTACGCCGGACGCATCGT AGGTTCTTTGClTTTCCCKJCTCTAGCGGTftTAAACwACAGGwCrcCTAGGXGXTOCGGCCTGCGTAGCA 
1410 1420 1420 1440 14:0 1460 1470
N&rl NarXI I
GOCCOGCATCACC'GSCGCCACAGKn^CGGTTGCTGQCGCCTATATCGCCGACATCACCGATGGSCSAAfiAT 
CCX?GCC<3TAGTGGCCGCGGTGTCCACOCC^ACGACCGCGCATATAGCCGCTGTAGTGGCTACCCCTTCTA 
HSO 149Q 1500 1510 1520 1S2Q 1540
BspHI £cq 4.7i !
CGGGCTC^CACTTCGGGCTCATGAGCGC^TGTTTCGGCGTGSGTATGGTGGCAGGCCCCGTGGCCGGGG
GCGCGAGOSGTCAAGCCCGAGTACTCC^G^CAAAGCCGCACCCATACCACCGTCCGGGGCACCGGCCCC
15S0 15£0 1570 1580 1.590 1600 1610
N a rX  S p h II jGACTC-TTGGGCGCCATGTCCTTGCATGCACCAXTCCTTGCC-GCGXCCrGTGCTC.AlCGSCCTCPACCTACT
CTGACAACCCGCGGTAGAGGAACGTACGTG37AAGGAACGCCGCCGCCACGA<3TTGCCGGAGTTGGATCA
1620 15:0 2540 2650 26S0 1670 1680
S a i lIACTGGGCTGCTTCCTAAIXSCAGGAGTCSCATAAGGGAGAGCGTCGACCGATGCCCTTGAGAGCCTTCAAC 
TGACCCGACGAAGGATTACGTCC7CAGCGT7iTTCCCTCTCGCAGCTGGCTACGGG7>ACTCTCGGAAGTTG 
1650 1700 1710 2720 1730 1740 1750
•GG3CGCGGGGCA?GACrATCC-rCC<:CGCACl,TATGACTGTCTTCT-GTATCA 
C^TCAGTCGAGGAAGGCCACCCGCGCCCCGTACTGATAGCA.C^GGCGGGA\TACTGACAGAAOAAA.TAGT 
1760 1770 1780 1790 1500 2820 2820
ECO 47  
1TGCAACGCGTAGGACAC^GGCCC^AGCGCTCTGSGTCAITTOTCCJGCGAGGACCGCrjTCGCrGGAGCGC ACGTTGAGCATCC^GTCCACGGCCGTCGCGAGACCCAGTAA?lAC-CCGCTCCTC*GCGAAAGCGACCTCGCG 
2830 2840 1850 I8 6 0  1570 2880 1853
G s u l
G J y r .. TrA^ G_ J ^ ^ v^ ,  ,
CTGCTACTAGCCGGACAGCGAACGCCATA.AGCCTTAGAACQT-3CGGGAGCGAGTTCC-G.^GCAGTGACCA- 
3200 1223 2920 1930 2940 1950 I960
E g ! ZiCCCGCCACCAAACGTTTCGGCGAGAS.GCAGGCCATTATCGCCGGCATGGC<5GCCC?ACGCC»CTGGGCTACG 
GGGCGGTGCKTTGCAAAGCCGCTCTTCGTCCSCTAATAGCGGCCGTACCCCCXWCTGCOCGACCCGATGC 
2970 lseo 29«3 2QGG 2010 2020 2030
N r u l
TCTTGCTGGCGT'rCGCGACGCGAGGCTGGATGGCC'JTCCCCATTATGATTCrTCTCGCTTCCGGCGGCAT 
AGAACGACCGCAAOCGCTGCGCTCCGACCTACCGGAAGGGrGTAATACTAAGAAGAGCGMGGCCGCCSTA 
2040 2050 2050 2070 2080 2090 2100
283
PHISM .TXT: 5429 bases (linear) Pbg& 4
BspXJ.iCGGGATGCCCGC3TTCCA^3CCArCC7<JTCCAGGCX^TAaXTGACGACCA?CAGGGACAGCTTCAJVGGA
GCCCl1AC<>TAC7CAACC;T7C'iGTACG'.“.CAC"3rCCGTCCA7CTACTGC7GGT,AC?7CCCTa37CGAAG'?7CCT
2 U 0  2:20  2:35  2140 21S0 2260 2170
7CGCTCGCGGC7CT-TACCAGCCm^CrTCGATCACTC<iACCSC'rvJA.TCG7CACqGCGATTTAZiGCCGCCT 
AGCGAGCGCCGAGAATGGTCGGATfI’C-AAGC7AGTGACCTGGCGACTAGCAGTGCCGCT2'sAATACGGCGGA 
21SO 2190 2200 2210 5220 2230 2240
2 g i l  N a r lI ICC-SCGAGCACA7C-C-AACGG-G75vGCATGGATrGTAGGCGCCGCCCTATACCTTG7CTG'CCT'CCCCGCGTT 
GCCGCTCGT’GTACClTGCCCAAvCCG'rACCTfACATCCGCGGCGC-GATAT'GGfACAGACGGAC-GGC-CGCAA 
2250 2553 2270 2280 2290 2300 2310
GCGTCGCGGTGCAT00XGCCG«GCCACCTCGACCTGAAT6GAAGCC<KSCGGCACCTCGCTAACGGATTCA
CGCAGCGCCACGTACCTCGC'CCCGGTGGAGCO.'GGACTTACCTTCGGCCGCCGTGGAGCGnTTC-CCTAAGT 
2320 2330 2340 2350 2360 2370 '2380
F sp I
CCACTCCAAGAATTGGXGCCAATCAATTCTTSCGGAGAACTCrrGAATCCGCAAACCftACCCrrGGCAGAA 
GGTCAGGTIX^AACCTCCK;TTAGTTAAGAaC3CCTCTTGACftOTACGa?rTT0kHTGGC*AACCGTCTT 
2350 2400 2410 2420 2430 244.0 24S0
Gsul!
CATATCCATCGCGrCCGCCATCTCCAGCAGCCGCACGCGGCGCATCTCGGGCAGCGTTGGGTCCTGGCCA G7ATrt3G7A3CGCAKC3GTA5A£GTCJrCG5CGr5C5CCGCGTX'S«>GCCC<»TC3CAACCCr,GGACCGGT 
2450 2470 24S0 2490 2500 5310 2520
?5UlI
CGGG7GCGCA7C-ArCGTGC7CCTG7CG77-GAGGA.CCCGG'CTAGGCl'GGCGG&377GCCITACTC”GTOtAGQ 
GCCCACGCCTTACTAGCACGACKSACAGCAACTCCTGGGCCGATCCGACCGCCCCAACGGAATGACCAATCG 
2530 2540 2553 2560 2570 2580 2590
ACAATGAATCACCOATACGCGA^GAACGTGAACX^ACTOCTGCTGCRAAACGTCTGCGACXrrSAGCAAC 
TCTTACTTAGTGGCTATGCGCTCGCTTGCACTTCGCTGACGACGACGTTTTGCAGACGCTGGACTCGTTG 
2600 2620 2520 2630 2640 2650 2560
AACATGAATCASTCTlGGGITTCCGTGTrTGGTAAJiGTCTGa^AACGCGGAAGTCAGCGCCCTGCACCATT 
TTG,rACT7ACCAGAAGCCAJlrtGGCAC2AAAGCATTTCAGACCTTTGCGCCTTCAG7CGCGGGACGT(3GTAA 
2673 2680 2590 2700 2710 272Q 2730
ATGT7CCG3ATCTGCATC3CAGGAT3CTGCTG3CTACCCTGTGGAACACCTACA7CTISTATTAACGAAGC 
TACnAG^CTAGACGTACKIGTCCTACGACGACCGATGGGACACCTTCPrGGATCTAGACATAATTGCPTCG 
2740 2750 2760 2770 27S0 2790 2800
284
PHISI-1.TXT: 5429 bases (linear) Pngs 5
ECO 47IGCTGOCATTCACCCTGAGTQATTTTTCTCTQGTCCCGCOKrATCCATACCOCCAGTTGTTTACCCTCACAC^ CC<n,AnCTG^ACTCnCTAAAAAGAiGACCA55GC0QCGTA'GGT«\TG<5CGGTCAACAAA.TG<JGnGTG?
2810 2820 2820 2640 2680 2850 2370
ACGTTCCAGT^CCGGGCATG?TCATCATCAG?A.ACCCGTATC'GTGAGO\TCCTCTCTCC-T7TCATCG3T 
TGC/^GGTCATTGGCCCGTACAA.C-TAGTAG'rCATTC-GGCATAGCACrCGTACfCGvGAGAGCArAGTAGCCA 
2880 2690 2503 2910 2920  2930 2940
ATCATTACCCCCATeAACAGAAATCCCCCTTACACGGAGGCATCAGTGACCAAACACfGAAAAAACaSCCC
2950 2960 2970 2980 2990 3000 3010
G s u lI
TTAACATGGCCCGCTTTATCAGAAGCCAGACATTrJlCGCTTCTOSSAGAAACTCAACGAGCTGGACGaSGA 
AATTG?ACCGG^GAAATAGTCTTCGGTC3t3TAATT5CGAAGACCTCTTTGAG?TGCTCGACCTGCGCCT  
3C23 3020 2340 3050 3063 3070 3CS0
Jian I P v u l lI ITGA.ACAGGCAGACATCTGTGA>vTCGCTTCACGACCACGC?GATGAGCTT?ACCGCAGCTGCCT<:GCGCGT 
ACTTGTCCGT'CTGTAGACACTTAGCGAAGTGCTOSTGCGACTACTCG^ATGGCGTCGACGGAGCGCGCA 
3090 3200 3110 3120 2120 2240 2150
TTCGGTGATGACSGTGAAAACCTCTGACACA7GCAGCTCCCG3AGACGGTCA<^GCrT£3TCTGTAftCCGG
AAGCCACTACTGCCACT7T73GAGACTGTC!7ACGTCGAQGGCCTCTGCCAGTGTC(3AACAGACrt,TTCGCC
3 ISC 3170 2260 2150 22CQ 2220 2210
A7GCCGCGA5CASACAAGCCCG?CAGGGCGCGTCAGCGGGTGTTGGCGG5TGTCGGGSCGCASrCCA.?GA2
TACCKKXXTCGTCTGTTCGGGCAGTCCCGCGCAGTCGCCCACAACCGCCCACACCCCCGCGTCGGTACTG
3220 3240 2250 326G 2270 3280 3290
CCAGTCACGTAGCGATAGCGGAGTGTATACTGGCTTAAC7ATGCX3C3CATCAGAGCAGArr<3TACTCAGAG
GGTCMTGCATCGCrATCGCCTCACATATCACCGAA.TTGATACGCCGTAGTCTCGTCTAACATGaC?rCTC
3300 2320 2320 3330 3340 3350 3360
NdelI
TGCACCA7ATGCCK5TGTGAAATACCGCACAGATGCGTMGGAGAAMTACCGCATCAGGCGCTCTTCCGC
2370 3380 3380 3400 3410 3420 3430
TTOCTD3CTCACTGACTCGCTGGGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCG
AAGGAGCGAGTGACTGAGCGACGCGAGCCAGCAAGCCGACGCCGCTC'GCCATAGTCGAGTGAGTTTCCGC 
3440 2450 3463 2479 3480 3490 2500
GTAATACOG7TATCCACAGAATCAGGGX5ATAACGCAGGAAA«AACyVT(nx*AGCAAAAGGCCAGCfiAAAGG 
CATTATCCCAJVTAGGTGTCrTAGTCCCCTATTGCGTCCTTTCTTGTACACTCGTlTTCCGGTCGTTTTCC  
3510 3S20 3523 3540 3555 2SS0 3570
285
PHISi-t.TXT: 5429 bases (linear) Page 6
CCAG0£ACCGTAAAAAGGCCGCG?TC£TGGCST?TTICCATAGGC7CCGCCCCCCTGACXSAGCATCACAA
GGTCCrTGGCATTTTTCCGGCOCAACGACCGCAAAAAGGTATCCGAGGCGGGQGGACTGCTCGTAGrXGTT
25cO 2530 3600 3610 3620 3630 3640
AAATCGACGCTCAAGTCAGAGG7®K:GA?ACCCGACAG3ACTATAAAGATACCA<K3CGT?TCCCCCTGGA
TTTJySCTGCGAGTTCAGTCTCCACCGCTrTGCGCTSTCCTCATATTTCTATSGTCCGCAAAGGGGGACCT
3650 3660 367Q 3620 36S0 2700 3710
TO5AGGGAGC^GCQAGA<X5/W:AAG0CTCGGACGGCGAATGGCCTATGGACAGGCG<3AAAGAGGGAA<5CC
2720 3730 2740 2750 3760 3770 3760
GAAGC<nXjfGCGCTTTCTCA3’AGCTCACGCTGTAGGTATCTCAGTTC'G3TGTAQGTC<3TTCGCTCCAAGCT 
CTTCGCACCGCGAAAGAG7ATCGAG7<X<*ACATCCATAGAGTCAAGCCACA?CCAGCAAGC£AGGTTCG&  
3750 3600 3610 3520 3530 3S40 3350
g g g c t g t g t g c a c g ?a ,c c c c c c g t t c a g c c c g a c c g c t g c c *c c t t a t c c g g t a a c t a t c g t c t t g a is t c c
CCCGACACACJ3TGCTTGGGC3GGCAAGICGGGCTGGCGACGCGOAATAGGCCATTGATAGCA£?aACTCAGG
3S60 3370 3830 3850 2800 3510 3S20
AACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACHGGArTAGCAGAGCGA<Kn'ATG  
TTG<^CATTCTGTGCKwATAGCXSTGACarrCCXCGGTGACCATTGTCCTAATCGTCTOGCTCCATAC  
3930 3340 3950 2960 3370 2280 3990
TAGGCCGT(2CTACAGAGGrCTTC%^GT’GGTGGCC?AACTACGGCTACAC7AGAAGC.ACAGTATTTGGTAT 
ATCC«X1AC«AT<37C7CAA5M OTCACCACCGGATTGATGCCGATGTGATCTTCCTGTCATAAACCATA  
4000 4012 4020 4030 4040 4050 4060
CTGCGCTCTCKrrGAA<K:CA3TTACCTTCGGAAAAAC^GTTGGTAGCTCTTGATCC<SvCAAACAAACCACC  
g a c g c g a g a c g a c t t c g g t c a a .g g g a a g c c t t t t t c t c a a c c a t c g a g a a c t a g g c c g t t t g t t t g g t g g  
4070 4QS0 4050 4100 4110 4120 4120
reCAAOCAGCAGATTACGCGCAGAAAAA^<K5ATCTCAAGAAC3ft.TC
ITTTTTTTCC TAG AG TTC TTC TA G  
5140 4150 4260 4.170 4150 41S0 4200
BspBI
CTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAG
CSAAACTAGAAAAGATGCCCCAGACTGCGAGTCAanTGCTTTTSACn'GCAATTCCCTAAAACCAGTACTC
4210 4220 4230 4240 4250 4260 4270
Dr a I Dr s i
ATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATCJAAGTTTTAAATCrtATCTAfVAGTATA
TAATAGTTTTTCCTAGAAGTGGATCTACKSAAAATTTAATTTITACTTXAAAATTTAGTTAGATT-TCATAT  
4280 4290 4300 4310 4220 4330 4340
286
PHISM.TXT: 5429 bases {linear) Peg© 7
TATGAin'A.VvCTTGGTCT<^CAGTTACCAATGCTZ!AATCA5TGAG5CACCTA7CXCAGC'3ATCTGTCTAT
ATACTCATTTGAACCAGACTGTCAATGGTTACGAATTAGTCACTCCOTGGATAGAGTCGCTAGACAGATA
4250 4360 4270 4350 4220 4400 <410
TTCGTTCATCCATAGiTrSCCTGACTCCCCGTCGTGTAGATMCTACGATACXKKrAGGGCTTACCATCTGG 
4420 4430 4440 4450 4450 4470 44S0
G s u li
CCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATnAACCAGCCA  
®XjlGTCACGACGTTACTATCK5CGCTCT(3G(?TGCGAGTGGCCGAGGT'CTAAATAGTCGlTTATTiX»GTCGGT 
44S0 4300 45X0 <520 4530 4540 <550
B g l l!GCCGGAAG&GCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCC  
CGGCCTTCCCGGCTCGCGTCTTCACCACGACGTTCAAATASGCGGAGGTAGGTCAGATAATTAACAACGG  
4560 4570 <560 4550 4600 45X0 4620
F s p I  P s t I! IGGGAAGCrAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTGCAGGCATCGT 
CCCTTCGATCTCATTCATCAAGCGOTCAATrATCAftACGCGTTGCAACAACGGTAACGACGTCCGTAGCA  
4520 4643 4650 4660 4670 46SQ 4690
GGrGTCAC<^TCGTCGT?7GGTATCKKrrTCATTCAGCTCCGGTTCCCftAC3ATCaAGGCGAGTTACATGA 
CCAC^GT-SCGAGCAGCAAACCATACCGAAGTAAGTCGAGGCCAAQGOTTGCrpAGOTCCCiC-rCMTGTACT 
47C0 4713 4720 4720 4740 4750 <753
P v u l
TCCCCCATGTTGTGCAJiAAAACKIGCTTTAGCTCCTTCGG^CTCCGATCGTTGTCAGAAGTAAGTTGGCCG
4770 4750 4750 4500 4S1Q 4520 4B30
CAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTOTCATGCCATCCGTiVAGA^i'GCTT
GTCACMTAGTGAGTACCrtATl^GTCGTGACGTATTAAOAGAATCACACTACGGTACGCATTCTACGAA
4640 4550 4S60 4870 <880 4S90 <500
Seal
fTTCTGTGACTGGTGAGTACTCAACCA5,GTCATTCT’GAGAATAGTt?TATGCGGCGACCGAGTTGCTCTT<2C 
AAGACACTGACCACTCATGAOTTGGTTCAGTAAGACTCTTATCACATACGCCGCIOGCSCAACCACAACO 
4910 4220 4230 4940 4250 4960 4S70
O r a l  XSwiI! ICCGGCCnOACACSGGATAATACCGCGCCACATACCAGAACTTTAAAAGTGCTCATCATTGGAAAACSTT 
GOCCGCAGTTGTCCCCTATTATGGCGCGGTGTATCGTCTTGAAATTTTCACGAGTAGTAACCTSTTGCftA 
49S0 4293 5000 5010 5020 5030 5040
287
PHISM  .TXT: 5429 bases (linear) Page a
CTTCGG<^OAAAACTCTCA^GGATCT?ACCSCTGTTGAGATCaWSTTC(^TGTAACCCACTCSTGCACC 
G a A W C C G C T T T T G ^ J G W IT C C T A C ^ T G G C G A C A A C T C T A G G T C M G C T J ^ T T O C G ia M C ftO a iO a  
5-050 “ C$3 5070- $080 SOSO 5100 SUO
OUU^PGATCITCAGC aTC nTrAC rTTC A CaUM G TTTCTG G G riXM UaaiftAA AC AG G A AO G C^A AA TQ CC  
G TTG A C TA G ^G TC G Taa^JU trG A A A G TG G TCG CA A A G A C C C A C TC G TITTTC TC C TTCC G TrrTA C O G  
5120 5130 5140 5150 51S0 S170 $180
GCAAAA^GGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATA'rTATTGAA  
CGTTTTTTCCCTTATTCXrCGCTGTGCCTTTACAACTTATGAGT^TGAGAAGG-AAAAAGTrATAftTAACTT 
S1S0 5290 5210 5220 5230 5240 525Q
BsrpHI
iGCATTTATCAGGGTTAT^GTCTCATCAGCGGAT.ACATATTTGAAOTATTTAGAAAAATAAACAAATAQG  
C G TAA ATA G T^C AATA^CAG AG TA C rC G CC TATG TA TAA A CTTAC A TAA ATC TrTTTA TTTG TTTATCC  
5260 5270 528-0 5290 $300 5310 5320
A a c lX  B spH I
C^TTCGGCGCACATTTCCCCa^AAGT-QCCACCTGACGTCTAAGAAACCAlEATTATCA^ACATCAACC I 
CCAA«SGCX5CGTG7AAAK(XKrrTTTCAOGGTCK5ACTOCASATTCTTPGOTAATAATAGTACTGTAMTOO 
5330 5340 5350 5360 5370 $380 5390
P ^A A A A A T A G <S C G TA TC A C G A G  rC C C T T T C G T C T T C A A  
ATATTTTTAT'CCGCATAGTGCTCCGGGAA^/GCAGAAGTT 
5400 $410 5420 5430
FIGURE 44. Sequence of plasmid pHISi-l.
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FIGURE 45. Map of autonomously replicating plasmid YEp/77yc181
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gcttgcatgctcccccgttgaatgatggaacagcaccaactatcttcgaagcacactacttccagttacttgctatcaaggtttcctcgtctttttctgctcaactccaattcccgagcctaccgccgccagctcattgtcgaacctcatacaaccaattaataatgaaaattcaaaaccgtataacgcgactacaatggaagataccccatccgaattccccgcaagttatttctttcaactatactcctgatctatagtcttttttttgagggcttatttggtcaagttgccagaaattggtagatacttatgatttaaaataagtgtaaaacgaaaagtcaggttgcttgaccacacctatgaacatttatgaatttaaaaaagagattcggcgacaccacctaaatttttaactgcgttcaatgacgtggcgatagcagaaccgtgcttgtctggc
aacttcttttttgtctcaccgacactaaagagatgtcgttcacacgaaacctctaatgagtgaatttgaatataaatagacattgttctcacaatatttcgctttgcaaatccaaaaaagaattttaatcccttcactttaacaactcaagcctcctctatcacggctagactgtcaccttttggaatcaatgatgtataaccaaacccacagatctatgcacttcaacttttatacatctctaagtttcaattttttaaggacctaaattcagaagcttctccaatcaattacgaaaaggttgttgacatgatttttatatacaaatttttcttgttcttttctcaggtctctaccggcattccattttcatttataaaatctttttaagcatcaccgacaccagttctatcttcaatgaatttcaacaggtcaaccttgcatggttcgaaagaggcca
ctttttttttatatccgcaagaaaaaattagttccagagctttttccttccaacggtataataaaaaaagcctgcaattagttccctttcaagctataccgatggataaaaagagaaaggaaagtgggaacactaacagtacaaattctcacgttcatgataaaattgatggttggacggctacagggattaactatctaaaaaaagagaaatcgtagatgtgcatcgtggttttgccttaatcttggccatgactagaatcttcatgaatggacttcttggttgtcggcatggaaaaggcttctaaatatattaaataataaagtgacttgagtaactcatagcatgagatgcccgaaagtaatttcgtgtttatgtacgcaaggatttcttcggtggtgatacctgcagccttacctttcattgcagcattctttggctacaaaccaaaggacgcaga
cttttctctctgacaaaaaaacgacaaagatgatgaggggcttcattcaccggccttccttttgccgcttttaatcttttttccttgtttaagcatacaagcggaattaatcgaattgggtattgctgatagcaacggtcaagcgctttctaacttcatggatggtaataaccaaactgcgtttaataccttcgatgatgtctctcgaggactgaaaaaccaccatctcacttttatgtaatgtaacctcttaatgcccaaatatattaccgccagaggtttgtctacctgtcaaatcgtagcgaatttcgttataaaaacttaggtttttttcctgtaggtcgctcttattcccctaccgtcgtttctaaaatatcatatcttaacttcactgttggaatccaaaacctcttcaggcaaagacaagataaaatctggagatgcggtgtttggcaacaaa
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cccaaggaac ctgggataac tatcaccaaa catgttgctg gtgggttggg ttcttaacta atcaattgat gttgaacctt tgatggtttc ctccacagtt ggccaaaaca ttagctttat ggtggctcat gttgtagggc tgattctttg cacttctgga ccaagcgaca ccatcaccat aagtaaatac ctcccactaa cagtaccttt agcaaattgt taaaagagag tcggatgcaa gcgtacaatt gaagttcttt gttcaggtct aacactacct cacagcacct aacaaaacgg tccagcgcct catctggaag tagcagcacc accaattaaa gacattggaa cgaacatcag atggcttcgg ctgtgatttc gcaaaacgac gatcttctta atatccttga aatatatata ggtaagaaaa gttagaaagt attggaaaaa acaataggtc tcaagtattg tgatgcaagc ctattctata tgaaaagccg ctttttctcc caatttttca caggcgacct ctgaaattaa aatttgattc tgtgcgatag atgttgagga aaaaaataat tcttgcatct tacgatacct atctcgactc tagctagagg atagctgttt cctgtgtgaa ccacacaaca tacgagccgg ggggtgccta atgagtgagg gcgctcactg cccgctttcc cagctggatt aatgaatcgg gtttgcgtat tgggcgctct ctcgctgcgc tcggtcgttc gctcactcaa aggcggtaat gggataacgc aggaaagaac aaaggccagg aaccgtaaaa ttccataggc tccgcccccc gacgctcaag tcagaggtgg aagataccag gcgtttcccc tctcctgttc cgaccctgcc cctttctccc ttcgggaagc acgctgtagg tatctcagtt aagctgggct gtgtgcacga gctgcgcctt atccggtaac
ggaggcttca tcggagatga gtgattataa taccatttag ggatcatggc ggcagaatca caatgtagga aattcgttct tttctccata atcttgaaga ccaaggacca aataggcaat catgaaagcg gccattcttg acggtgtatt gttcactatc cgtcttcctt tctcttacca ttctctgaca acaacgaagt ggcttgattg gagataagtc agttacatgg tcttaagttg acggattttt agtaaacctt gtaccccatt taggaccacc catcaacctt cttggaggct tgggacacct gtagcatcga tgattttcga aatcgaactt aaatagcttt aagaacctta ttgaccaacg tggtcacctg ggggcagaca ttagaatggt tatattgctg aaatgtaaaa aagacgattg ctaaccacct cttaaataat attgtcaact atttagtcat gaacgcttct gttccggcct ctcacctttc gttgaaaaag gtatatgcgt caaaaaattt ccagtcatcg cgcccctgtg tgttctcgtt ggttgctaag agattcgaac gagtattccc acagttgggg atcaattcgt aatcatggtc attgttatcc gctcacaatt aagcataaag tgtaaagcct taactcacat taattgcgtt agtcgggaaa cctgtcgtgc ccaacgcgcg gggagaggcg tccgcttcct cgctcactga ggctgcggcg agcggtatca acggttatcc acagaatcag atgtgagcaa aaggccagca aggccgcgtt gctggcgttt tgacgagcat cacaaaaatc cgaaacccga caggactata ctggaagctc cctcgtgcgc gcttaccgga tacctgtccg gtggcgcttt ctcatagctc cggtgtaggt cgttcgctcc accccccgtt cagcccgacc tatcgtcttg agtccaaccc
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ggtaagacacaacaggattaagttcttgaagacagtatttttcggaaaaaccaccgctgggattacgcgcatcttttctacacgttaaggcttcacctagtcaatctaaaaccaatgctttctatttcgttagataactagtgctgcaatagatttatcacgcagaagtgctattaattgagttaatagtatcgtggtgtgctccggttccatgttgtgcatcgttgtcatggttatggcatccgtaagaaagtcattctcttgcccggccagaactttagggcgaaaacgttcgatgtaatcttttactggaaggcaaaggaaatgttgttgaagcattatatttgaatcgcgcacattaaccattattatcacgaggcgtgaaaacctagcttgtctgcagggcgcgtttaactatgcccataacgcatctcatgtattgcgacgtgagcattttcggtcctattccggaacttcagaacgcactttc
gacttatcgcgcagagcgaggtggtggcctggtatctgcggagttggtagtagcggtggtagaaaaaaagcggggtctgagattttggtcatccttttaagtatatatgaaatcagtgagtcatccatagcgatacgggagataccgcgagcaataaaccgtcctgcaacttgccgggaattgcgcaacgcacgctcgtcccaacgatcaaaaaaagcgggaagtaagttagcactgcattgcttttctggagaatagtggtcaatacggaaagtgctcatctcaaggatacccactcgtttcaccagcgatgccgcaaaaatactcatatatcagggttgtatttagaatccccgaaaaatcatgacatcctttcgtctctgacacatgtaagcggatgcagcgggtgtggcatcagagtttaagcataatatatatacacagtgagctaagcgctcgtaagttcctatgcgcttttgaaaaaaaccaa
cactggcagcgtatgtaggcaactacggctctctgctgaactcttgatccttttttgtttgatctcaagacgctcagtggatgagattatattaaaaatggtaaacttgggcacctatctttgcctgactgggcttaccagacccacgctagccagccggtttatccgccgctagagtaattgttgccatgtttggtatgaggcgagttattagctccttggccgcagtgaattctcttatgactggtgatatgcggcgagataataccgtcattggaaacttaccgctggcacccaacttttctgggtgaaagggaatactcttcctttattgtctcataaataaacaagtgccacctgtaacctataacgcgcgtttccagctcccggccgggagcagtggcgggtgtcagattgtacaacacgcactaggcaacacggtatgtgcgctttcggaaactctctagctaaaaccaaaagaaacgcaccg
agccactggtggtgctacagacactagaaggccagttaccggcaaacaaagcaagcagcaagatcctttgaacgaaaactcaaaaaggataagttttaaatctgacagttcagcgatctgccccgtcgtgtctggccccacaccggctccaagggccgagtccatccagtgtagttcgcctgctacaggcgcttcattcacatgatcccccggtcctccgttatcactcactgtcatgccgtactcaaccccgagttgctcgccacatagacgttcttcgttgagatccagatcttcagcagcaaaaacaagggcgacacttcaatattagagcggatacataggggttcacgtctaagaaaataggcgtggtgatgacgagacggtcacacaagcccgtcggggctggctgagagtgcaatgccgttctcagatataggagctcgcgttgctttgaagtgaaagtatagcgctctgaaggactgtaacg
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57 61 agctactaaa atattgcgaa taccgcttcc acaaacattg5801 ctcaaaagta tctctttgct atatatctct gtgctatatc5841 cctatataac ctacccatcc acctttcgct ccttgaactt5881 gcatctaaac tcgacctcta cattttttat gtttatctct5921 agtattactc tttagacaaa aaaattgtag taagaactat5961 tcatagagtg aatcgaaaac aatacgaaaa tgtaaacatt6001 tcctatacgt agtatataga gacaaaatag aagaaaccgt6041 tcataatttt ctgaccaatg aagaatcatc aacgctatca6081 ctttctgttc acaaagtatg cgcaatccac atcggtatag6121 aatataatcg gggatgcctt tatcttgaaa aaatgcaccc6161 gcagcttcgc tagtaatcag taaacgcggg aagtggagtc6201 aggctttttt tatggaagag aaaatagaca ccaaagtagc6241 cttcttctaa ccttaacgga cctacagtgc aaaaagttat6281 caagagactg cattatagag cgcacaaagg agaaaaaaag6321 taatctaaga tgctttgtta gaaaaatagc gctctcggga6361 tgcatttttg tagaacaaaa aagaagtata gattctttgt6401 tggtaaaata gcgctctcgc gttgcatttc tgttctgtaa6441 aaatgcagct cagattcttt gtttgaaaaa ttagcgctct6481 cgcgttgcat ttttgtttta caaaaatgaa gcacagattc6521 ttcgttggta aaatagcgct ttcgcgttgc atttctgttc6561 tgtaaaaatg cagctcagat tctttgtttg aaaaattagc6601 gctctcgcgt tgcatttttg ttctacaaaa tgaagcacag6641 atgcttcgtt
KEY:
Blue Locations of the AD10[S] and complement of AD10[R] PCR and 
sequencing primers.
Red EcoR1 restriction endonuclease site used for subcloning the rat 
brain library cDNAs.
FIGURE 46. Sequence of the cDNA/AD fusion library plasmid pGAD10.
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APPENDIX VII.
In order to determine the volume of nuclear extract used in the 
electrophoretic mobility shift assay and competition binding assay, to give a 
protein concentration of 1 0  pg per reaction, it was first necessary to 
determine the concentration of protein in the nuclear extracts. To achieve 
this a microtitre plate method utilising bicinchoninic acid was used and 
bovine serum albumin (0 to 10 pg/pl) served as the protein standard. The 
BCA reagent was mixed with the protein dilution or nuclear extract sample, 
incubated at room temperature and read on a microplate reader at 562 nm. 
The data for the preparation of a standard curve to determine the protein 
concentration (pg/pl) of the nuclear extracts is shown in table 5 and the 
standard curve is shown in Figure 47.
From cultures containing approximately 1 x 106 cells, 200 pi of 
nuclear extract were prepared producing a protein yield of between 1 . 0  and 
3.0 pg/pl depending on the source of the nuclear extract (as shown in table 
6)
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Concentration
(i^g/ i^)
Absorbance at 562 nm
Data
set
1
Data
set
2
Data
set
3
Data
set
4
Mean
Absorbance
Corrected
Absorbance
Reagent Blank 0.05 0.06 0.05 0.06 0.05
0  (xg/|xl 0.05 0.06 0.05 0.06 0.05 0 .0 0
1 M-g/pil 0.29 0.28 0.27 0.27 0.28 0.23
2  fxg/fxl 0.50 0.48 0.46 0.47 0.48 0.43
3 ng/ l^ 0.65 0.64 0.57 0.61 0.62 0.57
4 p-g/fxl 0.81 0.81 0.80 0.78 0.80 0.75
5 jag/pLl 0.98 0.99 1 .0 0 0.97 0.99 0.94
6  M-g/p-l 1.15 1 .2 0 1.16 1.19 1.17 1 .1 2
7 pig/pil 1.36 1.33 1.39 1.39 1.36 1.31
8  ng/ l^ 1.53 1.50 1.51 1.50 1.51 1.46
9 j-ig/pil 1.80 1.79 1.70 1 .6 8 1.74 1.69
1 0  p.g/^1 2.03 1.93 1.81 1.81 1.90 1.85
Table 5. Data obtained for the preparation of a standard curve to 
determine the protein concentration (|xg/|xl) of the nuclear 
extracts used in the EMSA and competition binding assays.
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Figure 47. Standard curve to determine the concentration of protein (pg/pl) 
in nuclear extracts.
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Sample
Absorbance at 562 nm
Data
set
1
Data
set
2
Mean
Absorbance
Corrected
Absorbance
Calculated
Concentration
(f^g/fil)
Reagent Blank 0.05 0.06 0.06
C6 glioma 0.25 0.26 0.26 0 .2 0 1 .1 (ig/jxl
HeLa 0.24 0.23 0.24 0.18 1 .0  |xg/p.l
RBX 0.61 0.64 0.62 0.56 3.0 fig/fxl
33B
oligodendrocyto
ma
0.32 0.29 0.31 0.24 1.3 pig/jn!
Table 6 . The concentration (pg/|il) of protein in the nuclear extracts as 
determined from the graph shown in figure 47.
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